ABCA1 p.Val825Ile
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 22377775
[PubMed]
Sun YM et al: "The polymorphism of the ATP-binding cassette transporter 1 gene modulates Alzheimer disease risk in Chinese Han ethnic population."
No.
Sentence
Comment
3
Methods: We studied the role of R219K and V825I polymorphisms of ABCA1 in modulating the risk of AD in 321 AD patients and 349 comparisons of Chinese Han.
X
ABCA1 p.Val825Ile 22377775:3:42
status: NEW4 Genotyping of R219K and V825I were performed by PCR-restriction fragment length polymorphism analysis.
X
ABCA1 p.Val825Ile 22377775:4:24
status: NEW8 However, no discrepancy was found in V825I.
X
ABCA1 p.Val825Ile 22377775:8:37
status: NEW10 In V825I, AAO was diseased by 4.3 years in II genotype compared with VV genotype in APOE ε4 noncarrying group and 3.4 years in APOE ε4ε4 noncarrying group.
X
ABCA1 p.Val825Ile 22377775:10:3
status: NEW22 But clinical investigation of its relationship to AD has commenced in these years and the results were controversial.19 Also, the investigation in Chinese ethnic Han people is rare.20 Here, we examined two single nucleotide polymorphisms (SNPs) in the coding regions of ABCA1: R219K (rs2230806) located in exon 7 with a G to A nucleotide change, which is most popular SNP in both CAD and AD examinations; V825I (rs2066715) located in exon 17 with a G to A as well, which associated with HDL-C and played an important role in CAD but was rarely reported in AD patients.21,22 We conducted a case-control study to investigate the genetic association of these two SNPs with AD in a population of Chinese Han in eastern China.
X
ABCA1 p.Val825Ile 22377775:22:405
status: NEW36 Genotyping of R219K, V825I, and APOE Genomic DNA was extracted from the sodium citrate treated blood samples of both AD patients and comparisons by TIANamp blood DNA Kit (TIAN- GEN).
X
ABCA1 p.Val825Ile 22377775:36:21
status: NEW37 The genotypes of R219K and V825I were the same as the previous report.23 The APOE genotypes were determined as described by Donohoe et al.24 Statistical Analysis Statistical analyses were performed using SPSS version 12.0 (SPSS Inc., Chicago, IL).
X
ABCA1 p.Val825Ile 22377775:37:27
status: NEW48 Genotype and Allele Frequency Distribution R219K and V825I were under Hardy-Weinberg equilibrium in both AD and comparison groups (p > 0.20) (see Table, Supplemental Digital Content 1, http://links.lww.com/AJGP/A26, which demonstrates Hardy-Weinberg equilibrium of the two SNPs inAD patientsandcomparisongroup).
X
ABCA1 p.Val825Ile 22377775:48:53
status: NEW59 As for V825I, no differences were found in either genotypes or allele frequencies though stratified by AAO, gender, APOE ε4 carrying status, or APOEε4ε4 carrying status (Table 2).
X
ABCA1 p.Val825Ile 22377775:59:7
status: NEW64 Influence of ABCA1 Polymorphisms on AAO and MMSE Score of AD As shown in Table 4, using ANOVA, we analyzed the effects of R219K and V825I genotypes on the AAO and MMSE scores of AD patients which were divided according to the onset age, gender, and APOE ε4 and ε4ε4 carrying status.
X
ABCA1 p.Val825Ile 22377775:64:132
status: NEW66 In the V825I, AAO was diseased by 4.3 years in II genotype compared with VV genotype in APOE ε4 noncarrying group and 3.4 years in APOE ε4ε4 noncarrying group.
X
ABCA1 p.Val825Ile 22377775:66:7
status: NEW69 V825I locates in the middle part of the protein corresponding to the sixth transmembrane α-helix and is highly conserved.25 From our results, we did not find the apparent differences either in genotypes or in allele frequencies in V825I though stratified by AAO, gender, and APOE ε4 and ε4ε4 status.
X
ABCA1 p.Val825Ile 22377775:69:0
status: NEWX
ABCA1 p.Val825Ile 22377775:69:237
status: NEW70 Katzov et al.26 obtained the same results after genotyping 390 LOAD and 185 controls of Swedish population, but in their subjects of EOAD, the V825I was monomorphic.
X
ABCA1 p.Val825Ile 22377775:70:143
status: NEW71 V825I polymorphism was rarely reported in AD patients, whereas it was associated with increased clinical events and severity of atherosclerosis in CAD patients,27,28 and significantly increased HDL-C in women.
X
ABCA1 p.Val825Ile 22377775:71:0
status: NEW72 Wang et al.23 found no association of V825I with lipids levels in Chinese Han ethnic stroke patients.
X
ABCA1 p.Val825Ile 22377775:72:38
status: NEW73 This may imply that V825I is conservative and exerts minor influence on cholesterol efflux activity.
X
ABCA1 p.Val825Ile 22377775:73:20
status: NEW74 One recent research demonstrated the V825I substitution on ABCA1 function in cells, which indicated 825I variant having higher activity in mediating cholesterol efflux than the wild type (825V).29 They also observed a trend toward higher symptom onset age in 825I allele carriers in CAD patients, and unfortunately the AAO between the groups of genotypes did not reach significance.
X
ABCA1 p.Val825Ile 22377775:74:37
status: NEW76 So V825I might not be that conservative and might have some effect on AD pathogenesis.
X
ABCA1 p.Val825Ile 22377775:76:3
status: NEW82 Genotypes and Allele Frequencies of R219K and V825I Polymorphisms in ABCA1 Gene in AD Patients and Comparison Group Comparison Comparison R219K AD (%) Group (%) V825I AD (%) Group (%) Total, n 321 349 321 349 RR 93 (29.0) 125 (35.8) VV 92 (28.7) 109 (31.2) RK 180 (56.1) 156 (44.7) VI 158 (49.2) 170 (48.7) KK 48 (15.0) 68 (19.5) II 71 (22.1) 70 (20.1) χ2 (p) 8.705 (0.013)a 0.715 (0.699) R frequency 366 (57.0) 407 (58.2) V frequency 342 (53.3) 388 (55.6) K frequency 276 (43.0) 293 (41.8) I frequency 300 (46.7) 310 (44.4) χ2 (p) 0.183 (0.669) 0.724 (0.395) EOAD, n 124 149 124 149 RR 42 (33.9) 53 (35.6) VV 31 (25.0) 50 (33.6) RK 66 (53.2) 73 (49.0) VI 62 (50.0) 66 (44.3) KK 16 (12.9) 23 (15.4) II 31 (25.0) 33 (22.1) χ2 (p) 0.598 (0.741) 2.375 (0.305) R frequency 150 (60.5) 179 (60.1) V frequency 124 (50.0) 166 (55.7) K frequency 98 (39.5) 119 (39.9) I frequency 124 (50.0) 132 (44.3) χ2 (p) 0.1 (0.921) 1.769 (0.184) LOAD, n 197 200 197 200 RR 51 (25.9) 72 (36.0) VV 61 (31.0) 59 (29.5) RK 114 (57.9) 83 (41.5) VI 96 (48.7) 104 (52.0) KK 32 (16.2) 45 (22.5) II 40 (20.3) 37 (18.5) χ2 (p) 10.636 (0.005)b 0.448 (0.799) R frequency 216 (54.8) 227 (56.8) V frequency 218 (55.3) 222 (55.5) K frequency 178 (45.2) 173 (43.2) I frequency 176 (44.7) 178 (44.5) χ2 (p) 0.229 (0.584) 0.002 (0.962) Male, n 123 125 123 125 RR 41 (33.3) 42 (33.6) VV 31 (25.2) 41 (32.8) RK 66 (53.7) 58 (46.4) VI 64 (52.0) 60 (48.0) KK 16 (13.0) 25 (20.0) II 28 (22.8) 24 (19.2) χ2 (p) 2.488 (0.288) 1.81 (0.405) R frequency 148 (60.2) 142 (56.8) V frequency 126 (51.2) 142 (56.8) K frequency 98 (39.8) 108 (43.2) I frequency 120 (48.8) 108 (43.2) χ2 (p) 0.577 (0.447) 1.555 (0.212) Female, n 198 224 198 224 RR 52 (26.3) 83 (37.1) VV 61 (30.8) 68 (30.4) RK 114 (57.6) 98 (43.8) VI 94 (47.5) 110 (49.1) KK 32 (16.2) 43 (19.2) II 43 (21.7) 46 (20.5) χ2 (p) 8.369 (0.015)a 0.134 (0.935) R frequency 218 (55.1) 264 (58.9) V frequency 216 (54.5) 246 (54.9) K frequency 178 (44.9) 184 (41.1) I frequency 180 (45.5) 202 (45.1) χ2 (p) 1.291 (0.256) 0.11 (0.915) APOE ε4 carrying, n 150 143 150 143 RR 48 (32.0) 52 (36.4) VV 37 (24.7) 44 (30.8) RK 82 (54.7) 62 (43.4) VI 78 (52.0) 74 (51.7) KK 20 (13.3) 29 (20.3) II 35 (23.3) 25 (17.5) χ2 (p) 4.426 (0.109) 2.211 (0.331) R frequency 178 (59.3) 166 (58.0) V frequency 152 (50.7) 162 (56.6) K frequency 122 (40.7) 120 (42.0) I frequency 148 (49.3) 124 (43.4) χ2 (p) 0.101 (0.751) 2.103 (0.147) APOE ε4 noncarrying, n 171 206 171 206 RR 45 (26.3) 73 (35.4) VV 55 (32.2) 65 (31.6) RK 98 (57.3) 94 (45.6) VI 80 (46.8) 96 (46.6) KK 28 (16.4) 39 (18.9) II 36 (21.1) 45 (21.8) χ2 (p) 5.33 (0.070) 0.039 (0.981) R frequency 188 (55.0) 240 (58.3) V frequency 190 (55.6) 226 (54.9) K frequency 154 (45.0) 172 (41.7) I frequency 152 (44.4) 186 (45.1) χ2 (p) 0.82 (0.365) 0.037 (0.847) APOE ε4ε4 carrying, n 35 3 35 3 RR 11 (31.4) 1 (33.3) VV 7 (20.0) 1 (33.3) RK 17 (48.6) 2 (66.7) VI 20 (57.1) 1 (33.3) KK 7 (20.0) 0 (0.0) II 8 (22.9) 1 (33.3) (Continued ) TABLE 2.
X
ABCA1 p.Val825Ile 22377775:82:46
status: NEWX
ABCA1 p.Val825Ile 22377775:82:161
status: NEW83 (Continued ) Comparison Comparison R219K AD (%) Group (%) V825I AD (%) Group (%) χ2 (p) 0.656 (1.000)c 1.321 (0.577)c R frequency 39 (55.7) 4 (66.7) V frequency 34 (48.6) 3 (50.0) K frequency 31 (44.3) 2 (33.3) I frequency 36 (51.4) 3 (50.0) χ2 (p) (0.692)c (1.000)c APOE ε4ε4 noncarrying, n 286 346 286 346 RR 82 (28.7) 124 (35.8) VV 85 (29.7) 108 (31.2) RK 163 (57.0) 154 (44.5) VI 138 (48.3) 169 (48.8) KK 41 (14.3) 68 (19.7) II 63 (22.0) 69 (19.9) χ2 (p) 9.9 (0.007)b 0.452 (0.798) R frequency 327 (57.2) 402 (58.1) V frequency 308 (53.8) 385 (55.6) K frequency 245 (42.8) 290 (41.9) I frequency 264 (46.2) 307 (44.4) χ2 (p) 0.11 (0.741) 0.405 (0.525) Notes: For all the χ2 of genotypes, df = 2; for all the χ2 of allele frequencies, df = 1.
X
ABCA1 p.Val825Ile 22377775:83:58
status: NEW92 Effects of Two Single Nucleotide Polymorphisms (R219K and V825I) of ABCA1 Gene on AAO and MMSE Score in AD Patients R219K V825I RR (%) RK (%) KK (%) F (p) VV (%)g VI (%) II (%) F (p) Total, n 93 (29.0) 180 (56.1) 48 (15.0) 92 (28.7) 158 (49.2) 71 (22.1) AAO 65.4 ± 10.42 67.8 ± 9.46 67.3 ± 9.36 1.813 (0.165) 68.4 ± 9.34 66.8 ± 9.84 65.6 ± 10.01 1.764 (0.173) MMSE 14.1 ± 6.44 14.4 ± 6.00 14.5 ± 6.25 0.113 (0.893) 14.8 ± 5.87 14.0 ± 6.31 14.4 ± 5.87 0.545 (0.580) EOAD, n 42 (33.9) 66 (53.2) 16 (12.9) 31 (25.0) 62 (50.0) 31 (25.0) AAO 55.5 ± 5.33 57.0 ± 4.97 55.7 ± 4.92 1.222 (0.298) 57.0 ± 5.20 56.3 ± 5.04 55.7 ± 5.19 0.470 (0.626) MMSE 13.6 ± 6.84 13.0 ± 6.63 14.3 ± 8.62 0.237 (0.790) 13.9 ± 7.38 12.2 ± 6.92 15.2 ± 6.21a 2.119 (0.125) LOAD, n 51 (25.9) 114 (57.9) 32 (16.2) 61 (40.0) 96 (48.7) 40 (20.3) AAO 73.5 ± 5.23 74 ± 4.57 73.1 ± 4.1 0.523 (0.594) 74.2 ± 4.11 73.6 ± 4.99 73.2 ± 4.70 0.628 (0.535) MMSE 14.4 ± 6.14 15.2 ± 5.48 14.6 ± 4.81 0.427 (0.653) 15.3 ± 5.37 15.2 ± 5.63 13.7 ± 5.58 1.179 (0.310) Male, n 41 (33.3) 66 (53.7) 16 (13.0) 31 (25.2) 64 (52.0) 28 (22.8) AAO 65.1 ± 9.65 67.2 ± 9.38 67.9 ± 9.81 0.850 (0.430) 68.0 ± 10.50 66.8 ± 9.04 64.7 ± 9.51 0.887 (0.415) MMSE 15.2 ± 6.27 16.1 ± 6.21 15.0 ± 5.72 0.404 (0.668) 16.7 ± 5.67 14.9 ± 6.49 16.4 ± 5.77 1.110 (0.333) Female, n 52 (26.3) 114 (57.6) 32 (16.1) 61 (30.8) 94 (47.5) 43 (21.7) AAO 65.7 ± 11.80 68.1 ± 9.53 67.0 ± 9.27 1.036 (0.357) 68.7 ± 8.78 66.9 ± 10.39 66.2 ± 10.38 0.960 (0.385) MMSE 13.2 ± 6.50 13.4 ± 5.67 14.2 ± 6.57 0.301 (0.740) 13.9 ± 6.03 13.4 ± 6.15 13.1 ± 5.63 0.255 (0.775) APOE ε4 carrying, n 48 (32.0) 82 (54.7) 20 (13.3) 37 (24.7) 78 (52.0) 35 (23.3) AAO 65.7 ± 9.95 67.8 ± 8.64 62.7 ± 8.85b 2.798 (0.064) 67.9 ± 8.92 65.7 ± 9.41 66.7 ± 9.14 0.742 (0.478) MMSE 13.8 ± 6.04 14.8 ± 5.69 14.5 ± 7.13 0.369 (0.692) 15.3 ± 6.15 13.7 ± 6.32 15.2 ± 4.86 1.212 (0.301) APOE ε4 noncarrying, n 45 (26.3) 98 (57.3) 28 (16.4) 55 (32.2) 80 (46.8) 36 (21.1) AAO 65.1 ± 11.01 67.8 ± 10.14 70.6 ± 8.37c 2.627 (0.075) 68.8 ± 9.68 68.0 ± 10.16 64.5 ± 10.79d 2.160 (0.119) MMSE 14.3 ± 6.90 14.1 ± 6.27 14.5 ± 5.68 0.036 (0.964) 14.6 ± 6.13 14.3 ± 6.34 13.4 ± 6.69 0.252 (0.778) APOE ε4ε4 carrying, n 11 (31.4) 17 (48.6) 7 (20.0) 7 (20.0) 20 (57.1) 8 (22.9) AAO 64.8 ± 9.67 66.5 ± 6.79 67.6 ± 7.41 0.283 (0.756) 65.0 ± 8.37 66.0 ± 7.70 67.6 ± 8.16 0.215 (0.807) MMSE 14.9 ± 6.99 14.4 ± 4.70 13.4 ± 5.29 0.162 (0.851) 13.9 ± 4.41 14.5 ± 6.43 15.0 ± 4.03 0.077 (0.926) APOE ε4ε4 noncarrying, n 82 (28.7) 163 (57.0) 41 (14.3) 85 (29.7) 138 (48.3) 63 (22.0) AAO 65.5 ± 10.57 67.9 ± 9.70 67.2 ± 9.73 1.597 (0.204) 68.7 ± 9.41 67.0 ± 10.12 65.3 ± 10.24e 2.132 (0.121) MMSE 13.9 ± 6.40 14.4 ± 6.13 14.7 ± 6.44 0.206 (0.814) 14.9 ± 6.24 13.9 ± 6.31 14.3 ± 6.08 0.667 (0.514) Notes: MMSE score and AAO were analyzed by ANOVA and post-hoc LSD multiple comparisons and were expressed in mean ± SD.
X
ABCA1 p.Val825Ile 22377775:92:58
status: NEWX
ABCA1 p.Val825Ile 22377775:92:122
status: NEW115 However, there was no association of V825I with AD in spite of stratification.
X
ABCA1 p.Val825Ile 22377775:115:37
status: NEW
PMID: 21315358
[PubMed]
Aguilar-Salinas CA et al: "The non-synonymous Arg230Cys variant (R230C) of the ATP-binding cassette transporter A1 is associated with low HDL cholesterol concentrations in Mexican adults: a population based nation wide study."
No.
Sentence
Comment
127
Only two sequence variants (I883 M and V825I) were associated with plasma HDL-C levels in both white men and black men, but the effect of these variants on HDL-C levels was modest (<4 mg/dl).
X
ABCA1 p.Val825Ile 21315358:127:39
status: NEW
PMID: 21247457
[PubMed]
Cao XL et al: "Genetic variant of V825I in the ATP-binding cassette transporter A1 gene and serum lipid levels in the Guangxi Bai Ku Yao and Han populations."
No.
Sentence
Comment
0
RESEARCH Open Access Genetic variant of V825I in the ATP-binding cassette transporter A1 gene and serum lipid levels in the Guangxi Bai Ku Yao and Han populations Xiao-Li Cao1,2 , Rui-Xing Yin1* , Dong-Feng Wu1 , Lin Miao1 , Lynn Htet Htet Aung1 , Xi-Jiang Hu1 , Qing Li1 , Ting-Ting Yan1 , Wei-Xiong Lin3 , Shang-Ling Pan4 Abstract Background: Several genetic variants in the ATP-binding cassette transporter A1 (ABCA1) gene have associated with modifications of serum high-density lipoprotein cholesterol (HDL-C) levels and the susceptibility for coronary heart disease, but the findings are still controversial in diverse racial/ethnic groups.
X
ABCA1 p.Val825Ile 21247457:0:40
status: NEW2 The present study was undertaken to detect the possible association of V825I (rs2066715) polymorphism in the ABCA1 gene and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations.
X
ABCA1 p.Val825Ile 21247457:2:71
status: NEW4 Polymerase chain reaction and restriction fragment length polymorphism assay combined with gel electrophoresis were performed for the genotyping of V825I variant, and then confirmed by direct sequencing.
X
ABCA1 p.Val825Ile 21247457:4:148
status: NEW13 Conclusion: The present study suggests that the V825I polymorphism in the ABCA1 gene is associated with male serum HDL-C and ApoAI levels in the Han, and serum TC levels in the Bai Ku Yao populations.
X
ABCA1 p.Val825Ile 21247457:13:48
status: NEW14 The difference in the association of V825I polymorphism and serum lipid levels between the two ethnic groups might partly result from different ABCA1 gene-enviromental interactions.
X
ABCA1 p.Val825Ile 21247457:14:37
status: NEW32 A common variant of V825I in the ABCA1 gene is a missense SNP in the exon 17 that locates in the middle part of the protein corresponding to sixth transmembrane a-helix with mutation of GTC®ATC.
X
ABCA1 p.Val825Ile 21247457:32:10
status: NEWX
ABCA1 p.Val825Ile 21247457:32:20
status: NEW33 The ABCA1 V825I polymorphism has been found to be associated with modifications of serum HDL-C levels in some studies [26-29] but not in others [30-33].
X
ABCA1 p.Val825Ile 21247457:33:10
status: NEW41 Therefore, the aim of the present study was to detect the association of V825I polymorphism in the ABCA1 gene and several environmental factors with serum lipid phenotypes in the Guangxi Bai Ku Yao and Han populations.
X
ABCA1 p.Val825Ile 21247457:41:73
status: NEW107 Genotypic and allelic frequencies Table 2 gives the genotypic and allelic frequencies of V825I polymorphism in the ABCA1 gene.
X
ABCA1 p.Val825Ile 21247457:107:89
status: NEW111 The nucleotide sequence of V825I polymorphism The results were shown as GG, GA and AA genotypes by PCR-RFLP, the GG, GA and AA genotypes were also confirmed by sequencing (Figure 3); respectively.
X
ABCA1 p.Val825Ile 21247457:111:27
status: NEW119 Figure 2 Genotyping of V825I polymorphism in the ABCA1 gene.
X
ABCA1 p.Val825Ile 21247457:119:23
status: NEW132 Table 2 Genotypic and allelic frequencies of the ABCA1 V825I polymorphism between the Bai Ku Yao and Han populations [n (%)] Group n Genotype Allele GG GA AA G A Bai Ku Yao 677 228 (33.7) 321 (47.4) 128 (18.9) 777 (57.4) 577 (42.6) Han Chinese 646 216 (33.4) 314 (48.6) 116 (18.0) 746 (57.7) 546 (42.3) c2 - 0.265 0.034 P - 0.876 0.854 Bai Ku Yao Male 324 110 (34.0) 153 (47.2) 61 (18.8) 373 (57.6) 275 (42.4) Female 353 118 (33.4) 168 (47.6) 67 (19.0) 404 (57.2) 302 (42.8) c2 - 0.210 0.016 P - 0.990 0.900 Han Chinese Male 315 104 (33.0) 154 (48.9) 57 (18.1) 362 (57.5) 268 (42.5) Female 331 112 (33.8) 160 (48.3) 59 (17.8) 384 (58.0) 278 (42.0) c2 - 0.490 0.030 P - 0.976 0.863 Figure 3 A part of the nucleotide sequence of the ABCA1 V825I polymorphism.
X
ABCA1 p.Val825Ile 21247457:132:55
status: NEWX
ABCA1 p.Val825Ile 21247457:132:737
status: NEW142 These results indicate that the prevalence of the A allele variation of Table 3 Genotypic frequencies of the ABCA1 V825I polymorphism and serum lipid levels between the Bai Ku Yao and Han populations Genotype n TC (mmol/L) TG (mmol/L) HDL-C (mmol/L) LDL-C (mmol/L) ApoAI (g/L) ApoB (g/L) ApoAI/ApoB Bai Ku Yao GG 228 4.28 ± 0.79 1.09 (0.80) 1.63 ± 0.39 2.52 ± 0.65 1.30 ± 0.34 0.84 ± 0.21 1.65 ± 0.69 GA 321 4.26 ± 0.82 0.96 (0.61) 1.64 ± 0.41 2.52 ± 0.68 1.28 ± 0.29 0.83 ± 0.22 1.64 ± 0.63 AA 128 4.52 ± 1.26 0.95 (0.61) 1.72 ± 0.45 2.69 ± 1.04 1.33 ± 0.35 0.86 ± 0.26 1.73 ± 0.91 F - 3.839 4.621 2.073 2.358 1.460 0.663 0.862 P - 0.022 0.099 0.127 0.095 0.233 0.516 0.423 Male GG 110 4.29 ± 0.80 1.25 (0.91) 1.65 ± 045 2.43 ± 0.68 1.36 ± 0.39 0.82 ± 0.21 1.81 ± 0.86 GA 153 4.26 ± 0.88 1.00 (0.66) 1.67 ± 0.45 2.47 ± 0.73 1.32 ± 0.33 081 ± 021 1.76 ± 0.74 AA 61 4.53 ± 1.62 1.02 (0.68) 1.74 ± 0.56 2.63 ± 1.33 1.40 ± 0.44 0.83 ± 0.30 1.96 ± 1.19 F - 1.850 4.969 0.974 1.377 1.040 0.081 1.370 P - 0.159 0.083 0.379 0.254 0.355 0.922 0.256 Female GG 118 4.26 ± 0.80 0.97(0.62) 1.60 ± 0.33 2.59 ± 0.62 1.25 ± 0.26 0.87 ± 0.20 1.50 ± 0.44 GA 168 4.26 ± 0.77 0.94(0.56) 1.62 ± 0.36 2.57 ± 0.63 1.24 ± 0.25 0.85 ± 0.22 1.53 ± 0.47 AA 67 4.50 ± 0.80 0.92(0.49) 1.69 ± 0.31 2.73 ± 0.68 1.27 ± 0.22 0.89 ± 0.20 1.51 ± 0.45 F - 2.860 0.595 1.530 2.080 0.474 1.150 0.578 P - 0.059 0.743 0.220 0.126 0.623 0.320 0.560 Han Chinese GG 216 4.77 ± 0.99 1.00 (0.57) 1.92 ± 0.51 2.61 ± 0.72 1.43 ± 0.27 0.89 ± 0.22 1.70 ± 0.58 GA 314 4.71 ± 1.06 1.01 (0.68) 1.90 ± 0.48 2.62 ± 0.81 1.42 ± 0.28 0.89 ± 0.24 1.69 ± 0.57 AA 116 4.63 ± 0.90 1.02 (0.70) 1.78 ± 0.48 2.64 ± 0.67 1.36 ± 0.27 0.90 ± 0.21 1.58 ± 0.51 F - 0.600 0.682 3.797 0.190 3.650 0.220 1.930 P - 0.540 0.711 0.023 0.674 0.027 0.800 0.145 Male GG 104 4.77 ± 1.03 1.01 (0.59) 1.89 ± 0.55 2.62 ± 0.73 1.42 ± 0.30 0.90 ± 0.23 1.69 ± 0.68 GA 154 4.59 ± 1.13 1.01 (0.64) 1.80 ± 0.49 2.56 ± 0.86 1.36 ± 0.29 0.87 ± 0.25 1.68 ± 0.61 AA 57 4.50 ± 1.04 1.03 (0.78) 1.71 ± 0.49 2.58 ± 0.72 1.32 ± 0.30 0.88 ± 0.22 1.61 ± 0.59 F - 1.039 0.062 3.590 0.037 3.020 0.102 0.575 P - 0.355 0.970 0.029 0.964 0.049 0.903 0.564 Female GG 112 4.72 ± 0.96 0.96 (0.56) 1.94 ± 0.47 2.59 ± 0.71 1.43 ± 0.24 0.89 ± 0.21 1.70 ± 0.48 GA 160 4.83 ± 0.97 1.02 (0.77) 1.99 ± 0.45 2.68 ± 0.75 1.43 ± 0.26 0.91 ± 0.22 1.72 ± 0.53 AA 59 4.76 ± 0.75 0.99(0.58) 1.85 ± 0.47 2.70 ± 0.63 1.39 ± 0.23 0.93 ± 0.20 1.55 ± 0.42 F - 0.390 1.182 2.150 0.538 2.640 0.760 2.133 P - 0.677 0.554 0.118 0.585 0.073 0.469 0.120 TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B; ApoAI/ApoB, the ratio of apolipoprotein AI to apolipoprotein B.
X
ABCA1 p.Val825Ile 21247457:142:115
status: NEW145 Table 4 Correlative factors for serum lipid parameters between the Bai Ku Yao and Han populations Lipid parameter Relative factor Standardized coefficient Standard error t P Bai plus Han TC Body mass index 0.100 0.150 2.318 0.021 Age 0.194 0.002 7.234 0.000 Ethnic group -1.159 0.050 -6.200 0.001 Diastolic blood pressure 0.094 0.003 3.400 0.001 Weight 0.164 0.006 0.164 0.000 Sex 0.087 0.061 0.087 0.005 TG Weight 0.216 0.004 7.889 0.000 Alcohol consumption 0.114 0.042 4.168 0.000 HDL-C Age 0.211 0.001 8.214 0.000 Ethnic group -0.235 0.023 -9.336 0.000 Alcohol consumption 0.233 0.018 8.246 0.000 Sex 0.127 0.026 4.541 0.000 Body mass index -0.069 0.004 -2.689 0.007 LDL-C Body mass index 0.093 0.012 2.097 0.036 Age 0.188 0.001 6.975 0.000 Alcohol consumption -0.090 0.029 -3.092 0.002 Weight 0.209 0.004 4.412 0.000 Sex 0.084 0.051 2.491 0.013 ApoAI Age 0.221 0.001 8.308 0.000 Alcohol consumption 0.230 0.012 8.126 0.000 Ethnic group -0.171 0.015 -6.759 0.000 Diastolic blood pressure 0.061 0.001 2.272 0.023 Sex 0.057 0.017 2.021 0.044 ApoB Body mass index 0.237 0.002 8.922 0.000 Age 0.160 0.000 5.999 0.000 Ethnic group -0.087 0.012 -3.393 0.001 Diastolic blood pressure 0.105 0.001 3.784 0.000 Sex 0.081 0.012 3.098 0.002 ApoAI/ApoB Alcohol consumption 0.165 0.023 6.103 0.000 Body mass index -0.155 0.006 -5.722 0.000 Bai Ku Yao TC Body mass index 0.216 0.014 5.821 0.000 Age 0.139 0.002 3.730 0.000 Genotype 0.076 0.048 2.051 0.041 TG Alcohol consumption 0.197 0.068 4.194 0.000 Body mass index 0.133 0.016 3.505 0.000 Sex -0.154 0.099 -3.099 0.002 Smoking -0.125 0.066 -2.485 0.013 HDL-C Alcohol consumption 0.204 0.022 5.502 0.000 Age 0.177 0.001 4.765 0.000 LDL-C Body mass index 0.219 0.012 5.812 0.000 Age 0.114 0.002 3.034 0.003 Alcohol consumption -0.080 0.042 -2.107 0.035 ApoAI Alcohol consumption 0.310 0.017 8.602 0.000 Age 0.167 0.001 4.639 0.000 ApoB Alcohol consumption 0.287 0.039 7.748 0.000 Body mass index -0.153 0.011 -4.138 0.000 ApoAI/ApoB Body mass index 0.207 0.004 5.463 0.000 Age 0.102 0.001 2.674 0.008 Sex 0.106 0.017 2.800 0.005 V825I in the ABCA1 gene may have an ethnic specificity.
X
ABCA1 p.Val825Ile 21247457:145:2070
status: NEW147 Conversely, several previous studies found that the V825I polymorphism in the ABCA1 gene was associated with increased serum HDL-C levels [26-29].
X
ABCA1 p.Val825Ile 21247457:147:52
status: NEW149 They thought that the lack of significant association in men for V825I was partly due to less-significant effects on HDL-C in men.
X
ABCA1 p.Val825Ile 21247457:149:65
status: NEW153 Li et al. [29] found that the V825I polymorphism may affect ApoAI levels in Han Chinese population, but the influence depended on the haplotype generated from V825I and R1587K.
X
ABCA1 p.Val825Ile 21247457:153:30
status: NEWX
ABCA1 p.Val825Ile 21247457:153:159
status: NEW155 In the current study, the association of V825I polymorphism and serum ApoAI levels, to some extent at least, was in agreement with a previous study in Han Chinese [29], but the influence on decreased serum HDL-C level in Han Chinese was reverse to that from Danish general population and European ancestry population [26-29].
X
ABCA1 p.Val825Ile 21247457:155:41
status: NEWX
ABCA1 p.Val825Ile 21247457:155:87
status: NEW156 However, several previous reports failed to find a significant association between the V825I polymorphism in the ABCA1 gene and serum HDL-C levels [30-33].
X
ABCA1 p.Val825Ile 21247457:156:87
status: NEW158 Tan et al. [31] reported that no obviously changes in serum lipid levels were observed in G or A allele carriers in Singapore CHD and CHD-free males (Chinese, Malays and Indian), but the V825I polymorphism clearly associated Table 4 Correlative factors for serum lipid parameters between the Bai Ku Yao and Han populations (Continued) Diastolic blood pressure 0.094 0.001 2.365 0.018 Han Chinese TC Age 0.254 0.002 6.807 0.000 Diastolic blood pressure 0.128 0.004 3.264 0.001 Weight 0.281 0.004 7.109 0.000 Sex 0.165 0.076 4.387 0.000 TG Weight 0.278 0.005 7.293 0.000 Alcohol consumption 0.078 0.060 2.033 0.043 HDL-C Age 0.260 0.001 7.014 0.000 Alcohol consumption 0.218 0.023 5.628 0.000 Sex 0.151 0.039 3.770 0.000 Weight -0.100 0.002 -2.606 0.009 Genotype -0.088 0.025 -2.444 0.015 LDL-C Age 0.249 0.002 6.620 0.000 Weight 0.196 0.005 3.524 0.000 Alcohol consumption -0.124 0.035 -3.299 0.001 ApoAI Age 0.307 0.001 8.091 0.000 Alcohol consumption 0.170 0.013 4.441 0.000 Sex 0.169 0.021 4.464 0.000 Diastolic blood pressure 0.085 0.001 2.231 0.026 Genotype -0.071 0.014 -1.988 0.047 ApoB Body mass index 0.261 0.003 6.957 0.000 Age 0.228 0.001 6.086 0.000 Diastolic blood pressure 0.106 0.001 2.732 0.006 ApoAI/ApoB Body mass index -0.167 0.007 -4.305 0.000 TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B. Table 5 Correlative factors for serum lipid parameters between males and females in both ethnic groups Lipid parameter Relative factor Standardized coefficient Standard error t P Bai Ku Yao Male TC Body mass index 0.268 0.023 5.036 0.000 Age 0.130 0.007 2.434 0.015 TG Body mass index 0.216 0.031 3.973 0.000 HDL-C Alcohol consumption 0.229 0.037 5.033 0.000 Age 0.275 0.002 4.286 0.000 Body mass index -0.116 0.011 -0.201 0.028 LDL-C Body mass index 0.261 0.021 4.854 0.000 ApoAI Alcohol consumption 0.313 0.028 5.887 0.000 Age 0.187 0.001 3.519 0.000 ApoB Body mass index 0.293 0.006 5.496 0.000 ApoAI/ApoB Alcohol consumption 0.272 0.068 4.983 0.000 Body mass index -0.188 0.022 -3.449 0.001 Female TC Body mass index 0.170 0.016 3.253 0.001 Age 0.148 0.003 2.824 0.005 TG Alcohol consumption 0.205 0.080 3.919 0.000 LDL-C Body mass index 0.168 0.013 3.209 0.001 Age 0.162 0.002 3.012 0.002 ApoAI Age 0.159 0.001 2.300 0.003 Body mass index 0.160 0.001 2.030 0.022 ApoB Systolic blood pressure 0.328 0.008 3.067 0.002 Body mass index 0.202 0.003 3.321 0.001 Weight 0.025 0.117 2.053 0.041 ApoAI/ApoB Diastolic blood pressure -0.155 0.003 -2.937 0.004 Han Chinese Male TC Weight 0.334 0.006 6.638 0.000 Age 0.228 0.003 4.424 0.000 Alcohol consumption 0.152 0.065 2.932 0.004 TG Weight 0.385 0.009 7.379 0.000 HDL-C Age 0.336 0.002 6.729 0.000 Alcohol consumption 0.309 0.031 6.148 0.000 Weight -0.016 0.003 -3.278 0.007 Genotype -0.131 0.035 -2.711 0.000 LDL-C Weight 0.287 0.004 5.389 0.000 Age 0.174 0.007 3.273 0.001 ApoAI Age 0.377 0.001 7.609 0.000 Alcohol consumption 0.278 0.017 5.622 0.000 Genotype -0.125 0.020 -2.599 0.010 ApoB Body mass index 0.295 0.004 5.718 0.000 Age 0.208 0.001 3.930 0.000 Smoking 0.124 0.014 2.422 0.016 Alcohol consumption 0.106 0.015 2.005 0.046 ApoAI/ApoB Age 0.118 0.020 2.100 0.037 Body mass index -0.172 0.011 -3.054 0.002 Female TC Age 0.278 0.007 5.317 0.000 Weight 0.210 0.006 4.075 0.000 Diastolic blood pressure 0.152 0.005 2.855 0.005 with CHD status in male Malays.
X
ABCA1 p.Val825Ile 21247457:158:187
status: NEW160 To our knowledge, the association of the V825I polymorphism and serum TC levels has not been described previously.
X
ABCA1 p.Val825Ile 21247457:160:41
status: NEW174 But the V825I polymorphism in the ABCA1 gene is found to be associated with male serum HDL-C and ApoAI levels in the Han, and serum TC levels in the Bai Ku Yao populations.
X
ABCA1 p.Val825Ile 21247457:174:8
status: NEW176 The difference in the association of V825I polymorphism and serum lipid levels between the two ethnic groups might partly result from different ABCA1 gene-enviromental interactions.
X
ABCA1 p.Val825Ile 21247457:176:37
status: NEW31 A common variant of V825I in the ABCA1 gene is a missense SNP in the exon 17 that locates in the middle part of the protein corresponding to sixth transmembrane a-helix with mutation of GTC&#ae;ATC.
X
ABCA1 p.Val825Ile 21247457:31:20
status: NEW40 Therefore, the aim of the present study was to detect the association of V825I polymorphism in the ABCA1 gene and several environmental factors with serum lipid phenotypes in the Guangxi Bai Ku Yao and Han populations.
X
ABCA1 p.Val825Ile 21247457:40:73
status: NEW106 Genotypic and allelic frequencies Table 2 gives the genotypic and allelic frequencies of V825I polymorphism in the ABCA1 gene.
X
ABCA1 p.Val825Ile 21247457:106:89
status: NEW110 The nucleotide sequence of V825I polymorphism The results were shown as GG, GA and AA genotypes by PCR-RFLP, the GG, GA and AA genotypes were also confirmed by sequencing (Figure 3); respectively.
X
ABCA1 p.Val825Ile 21247457:110:27
status: NEW118 Figure 2 Genotyping of V825I polymorphism in the ABCA1 gene.
X
ABCA1 p.Val825Ile 21247457:118:23
status: NEW131 Table 2 Genotypic and allelic frequencies of the ABCA1 V825I polymorphism between the Bai Ku Yao and Han populations [n (%)] Group n Genotype Allele GG GA AA G A Bai Ku Yao 677 228 (33.7) 321 (47.4) 128 (18.9) 777 (57.4) 577 (42.6) Han Chinese 646 216 (33.4) 314 (48.6) 116 (18.0) 746 (57.7) 546 (42.3) c2 - 0.265 0.034 P - 0.876 0.854 Bai Ku Yao Male 324 110 (34.0) 153 (47.2) 61 (18.8) 373 (57.6) 275 (42.4) Female 353 118 (33.4) 168 (47.6) 67 (19.0) 404 (57.2) 302 (42.8) c2 - 0.210 0.016 P - 0.990 0.900 Han Chinese Male 315 104 (33.0) 154 (48.9) 57 (18.1) 362 (57.5) 268 (42.5) Female 331 112 (33.8) 160 (48.3) 59 (17.8) 384 (58.0) 278 (42.0) c2 - 0.490 0.030 P - 0.976 0.863 Figure 3 A part of the nucleotide sequence of the ABCA1 V825I polymorphism.
X
ABCA1 p.Val825Ile 21247457:131:55
status: NEWX
ABCA1 p.Val825Ile 21247457:131:737
status: NEW141 These results indicate that the prevalence of the A allele variation of Table 3 Genotypic frequencies of the ABCA1 V825I polymorphism and serum lipid levels between the Bai Ku Yao and Han populations Genotype n TC (mmol/L) TG (mmol/L) HDL-C (mmol/L) LDL-C (mmol/L) ApoAI (g/L) ApoB (g/L) ApoAI/ApoB Bai Ku Yao GG 228 4.28 &#b1; 0.79 1.09 (0.80) 1.63 &#b1; 0.39 2.52 &#b1; 0.65 1.30 &#b1; 0.34 0.84 &#b1; 0.21 1.65 &#b1; 0.69 GA 321 4.26 &#b1; 0.82 0.96 (0.61) 1.64 &#b1; 0.41 2.52 &#b1; 0.68 1.28 &#b1; 0.29 0.83 &#b1; 0.22 1.64 &#b1; 0.63 AA 128 4.52 &#b1; 1.26 0.95 (0.61) 1.72 &#b1; 0.45 2.69 &#b1; 1.04 1.33 &#b1; 0.35 0.86 &#b1; 0.26 1.73 &#b1; 0.91 F - 3.839 4.621 2.073 2.358 1.460 0.663 0.862 P - 0.022 0.099 0.127 0.095 0.233 0.516 0.423 Male GG 110 4.29 &#b1; 0.80 1.25 (0.91) 1.65 &#b1; 045 2.43 &#b1; 0.68 1.36 &#b1; 0.39 0.82 &#b1; 0.21 1.81 &#b1; 0.86 GA 153 4.26 &#b1; 0.88 1.00 (0.66) 1.67 &#b1; 0.45 2.47 &#b1; 0.73 1.32 &#b1; 0.33 081 &#b1; 021 1.76 &#b1; 0.74 AA 61 4.53 &#b1; 1.62 1.02 (0.68) 1.74 &#b1; 0.56 2.63 &#b1; 1.33 1.40 &#b1; 0.44 0.83 &#b1; 0.30 1.96 &#b1; 1.19 F - 1.850 4.969 0.974 1.377 1.040 0.081 1.370 P - 0.159 0.083 0.379 0.254 0.355 0.922 0.256 Female GG 118 4.26 &#b1; 0.80 0.97(0.62) 1.60 &#b1; 0.33 2.59 &#b1; 0.62 1.25 &#b1; 0.26 0.87 &#b1; 0.20 1.50 &#b1; 0.44 GA 168 4.26 &#b1; 0.77 0.94(0.56) 1.62 &#b1; 0.36 2.57 &#b1; 0.63 1.24 &#b1; 0.25 0.85 &#b1; 0.22 1.53 &#b1; 0.47 AA 67 4.50 &#b1; 0.80 0.92(0.49) 1.69 &#b1; 0.31 2.73 &#b1; 0.68 1.27 &#b1; 0.22 0.89 &#b1; 0.20 1.51 &#b1; 0.45 F - 2.860 0.595 1.530 2.080 0.474 1.150 0.578 P - 0.059 0.743 0.220 0.126 0.623 0.320 0.560 Han Chinese GG 216 4.77 &#b1; 0.99 1.00 (0.57) 1.92 &#b1; 0.51 2.61 &#b1; 0.72 1.43 &#b1; 0.27 0.89 &#b1; 0.22 1.70 &#b1; 0.58 GA 314 4.71 &#b1; 1.06 1.01 (0.68) 1.90 &#b1; 0.48 2.62 &#b1; 0.81 1.42 &#b1; 0.28 0.89 &#b1; 0.24 1.69 &#b1; 0.57 AA 116 4.63 &#b1; 0.90 1.02 (0.70) 1.78 &#b1; 0.48 2.64 &#b1; 0.67 1.36 &#b1; 0.27 0.90 &#b1; 0.21 1.58 &#b1; 0.51 F - 0.600 0.682 3.797 0.190 3.650 0.220 1.930 P - 0.540 0.711 0.023 0.674 0.027 0.800 0.145 Male GG 104 4.77 &#b1; 1.03 1.01 (0.59) 1.89 &#b1; 0.55 2.62 &#b1; 0.73 1.42 &#b1; 0.30 0.90 &#b1; 0.23 1.69 &#b1; 0.68 GA 154 4.59 &#b1; 1.13 1.01 (0.64) 1.80 &#b1; 0.49 2.56 &#b1; 0.86 1.36 &#b1; 0.29 0.87 &#b1; 0.25 1.68 &#b1; 0.61 AA 57 4.50 &#b1; 1.04 1.03 (0.78) 1.71 &#b1; 0.49 2.58 &#b1; 0.72 1.32 &#b1; 0.30 0.88 &#b1; 0.22 1.61 &#b1; 0.59 F - 1.039 0.062 3.590 0.037 3.020 0.102 0.575 P - 0.355 0.970 0.029 0.964 0.049 0.903 0.564 Female GG 112 4.72 &#b1; 0.96 0.96 (0.56) 1.94 &#b1; 0.47 2.59 &#b1; 0.71 1.43 &#b1; 0.24 0.89 &#b1; 0.21 1.70 &#b1; 0.48 GA 160 4.83 &#b1; 0.97 1.02 (0.77) 1.99 &#b1; 0.45 2.68 &#b1; 0.75 1.43 &#b1; 0.26 0.91 &#b1; 0.22 1.72 &#b1; 0.53 AA 59 4.76 &#b1; 0.75 0.99(0.58) 1.85 &#b1; 0.47 2.70 &#b1; 0.63 1.39 &#b1; 0.23 0.93 &#b1; 0.20 1.55 &#b1; 0.42 F - 0.390 1.182 2.150 0.538 2.640 0.760 2.133 P - 0.677 0.554 0.118 0.585 0.073 0.469 0.120 TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B; ApoAI/ApoB, the ratio of apolipoprotein AI to apolipoprotein B.
X
ABCA1 p.Val825Ile 21247457:141:115
status: NEW144 Table 4 Correlative factors for serum lipid parameters between the Bai Ku Yao and Han populations Lipid parameter Relative factor Standardized coefficient Standard error t P Bai plus Han TC Body mass index 0.100 0.150 2.318 0.021 Age 0.194 0.002 7.234 0.000 Ethnic group -1.159 0.050 -6.200 0.001 Diastolic blood pressure 0.094 0.003 3.400 0.001 Weight 0.164 0.006 0.164 0.000 Sex 0.087 0.061 0.087 0.005 TG Weight 0.216 0.004 7.889 0.000 Alcohol consumption 0.114 0.042 4.168 0.000 HDL-C Age 0.211 0.001 8.214 0.000 Ethnic group -0.235 0.023 -9.336 0.000 Alcohol consumption 0.233 0.018 8.246 0.000 Sex 0.127 0.026 4.541 0.000 Body mass index -0.069 0.004 -2.689 0.007 LDL-C Body mass index 0.093 0.012 2.097 0.036 Age 0.188 0.001 6.975 0.000 Alcohol consumption -0.090 0.029 -3.092 0.002 Weight 0.209 0.004 4.412 0.000 Sex 0.084 0.051 2.491 0.013 ApoAI Age 0.221 0.001 8.308 0.000 Alcohol consumption 0.230 0.012 8.126 0.000 Ethnic group -0.171 0.015 -6.759 0.000 Diastolic blood pressure 0.061 0.001 2.272 0.023 Sex 0.057 0.017 2.021 0.044 ApoB Body mass index 0.237 0.002 8.922 0.000 Age 0.160 0.000 5.999 0.000 Ethnic group -0.087 0.012 -3.393 0.001 Diastolic blood pressure 0.105 0.001 3.784 0.000 Sex 0.081 0.012 3.098 0.002 ApoAI/ApoB Alcohol consumption 0.165 0.023 6.103 0.000 Body mass index -0.155 0.006 -5.722 0.000 Bai Ku Yao TC Body mass index 0.216 0.014 5.821 0.000 Age 0.139 0.002 3.730 0.000 Genotype 0.076 0.048 2.051 0.041 TG Alcohol consumption 0.197 0.068 4.194 0.000 Body mass index 0.133 0.016 3.505 0.000 Sex -0.154 0.099 -3.099 0.002 Smoking -0.125 0.066 -2.485 0.013 HDL-C Alcohol consumption 0.204 0.022 5.502 0.000 Age 0.177 0.001 4.765 0.000 LDL-C Body mass index 0.219 0.012 5.812 0.000 Age 0.114 0.002 3.034 0.003 Alcohol consumption -0.080 0.042 -2.107 0.035 ApoAI Alcohol consumption 0.310 0.017 8.602 0.000 Age 0.167 0.001 4.639 0.000 ApoB Alcohol consumption 0.287 0.039 7.748 0.000 Body mass index -0.153 0.011 -4.138 0.000 ApoAI/ApoB Body mass index 0.207 0.004 5.463 0.000 Age 0.102 0.001 2.674 0.008 Sex 0.106 0.017 2.800 0.005 V825I in the ABCA1 gene may have an ethnic specificity.
X
ABCA1 p.Val825Ile 21247457:144:2070
status: NEW146 Conversely, several previous studies found that the V825I polymorphism in the ABCA1 gene was associated with increased serum HDL-C levels [26-29].
X
ABCA1 p.Val825Ile 21247457:146:52
status: NEW148 They thought that the lack of significant association in men for V825I was partly due to less-significant effects on HDL-C in men.
X
ABCA1 p.Val825Ile 21247457:148:65
status: NEW152 Li et al. [29] found that the V825I polymorphism may affect ApoAI levels in Han Chinese population, but the influence depended on the haplotype generated from V825I and R1587K.
X
ABCA1 p.Val825Ile 21247457:152:30
status: NEWX
ABCA1 p.Val825Ile 21247457:152:159
status: NEW154 In the current study, the association of V825I polymorphism and serum ApoAI levels, to some extent at least, was in agreement with a previous study in Han Chinese [29], but the influence on decreased serum HDL-C level in Han Chinese was reverse to that from Danish general population and European ancestry population [26-29].
X
ABCA1 p.Val825Ile 21247457:154:41
status: NEW157 Tan et al. [31] reported that no obviously changes in serum lipid levels were observed in G or A allele carriers in Singapore CHD and CHD-free males (Chinese, Malays and Indian), but the V825I polymorphism clearly associated Table 4 Correlative factors for serum lipid parameters between the Bai Ku Yao and Han populations (Continued) Diastolic blood pressure 0.094 0.001 2.365 0.018 Han Chinese TC Age 0.254 0.002 6.807 0.000 Diastolic blood pressure 0.128 0.004 3.264 0.001 Weight 0.281 0.004 7.109 0.000 Sex 0.165 0.076 4.387 0.000 TG Weight 0.278 0.005 7.293 0.000 Alcohol consumption 0.078 0.060 2.033 0.043 HDL-C Age 0.260 0.001 7.014 0.000 Alcohol consumption 0.218 0.023 5.628 0.000 Sex 0.151 0.039 3.770 0.000 Weight -0.100 0.002 -2.606 0.009 Genotype -0.088 0.025 -2.444 0.015 LDL-C Age 0.249 0.002 6.620 0.000 Weight 0.196 0.005 3.524 0.000 Alcohol consumption -0.124 0.035 -3.299 0.001 ApoAI Age 0.307 0.001 8.091 0.000 Alcohol consumption 0.170 0.013 4.441 0.000 Sex 0.169 0.021 4.464 0.000 Diastolic blood pressure 0.085 0.001 2.231 0.026 Genotype -0.071 0.014 -1.988 0.047 ApoB Body mass index 0.261 0.003 6.957 0.000 Age 0.228 0.001 6.086 0.000 Diastolic blood pressure 0.106 0.001 2.732 0.006 ApoAI/ApoB Body mass index -0.167 0.007 -4.305 0.000 TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B.
X
ABCA1 p.Val825Ile 21247457:157:187
status: NEW
PMID: 20800056
[PubMed]
Berge KE et al: "Mutations in APOA-I and ABCA1 in Norwegians with low levels of HDL cholesterol."
No.
Sentence
Comment
59
of patients (het/hom)a Mutation Nucleotide Exon/Intron (i) PolyPhen prediction (score) SNP rs ID, ref.# ABCA1 Missense 8/3 R219K c.656, GNA 7 Benign (0.489) rs2230806 0/1 R282Q c.845, GNA 9 Benign (0.592) Novel 1/0 V399A c.1196, TNC 11 Benign (0.040) rs9282543 1/0 M636V c.1906, ANG 15 Benign (0.418) Novel 3/0 V771M c.2311, GNA 16 Benign (0.931) rs2066718 2/0 V825I c.2473, GNA 17 Benign (0.440) rs2066715 3/1 I883M c.2649, ANG 18 Benign (0.147) rs2066714 1/0 C887F c.2660, GNT 19 Benign (0.888) Novel 3/0 E1172D c.3516, GNC 24 Benign (0.546) rs33918808 1/0 G1216V c.3647, GNT 25 Prob damb (2.154) Ref. [18] 1/0 L1244Q c.3731, TNA 25 Prob dam (2.269) Novel 1/0 C1477F c.4430, TNA 31 Prob dam (3.688) Ref. [17] 14/1 R1587K c.4760, ANT 35 Benign (0.284) rs2230808 1/0 V1674I c.5020, GNA 37 Benign (0.821) Novel 1/0 R1680Q c.5039, GNA 37 Poss damc (1.926) Ref. [17] 1/0 N1800H c.5398, ANC 40 Poss dam (1.845) Ref. [19] Nonsense/splice 1/0 IVS4+1, GNA c.302+1, GNA i4 - 1/0 C1429X c.4287, CNA 31 - 1/0 IVS32+1, GNA c.4559+1, GNA i32 - APOA-I 7/0 R160L c.551, GNT 4 Prob dam (2.491) Ref. [21] 1/0 del182K del c.616-618 AAG 4 - Novel a Het: heterozygote, hom: homozygote.
X
ABCA1 p.Val825Ile 20800056:59:361
status: NEW78 Variants R219K, V399A, V771M, V825I, I883M, E1172D, and R1587K have been reported as single nucleotide polymorphisms (SNPs) (Table 1).
X
ABCA1 p.Val825Ile 20800056:78:30
status: NEW80 In addition, R219K, V771M, V825I, I883M, E1172D, and R1587K have been found in similar frequencies in patients with low or high HDL cholesterol levels [18], indicating that these variants do not cause low HDL cholesterol levels.
X
ABCA1 p.Val825Ile 20800056:80:27
status: NEW
PMID: 21130966
[PubMed]
Rejeb J et al: "Associations between common polymorphisms of adenosine triphosphate-binding cassette transporter A1 and coronary artery disease in a Tunisian population."
No.
Sentence
Comment
68
The genotypes for each ABCA1 polymorphism (G1051A [R219K], G2706A [V771M], G2868A [V825I] and -565C/T [-477C/T]) were determined by polymerase chain reaction-restriction fragment length polymorphism analysis.
X
ABCA1 p.Val825Ile 21130966:68:83
status: NEW
PMID: 18621447
[PubMed]
Wang N et al: "The R219K polymorphism in the ATP-binding cassette transporter 1 gene has a protective effect on atherothrombotic cerebral infarction in Chinese Han ethnic population."
No.
Sentence
Comment
0
Neurobiology of Aging 31 (2010) 647-653 The R219K polymorphism in the ATP-binding cassette transporter 1 gene has a protective effect on atherothrombotic cerebral infarction in Chinese Han ethnic population Ning Wanga, Xie-Hua Xuea, Yi Lina, Ling Fanga, Shenxing Muronga, Zhi-Ying Wua,b,* a Department of Neurology and Institute of Neurology, First Affiliated Hospital, Center of Neuroscience, Fujian Medical University, 20 Chazhong Road, Fuzhou 350005, China b Department of Neurology and Institute of Neurology, Huashan Hospital, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Shanghai Medical College, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China Received 30 November 2007; received in revised form 29 April 2008; accepted 28 May 2008 Available online 14 July 2008 Abstract The association of R219K and V825I polymorphisms of ABCA1 gene with cerebral infarction has been rarely reported.
X
ABCA1 p.Val825Ile 18621447:0:858
status: NEW3 Genotyping of R219K and V825I were performed by PCR-RFLP analysis.
X
ABCA1 p.Val825Ile 18621447:3:24
status: NEW9 In addition, though there is no association of V825I with ACI, this polymorphism may have certain synergistic effect with hypertension in susceptibility to ACI.
X
ABCA1 p.Val825Ile 18621447:9:47
status: NEW11 Keywords: Cerebral infarction; ATP-binding cassette transporter 1; R219K; V825I 1.
X
ABCA1 p.Val825Ile 18621447:11:74
status: NEW19 The more common SNPs are R219K in exon 7 and V825I in exon 17.
X
ABCA1 p.Val825Ile 18621447:19:45
status: NEW26 Taken together, these controversial findings indicate that the function of R219K and V825I may be significant in certain environmental factors and population backgrounds.
X
ABCA1 p.Val825Ile 18621447:26:85
status: NEW27 Although the association of R219K and/or V825I with CAD has been widely reported in different ethnic populations, the association of them with cerebral infarction has been reported rarely (Andrikovics et al., 2006; Pasdar et al., 2007).
X
ABCA1 p.Val825Ile 18621447:27:41
status: NEW30 The aim of this study is to investigate the association of R219K and V825I with cerebral infarction and levels of plasma lipids in the Han ethnic group in Chinese population.
X
ABCA1 p.Val825Ile 18621447:30:69
status: NEW55 Genotyping of R219K and V825I Genotyping of R219K (primers: 5 -AAAGACTTCAA- GGACCCAG-3 and 5 -ACAAAGTCATGCTGTCCAAG- 3 ) and V825I (primers: 5 -GAGACTGACCAGGAAATGG- 3 and 5 -ATGCACTGCAGAGATTCTAG-3 ) was performed by PCR-RFLP analysis.
X
ABCA1 p.Val825Ile 18621447:55:24
status: NEWX
ABCA1 p.Val825Ile 18621447:55:124
status: NEW56 PCR product was digested with EcoNI for R219K and BsaI for V825I according to the manufacturer`s recommendations (New England Biolabs, Beverly, MA, USA), then followed by a 2.5% agarose gel electrophoresis.
X
ABCA1 p.Val825Ile 18621447:56:59
status: NEW58 Statistical analysis A chi-square analysis was performed to determine the Hardy-Weinberg equilibrium of R219K and V825I in the groups.
X
ABCA1 p.Val825Ile 18621447:58:114
status: NEW60 The influence of R219K and V825I on plasma lipids were evaluated using analysis of variance with genotype as group variable and total cholesterol, triglycerides, HDL-C, LDL-C, ApoA1 and ApoB as dependent variables.
X
ABCA1 p.Val825Ile 18621447:60:27
status: NEW63 * P < 0.05 Table 2 Genotype and allele frequency distributions of R219K and V825I R219K V825I Control ACI LI Control ACI LI All n = 152 (%) n = 193 (%) n = 131 (%) n = 152 (%) n = 193 (%) n = 131 (%) RR 41 (26.97) 75 (38.86) 32 (24.43) VV 41 (26.97) 45 (23.32) 39 (29.77) RK 77 (50.66) 96 (49.74) 76 (58.01) VI 76 (50.00) 110 (57.00) 71 (54.20) KK 34 (22.37) 22 (11.40)* 23 (17.56) II 35 (23.03) 38 (19.69) 21 (16.03) R frequency 52.3 63.73 53.43 V frequency 51.97 51.81 56.87 K frequency 47.7 36.27** 46.57 I frequency 48.03 48.19 43.13 Male n = 97 (%) n = 136 (%) n = 81 (%) n = 97 (%) n = 136 (%) n = 81 (%) RR 28 (28.86) 51 (37.50) 22 (27.16) VV 28 (28.86) 31 (22.80) 20 (24.69) RK 41 (42.28) 71 (52.21) 44 (54.32) VI 42 (43.30) 76 (55.88) 49 (60.49) KK 28 (28.86) 14 (10.29)** 15 (18.52) II 27 (27.84) 29 (21.32) 12 (14.82) R frequency 50 63.6 54.32 V frequency 50.52 50.09 54.94 K frequency 50 36.40** 45.68 I frequency 49.48 49.24 45.06 Female n = 55 (%) n = 57 (%) n = 50 (%) n = 55 (%) n = 57 (%) n = 50 (%) RR 13 (23.64) 24 (42.11) 10 (20.00) VV 13 (23.64) 14 (24.56) 19 (38.00) RK 36 (65.45) 25 (43.86) 32 (64.00) VI 34 (61.82) 34 (59.65) 22 (44.00) KK 6 (10.91) 8 (14.03) 8 (16.00) II 8 (15.54) 9 (15.79) 9 (18.00) R frequency 56.36 64.04 52 V frequency 54.55 54.39 60 K frequency 43.64 35.97 48 I frequency 45.45 45.61 40 <60 years n = 78 (%) n = 56 (%) n = 37 (%) n = 78 (%) n = 56 (%) n = 37 (%) RR 24 (30.77) 23 (41.07) 15 (40.54) VV 20 (25.64) 14 (25.00) 10 (22.73) RK 41 (52.56) 25 (44.64) 17 (45.95) VI 37 (47.44) 32 (57.14) 21 (47.73) KK 13 (16.67) 8 (14.29) 5 (13.51) II 21 (26.92) 10 (17.86) 6 (13.64) R frequency 57.05 63.39 63.51 V frequency 49.36 53.57 55.41 K frequency 42.95 36.61 36.49 I frequency 50.64 46.43 45.59 ≥60 years n = 74 (%) n = 137 (%) n = 94 (%) n = 74 (%) n = 137 (%) n = 94 (%) RR 17 (22.97) 52 (37.96) 20 (21.28) VV 21 (28.39) 31 (22.63) 29 (30.85) RK 36 (48.65) 71 (51.82) 56 (59.57) VI 39 (52.70) 78 (56.93) 50 (53.19) KK 21 (28.39) 14 (10.22)* 18 (19.15) II 14 (18.91) 28 (20.44) 15 (15.96) R frequency 46.30 63.87 51.06 V frequency 54.73 51.09 57.45 K frequency 52.70 36.13* 48.94 I frequency 45.27 48.91 42.55 ACI, atherothrombotic cerebral infarction; LI, lacunar infarction; *P < 0.01, **P < 0.005. culated.
X
ABCA1 p.Val825Ile 18621447:63:76
status: NEWX
ABCA1 p.Val825Ile 18621447:63:88
status: NEW75 Genotype and allele frequency distributions R219K and V825I were in Hardy-Weinberg equilibrium in the ACI, LI and control groups (P > 0.05, see Supplemental data).
X
ABCA1 p.Val825Ile 18621447:75:54
status: NEW84 In addition, V825I was not associated with absence/presence of ACI or LI.
X
ABCA1 p.Val825Ile 18621447:84:13
status: NEW89 The interaction between R219K/V825I and risk factors was showed in Table 5.
X
ABCA1 p.Val825Ile 18621447:89:30
status: NEW91 * P < 0.05 Table 5 The interaction among R219K, V825I and risk factors Genotypes and RF P OR 95% CI KK and hypertension Reference RK and hypertension* 0.002 3.09 1.54-6.19 RR and hypertension* 0.001 4.81 1.94-11.94 KK and DM2 Reference RK and DM2 0.108 2.822 0.79-10.01 RR and DM2 0.99 0.00 0.00 II and hypertension Reference VI and hypertension* 0.001 3.91 1.93-7.93 VV and hypertension* 0.04 2.42 1.04-5.62 II and DM2 Reference VI and DM2 0.105 2.33 0.64-9.91 VV and DM2 0.406 1.963 0.400-9.648 KK and II Reference RR and VI* 0.003 2.69 1.39-5.22 RR and VV 0.52 1.36 0.53-3.45 RK and VI 0.56 1.17 0.69-1.99 RK and VV 0.56 1.23 0.61-2.49 DM2, diabetes mellitus type 2; RF, risk factor.
X
ABCA1 p.Val825Ile 18621447:91:51
status: NEW94 There was no interaction between R219K/V825I and diabetes mellitus 2 (DM2).
X
ABCA1 p.Val825Ile 18621447:94:39
status: NEW97 This result further confirms that there is no association between V825I and ACI.
X
ABCA1 p.Val825Ile 18621447:97:66
status: NEW107 In addition, there was no association between V825I and lipids levels.
X
ABCA1 p.Val825Ile 18621447:107:46
status: NEW108 Table 6 Association of R219K and V825I with plasma lipid levels Lipid All Male Female RR n = 148 RK n = 249 KK n = 79 RR n = 101 RK + KK n = 213 RR n = 47 RK + KK n = 115 BMI (kg/m2) 23.35 ± 2.76 23.60 ± 2.46 23.62 ± 2.42 23.34 ± 2.94 23.65 ± 2.26 Hypertension (%) 43.24 46.18 37.97 43.56 45.07 42.55 42.61 DM2 (%) 11.49 12.05 13.92 9.9 13.15 14.89 11.3 Smoking (%) 8.78 6.43 7.6 12.87 9.39 0 1.74 Alcohol (%) 4.05 3.21 3.80 3.96 4.23 4.26 1.74 TC 4.79 ± 0.95 4.85 ± 1.07 4.88 ± 0.93 4.74 ± 0.87 4.68 ± 0.94 4.90 ± 1.12 5.23 ± 1.11 TG 1.78 ± 0.96 1.74 ± 0.98 1.53 ± 0.61* 1.79 ± 1.05 1.67 ± 0.97 1.75 ± 0.68 1.70 ± 0.99 HDL-C 1.07 ± 0.29 1.11 ± 0.30 1.12 ± 0.31 1.07 ± 0.29 1.05 ± 0.29 1.05 ± 0.03 1.22 ± 0.29**** LDL-C 3.03 ± 0.87 3.03 ± 0.92 2.98 ± 0.77 2.98 ± 0.79 2.86 ± 0.79 3.16 ± 1.04 3.32 ± 0.98 ApoA1 1.12 ± 0.24 1.18 ± 0.22** 1.22 ± 0.24*** 1.13 ± 0.24 1.14 ± 023 1.10 ± 0.25 1.28 ± 0.19**** ApoB 1.02 ± 0.28 1.06 ± 0.29 1.02 ± 0.24 1.00 ± 0.25 1.02 ± 0.28 1.05 ± 0.33 1.10 ± 0.27 Lipids VV n = 125 VI n = 257 II n = 94 VV + VI n = 246 II n = 68 VV + VI n = 136 II n = 26 BMI (kg/m2) 24.50 ± 2.75 23.17 ± 2.36 23.24 ± 2.47 23.59 ± 2.49 23.43 ± 2.47 23.62 ± 2.77 22.01 ± 2.60 Hypertension (%) 44.80 44.36 41.49 44.71 39.71 44.12 46.15 DM2 (%) 12.8 10.9 14.89 11.79 14.71 11.03 15.38 Smoking (%) 7.20 7.78 6.38 9.76 8.82 3.68 0 Alcohol (%) 2.40 3.89 4.26 2.44 4.41 2.21 3.84 TC 4.82 ± 0.99 4.91 ± 0.99 4.66 ± 1.06 4.72 ± 0.89 4.62 ± 0.99 5.17 ± 1.09 4.83 ± 1.36 TG 1.67 ± 0.92 1.70 ± 0.96 1.75 ± 0.91 1.71 ± 1.01 1.73 ± 0.95 1.7 ± 0.93 1.84 ± 0.76 HDL-C 1.12 ± 0.29 1.1 ± 0.30 1.05 ± 0.33 1.06 ± 0.28 1.05 ± 0.34 1.19 ± 0.30 1.04 ± 0.30 LDL-C 3.04 ± 0.92 3.06 ± 0.82 2.86 ± 0.96 2.95 ± 0.77 2.75 ± 0.85 3.27 ± 0.97 3.38 ± 1.26 ApoA1 1.19 ± 0.22 1.17 ± 0.23 1.12 ± 0.26 1.14 ± 0.23 1.12 ± 0.25 1.24 ± 0.21 1.14 ± 0.31 ApoB 1.04 ± 0.30 1.06 ± 0.26 1.01 ± 0.32 1.03 ± 0.26 0.97 ± 0.31 1.09 ± 0.28 1.11 ± 0.34 *P = 0.06, **P = 0.046, ***P = 0.03, ****P = 0.01.
X
ABCA1 p.Val825Ile 18621447:108:33
status: NEW112 V825I is located in the middle part of the protein corresponding to the sixth transmembrane ␣-helix.
X
ABCA1 p.Val825Ile 18621447:112:0
status: NEW132 This result is consistent with that of Andrikovics et al. but contrary to that of Pasdar et al. The data about the association of V825I with lipids levels are controversial.
X
ABCA1 p.Val825Ile 18621447:132:74
status: NEWX
ABCA1 p.Val825Ile 18621447:132:130
status: NEW133 Both Clee et al. and Tan et al. reported that there was no association of V825I with lipids levels (Clee et al., 2001; Tan et al., 2003).
X
ABCA1 p.Val825Ile 18621447:133:74
status: NEW135 However, our results did not exhibit any association of V825I with lipids levels and cerebral infarction.
X
ABCA1 p.Val825Ile 18621447:135:39
status: NEWX
ABCA1 p.Val825Ile 18621447:135:56
status: NEW136 This may be due to the substitution of V825I is conservative and the polymorphism may only exert minimal influence on cholesterol efflux activity (Tan et al., 2003).
X
ABCA1 p.Val825Ile 18621447:136:39
status: NEWX
ABCA1 p.Val825Ile 18621447:136:74
status: NEW137 There was few report associated with the synergistic effects among R219K, V825I and risk factors.
X
ABCA1 p.Val825Ile 18621447:137:74
status: NEW141 Although there is no association of V825I with ACI, this polymorphism may have certain synergistic effect with hypertension in susceptibility to ACI.
X
ABCA1 p.Val825Ile 18621447:141:36
status: NEW131 This result is consistent with that of Andrikovics et al. but contrary to that of Pasdar et al. The data about the association of V825I with lipids levels are controversial.
X
ABCA1 p.Val825Ile 18621447:131:130
status: NEW134 However, our results did not exhibit any association of V825I with lipids levels and cerebral infarction.
X
ABCA1 p.Val825Ile 18621447:134:56
status: NEW140 Although there is no association of V825I with ACI, this polymorphism may have certain synergistic effect with hypertension in susceptibility to ACI.
X
ABCA1 p.Val825Ile 18621447:140:36
status: NEW
PMID: 19596329
[PubMed]
Frikke-Schmidt R et al: "Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population."
No.
Sentence
Comment
2387
Common ABCA1 variants in the general population 5.1. Frequency of common variants in the extreme tails of the HDL distribution Several resequencing studies have identified a number of common non-synonymous variations in ABCA1 [57,58,81-84]: R219K, V771M, V825I, I883M, E1172D and R1587K.
X
ABCA1 p.Val825Ile 19596329:2387:255
status: NEW2389 In the largest resequencing study to date of Caucasians in the general population, two of the non-synonymous SNPs (V771M and R1587K) and/or their haplotypes differed in frequency between the population extremes of HDL cholesterol levels [52,57].
X
ABCA1 p.Val825Ile 19596329:2389:26
status: NEW2390 Further, the frequency of V825I differed when women were considered separately.
X
ABCA1 p.Val825Ile 19596329:2390:26
status: NEW2395 Frequencies of common variants and association with variation in lipid levels in the general population Frequencies for the most common non-synonymous ABCA1 SNPs (R219K, V825I, I883M, R1587K) are largely similar across studies that partly or as a whole represent general populations [57,58,81,82,86-88], whereas the less common SNPs (V771M, and E1172D) are reported in some [57,58,81,82,86,88], but not in all studies [58,87].
X
ABCA1 p.Val825Ile 19596329:2395:170
status: NEW2398 The V771M and V825I SNPs were associated with increases in HDL cholesterol in women, whereas the R1587K SNP was associated with decreased HDL cholesterol levels in both genders.
X
ABCA1 p.Val825Ile 19596329:2398:14
status: NEWX
ABCA1 p.Val825Ile 19596329:2398:84
status: NEW2399 This corresponded well with the findings from the initial screening where V771M and V825I (in women) were overrepresented in the high extreme, and R1587K was overrepresented in the low extreme of HDL cholesterol [57].
X
ABCA1 p.Val825Ile 19596329:2399:84
status: NEW2402 The HDL cholesterol and/or apoAI lowering effect of the rare allele of the very common R1587K SNP has now been observed in several different studies [57,81,82], whereas the HDL cholesterol increasing effect of the V771M and V825I/I883M SNPs appears to be confined to specific genders in different populations [57,58,87-89].
X
ABCA1 p.Val825Ile 19596329:2402:224
status: NEW2404 The isolated single site analysis by Frikke-Schmidt et al. revealed that the V825I, and not the I883M SNP, was responsible for the HDL increments [57].
X
ABCA1 p.Val825Ile 19596329:2404:77
status: NEW2386 Common ABCA1 variants in the general population 5.1. Frequency of common variants in the extreme tails of the HDL distribution Several resequencing studies have identified a number of common non-synonymous variations in ABCA1 [57,58,81-84]: R219K, V771M, V825I, I883M, E1172D and R1587K.
X
ABCA1 p.Val825Ile 19596329:2386:255
status: NEW2394 Frequencies of common variants and association with variation in lipid levels in the general population Frequencies for the most common non-synonymous ABCA1 SNPs (R219K, V825I, I883M, R1587K) are largely similar across studies that partly or as a whole represent general populations [57,58,81,82,86-88], whereas the less common SNPs (V771M, and E1172D) are reported in some [57,58,81,82,86,88], but not in all studies [58,87].
X
ABCA1 p.Val825Ile 19596329:2394:170
status: NEW2397 The V771M and V825I SNPs were associated with increases in HDL cholesterol in women, whereas the R1587K SNP was associated with decreased HDL cholesterol levels in both genders.
X
ABCA1 p.Val825Ile 19596329:2397:14
status: NEW2401 The HDL cholesterol and/or apoAI lowering effect of the rare allele of the very common R1587K SNP has now been observed in several different studies [57,81,82], whereas the HDL cholesterol increasing effect of the V771M and V825I/I883M SNPs appears to be confined to specific genders in different populations [57,58,87-89].
X
ABCA1 p.Val825Ile 19596329:2401:224
status: NEW2403 The isolated single site analysis by Frikke-Schmidt et al. revealed that the V825I, and not the I883M SNP, was responsible for the HDL increments [57].
X
ABCA1 p.Val825Ile 19596329:2403:77
status: NEW
PMID: 18706283
[PubMed]
Iatan I et al: "Effect of ABCA1 mutations on risk for myocardial infarction."
No.
Sentence
Comment
112
Additional insights into the effects of ABCA1 on MI have recently been described by Frikke-Schmidt et al. [35•] in a study where six nonsynonymous ABCA1 SNPs, R219K, V771M, V825I, I883M, E1172D, and R1587K (identified by resequencing ABCA1 in 190 individuals of Danish ancestry [24]), were genotyped in 9259 individuals from the Copenhagen City Heart Study to assess their risk of CHD (Table 2).
X
ABCA1 p.Val825Ile 18706283:112:180
status: NEW113 The principal finding of the study indicated that common genetic variation in ABCA1 predicts risk of CHD in the general population, but that their association was independent of plasma HDL-C levels: SNPs predicting increased MI risk were associated with either increases (V771 and V825I) or decreases (R1587K) in HDL-C, or no effect on HDL-C (R219K, I883M, E1172D).
X
ABCA1 p.Val825Ile 18706283:113:281
status: NEW135 Genetic variation in ABCA1 and risk of myocardial infarction Study* / year Population screened HDL-C, mmol/L ABCA1 variants Conclusions Evans and Beil [41] / 2003 Patients attending a lipid outpatient clinic ( n = 813) R219K genotype: R219K † The K219 allele was signifi cantly protective against CHD in patients with hyperlipidemia and elevated Lp(a), as well as decreasing TG levels RR: 1.32 ± 0.03 RK: 1.34 ± 0.03 KK: 1.27 ± 0.31 Harada et al. [29] / 2003 Japanese patients ( n = 410) I883M genotype: I883M, R219K The I883M polymorphism was signifi cantly associated with higher HDL-C in Japanese patients, but not with CHD II: 1.16 ± 0.30 IM: 1.26 ± 0.42 MM: 1.27 ± 0.37; P = 0.05 R219K genotype: RR: 1.26 ± 0.41 RK: 1.25 ± 0.40 KK: 1.24 ± 0.35 Tan et al. [42] / 2003 Cases: Chinese ( n = 512), Malay ( n = 110), and Indian ( n = 164) men with established CHD Chinese: CAD: 0.89 ± 0.28, Ctl: 1.19 ± 0.32; P < 0.0005 C-14T, 237indelG, V825I † , M883I † , A8994G The V825I and M883I polymorphisms are positive markers for the CHD phenotype in Malays, but with no effect on HDL-C Malays: CAD: 0.83 ± 0.27, Ctl: 1.15 ± 0.27; P < 0.0005 Controls: Chinese ( n = 271), Malay ( n = 179), and Indian ( n = 231) men Indians: CAD: 0.79 ± 0.24, Ctl: 1.00 ± 0.26; P < 0.0005 Tregouet et al. [31] / 2004 Subgroup of ECTIM cohort ( n = 452 cases and n = 465 controls) NA C-564T, R219K † , R1587K ABCA1 polymorphisms, but not haplotypes, are involved in variability of apoA-I and the susceptibility to CHD.
X
ABCA1 p.Val825Ile 18706283:135:1000
status: NEWX
ABCA1 p.Val825Ile 18706283:135:1045
status: NEW155 Genetic variation in ABCA1 and risk of myocardial infarction Study* / year Population screened HDL-C, mmol/L ABCA1 variants Conclusions Frikke-Schmidt et al. [35••] / 2008 Copenhagen City Heart Study: Women: R219K, V771M † , V825I † , I883M † , E1172D † , R1587K † Common genetic variation at the ABCA1 locus predicts IHD risk independently of plasma HDL-C levels.
X
ABCA1 p.Val825Ile 18706283:155:246
status: NEW
PMID: 18199144
[PubMed]
Slatter TL et al: "Novel rare mutations and promoter haplotypes in ABCA1 contribute to low-HDL-C levels."
No.
Sentence
Comment
9
The R1587K SNP was over-represented in low-HDL individuals, and the V825I and I883M SNPs over-represented in high-HDL individuals.
X
ABCA1 p.Val825Ile 18199144:9:68
status: NEW20 The C-14T promoter SNP (17), and the R1587K coding SNP (9) have been associated with low HDL-C, while the V771M (9), V825I (9, 10) and I883M (10, 18) coding SNPs have been associated with elevated HDL-C.
X
ABCA1 p.Val825Ile 18199144:20:117
status: NEW41 Genotyping of ABCA1 SNPs by RFLP Fourteen SNPs including five promoter SNPs (C-564T, G-407C, G-278C, G-99C, and C-14T), one 5#-UTR SNP [-76(-75) insG], six non-synonymous coding SNPs (R219K, V771M, V825I, I883M, E1172D, and R1587K) and two 3#-UTR SNPs [A-960G -383(-381)delGTT] were genotyped in the low-, mid-, and high-HDL-C groups by restriction fragment length polymorphism (RFLP) analysis.
X
ABCA1 p.Val825Ile 18199144:41:198
status: NEW55 Six of the non-synonymous variants were previously reported SNPs (R219K, V771M, V825I, I883M, E1172D and R1587K).
X
ABCA1 p.Val825Ile 18199144:55:80
status: NEW64 Two SNPs (V825I and I883M) were significantly over-represented in the high-HDL group [p ¼ 0.031 for I825 and p ¼ 0.030 for M883 (high vs low HDL-C)].
X
ABCA1 p.Val825Ile 18199144:64:10
status: NEW98 Our study also identified two ABCA1 SNPs (V825I and I883M) that were over-represented in high-HDL individuals.
X
ABCA1 p.Val825Ile 18199144:98:42
status: NEW105 a Coding haplotypes were derived from the following six non-synonymous SNPs (left to right): R219K (G.A), V771M (G.A), V825I (G.A), I883M (A.G), E1172D (G.C), and R1587K (G.A).
X
ABCA1 p.Val825Ile 18199144:105:119
status: NEW
PMID: 17951323
[PubMed]
Frikke-Schmidt R et al: "Genetic variation in ABCA1 predicts ischemic heart disease in the general population."
No.
Sentence
Comment
7
Two SNPs (V771M and V825I) were previously associated with increases in HDL-C, 1 (R1587K) with decreased HDL-C, whereas 3 (R219K, I883M and E1172D) did not affect HDL-C levels.
X
ABCA1 p.Val825Ile 17951323:7:20
status: NEW8 Despite this, 5 out of 6 SNPs (V771M, V825I, I883M, E1172D, R1587K) predicted increased risk of IHD.
X
ABCA1 p.Val825Ile 17951323:8:38
status: NEW10 A stepwise regression approach identified V771M, I883M, and E1172D as the most important predictors of IHD and additive effects on IHD risk were present for V771M/I883M and I883M/E1172D pairs.
X
ABCA1 p.Val825Ile 17951323:10:145
status: NEW16 In the present study we included 9259 individuals from the 1991 to 1994 examination, whom we genotyped for all nonsynonymous SNPs (R219K, V771M, V825I, I883M, E1172D, R1587K) identified by resequencing ABCA1 in 190 individuals of Danish ancestry.8 Information on diagnosis of IHD (nϭ1170; World Health Organization; International Classification of Diseases, 8th edition: codes 410 to 414; 10th edition: codes I20-I25) was collected and verified until 31st December 2000 by reviewing all hospital admissions and diagnoses entered in the national Danish Patient Registry, all causes of death entered in the national Danish Causes of Death Registry, and medical records from hospitals and general practitioners.
X
ABCA1 p.Val825Ile 17951323:16:145
status: NEW29 The cohort was participants in The Copenhagen City Heart Study who attended the 1991 to 1994 examination, and for whom combined genotypes for all 6 nonsynonymous SNPs (R219K, V771M, V825I, I883M, E1172D, R1587K) were available as well as all clinical and biochemical data (nϭ9028 out of nϭ9259; Table 1).
X
ABCA1 p.Val825Ile 17951323:29:182
status: NEW38 SNP Genotyping The ABI PRISM 7900HT Sequence Detection System (Applied Biosystem Inc) was used to genotype for all 6 nonsynonymous SNPs (R219K, V771M, V825I, I883M, E1172D, R1587K) identified by resequencing ABCA1 in 190 individuals, as previously described.8 Biochemical Analyses Colorimetric and turbidimetric assays (Hitachi autoanalyzer) were used to measure plasma levels of total cholesterol, HDL-C, triglycerides, and apolipoproteins B and -AI (all Boehringer Mannheim GmbH).
X
ABCA1 p.Val825Ile 17951323:38:151
status: NEW55 Frikke-Schmidt et al ABCA1 and Ischemic Heart Disease 181 the entire ABCA1 gene in 190 individuals of Danish descent were: 0.26 (R219K), 0.03 (V771M), 0.03 (E1172D), 0.06 (V825I), 0.12 (I883M), and 0.24 (R1587K).8 Similar allele frequencies have been reported for other White populations.14 Please see Data Supplements, Expanded Results for description of Hardy-Weinberg equilibrium.
X
ABCA1 p.Val825Ile 17951323:55:128
status: NEWX
ABCA1 p.Val825Ile 17951323:55:173
status: NEW57 A strong positive DЈ was present for R219K/V771M, M825I/I883M, and E1172D/ R1587K (DЈϾ0.9), whereas a strong negative DЈ was present for R219K/V825I, V771M/V825I, and V771M/I883M (DЈϽ-0.9).
X
ABCA1 p.Val825Ile 17951323:57:167
status: NEWX
ABCA1 p.Val825Ile 17951323:57:180
status: NEW60 Risk of IHD Prospective Study The cumulative incidence of IHD as a function of age was increased for V771M (GAϩAA versus GG, borderline Pϭ0.06), V825I (GAϩAA versus GG; Pϭ0.02), I883M (AGϩGG versus AA, Pϭ0.01), E1172D (GCϩCC versus GG, Pϭ0.03), and for R1587K (AA versus GG, borderline Pϭ0.06), but not for R219K (Figure 2).
X
ABCA1 p.Val825Ile 17951323:60:157
status: NEW61 The age adjusted hazard ratios (HRs) for IHD were: V771M (GAϩAA versus GG) 1.2 (95% confidence interval [CI] 1.0 to 1.5), V825I (GAϩAA versus GG) 1.2 (1.0 to 1.5), I883M (AGϩGG versus AA) 1.2 (1.0 to 1.4), E1172D (GCϩCC versus GG) 1.3 (1.0 to 1.6) and R1587K (AA versus GG) 1.2 (1.0 to 1.6), respectively (Table 2).
X
ABCA1 p.Val825Ile 17951323:61:128
status: NEW68 Probability values are for overall log-rank tests. For V771M, V825I, I883M, and E1172D, heterozygotes and homozygotes for the variant allele were pooled (combined genotype in red, common genotype in green).
X
ABCA1 p.Val825Ile 17951323:68:62
status: NEWX
ABCA1 p.Val825Ile 17951323:68:89
status: NEW74 The age-adjusted odds ratios (ORs) were: V771M (GAϩAA versus GG) 1.2 (0.9 to 1.5), V825I (GAϩAA versus GG) 1.2 (0.9 to 1.4), I883M (AGϩGG versus AA) 1.2 (1.0 to 1.4), E1172D (GCϩCC versus GG) 1.1 (0.8 to 1.4), and R1587K (GA versus GG) 1.2 (1.0 to 1.4).
X
ABCA1 p.Val825Ile 17951323:74:89
status: NEW81 ABCA1 SNPs and HDL-C Levels In genders combined, V771M and V825I were associated with increases in HDL-C of 0.04 and 0.05 mmol/L, respectively (Figure 3, upper panel).
X
ABCA1 p.Val825Ile 17951323:81:59
status: NEW89 Rs numbers: R219K (rs2230806); V771M (rs2066718); V825I (rs2066715); I883M (rs4149313); E1172D (rs33918808); R1587K (rs2230808).
X
ABCA1 p.Val825Ile 17951323:89:50
status: NEW97 Several studies have reported associations between V825I/ I883M and increased plasma HDL-C levels8,15,16 and associations between R1587K and a decreased HDL-C or apoAI.8,14,17 For in silico prediction of ABCA1 SNPs please see the Data Supplements Expanded Results.
X
ABCA1 p.Val825Ile 17951323:97:48
status: NEW103 However, the single site result on IHD risk for V825I is most likely attributable to LD with I883M, and the findings for R1587K are most likely attributable to LD with E1172D, the latter also supported by the haplotype analysis presented in the Data Supplements, Table III and Expanded Results.
X
ABCA1 p.Val825Ile 17951323:103:48
status: NEW1 Two SNPs (V771M and V825I) were previously associated with increases in HDL-C, 1 (R1587K) with decreased HDL-C, whereas 3 (R219K, I883M and E1172D) did not affect HDL-C levels.
X
ABCA1 p.Val825Ile 17951323:1:20
status: NEW2 Despite this, 5 out of 6 SNPs (V771M, V825I, I883M, E1172D, R1587K) predicted increased risk of IHD.
X
ABCA1 p.Val825Ile 17951323:2:38
status: NEW23 The cohort was participants in The Copenhagen City Heart Study who attended the 1991 to 1994 examination, and for whom combined genotypes for all 6 nonsynonymous SNPs (R219K, V771M, V825I, I883M, E1172D, R1587K) were available as well as all clinical and biochemical data (nafd;9028 out of nafd;9259; Table 1).
X
ABCA1 p.Val825Ile 17951323:23:182
status: NEW32 SNP Genotyping The ABI PRISM 7900HT Sequence Detection System (Applied Biosystem Inc) was used to genotype for all 6 nonsynonymous SNPs (R219K, V771M, V825I, I883M, E1172D, R1587K) identified by resequencing ABCA1 in 190 individuals, as previously described.8 Biochemical Analyses Colorimetric and turbidimetric assays (Hitachi autoanalyzer) were used to measure plasma levels of total cholesterol, HDL-C, triglycerides, and apolipoproteins B and -AI (all Boehringer Mannheim GmbH).
X
ABCA1 p.Val825Ile 17951323:32:151
status: NEW49 Frikke-Schmidt et al ABCA1 and Ischemic Heart Disease 181 at Semmelweis University (Egyetem) on December 3, 2015 http://atvb.ahajournals.org/ Downloaded from the entire ABCA1 gene in 190 individuals of Danish descent were: 0.26 (R219K), 0.03 (V771M), 0.03 (E1172D), 0.06 (V825I), 0.12 (I883M), and 0.24 (R1587K).8 Similar allele frequencies have been reported for other White populations.14 Please see Data Supplements, Expanded Results for description of Hardy-Weinberg equilibrium.
X
ABCA1 p.Val825Ile 17951323:49:273
status: NEW51 A strong positive Db18; was present for R219K/V771M, M825I/I883M, and E1172D/ R1587K (Db18;b0e;0.9), whereas a strong negative Db18; was present for R219K/V825I, V771M/V825I, and V771M/I883M (Db18;b0d;afa;0.9).
X
ABCA1 p.Val825Ile 17951323:51:167
status: NEWX
ABCA1 p.Val825Ile 17951323:51:180
status: NEW54 Risk of IHD Prospective Study The cumulative incidence of IHD as a function of age was increased for V771M (GAaf9;AA versus GG, borderline Pafd;0.06), V825I (GAaf9;AA versus GG; Pafd;0.02), I883M (AGaf9;GG versus AA, Pafd;0.01), E1172D (GCaf9;CC versus GG, Pafd;0.03), and for R1587K (AA versus GG, borderline Pafd;0.06), but not for R219K (Figure 2).
X
ABCA1 p.Val825Ile 17951323:54:157
status: NEW62 Probability values are for overall log-rank tests. For V771M, V825I, I883M, and E1172D, heterozygotes and homozygotes for the variant allele were pooled (combined genotype in red, common genotype in green).
X
ABCA1 p.Val825Ile 17951323:62:62
status: NEW75 ABCA1 SNPs and HDL-C Levels In genders combined, V771M and V825I were associated with increases in HDL-C of 0.04 and 0.05 mmol/L, respectively (Figure 3, upper panel).
X
ABCA1 p.Val825Ile 17951323:75:59
status: NEW83 Rs numbers: R219K (rs2230806); V771M (rs2066718); V825I (rs2066715); I883M (rs4149313); E1172D (rs33918808); R1587K (rs2230808).
X
ABCA1 p.Val825Ile 17951323:83:50
status: NEW91 Several studies have reported associations between V825I/ I883M and increased plasma HDL-C levels8,15,16 and associations between R1587K and a decreased HDL-C or apoAI.8,14,17 For in silico prediction of ABCA1 SNPs please see the Data Supplements Expanded Results.
X
ABCA1 p.Val825Ile 17951323:91:51
status: NEW
PMID: 17556888
[PubMed]
Klos KL et al: "Genetic determinants of HDL: monogenic disorders and contributions to variation."
No.
Sentence
Comment
81
Sequence analyses, most notably of the ABCA1 region, suggest that both common variants and rare mutations contribute to interindividual variation in Genetic determinants of HDL Klos and Kullo 347 Table1Commonpolymorphisms(minorallelefrequency>5%)reportedtobeassociatedwithplasmaHDL-Cinmorethanonestudy;thereporteddirectionofeffectoftheless commonallele,andtheircontributionstocovariate-adjustedHDL-Cvariationaloneandincombinationwithotherpolymorphismsofthesamegene GenesymbolGenenamePolymorphismEffecta Single-sitevariationMultisitevariation ABCA1ATP-bindingcassette,sub-familyA (ABC1),member1 596G>A"HDL-C[52,53]4%[52] R219K"HDL-C[28,29 ,30 ]6%[54] V771M"HDL-C[30 ,33] V825I/V825L"HDL-C[30 ];#HDL-C[32 ] APOA5ApolipoproteinA-VÀ1131T>C#HDL-C[55-57] APOC3ApolipoproteinC-III482C>T#HDL-C[55,58 ]0.2-1.4%[58 ]1-6%[58 ,59] SstIS2allelewith#HDL-C[60,61] APOEApolipoproteinEÀ219G>T#HDL-C[27 ,62] e2/e3/e40.8-6.5%[63,64 ]8.3-15.3%[65] ARAndrogenreceptorEx1CAGrepeat"HDL-Cwithlength[66] CETPCholesterol-estertransferproteinÀ1946VNTR"HDL-Cwiththeshortallele[36,67] À629C>A"HDL-C[36,38,39,67-69]4.6-5.2%[39,64 ]5.5-9.8%[39,68] Taq1B"HDL-C[35]3.9%[39]5.5-15%[39,54] MspIin8#HDL-C[36,67] A373P/R451Q#HDL-C[67,68]8%[70] I405V"HDL-C[35] LIPCHepaticlipaseÀ514C>T"HDL-C[45]Upto31%[54] À250G>A"HDL-C[41,43]4.7%[67] LIPGEndotheliallipaseT111I"HDL-C[72,73 ];#HDL-C[74] LPLLipoproteinlipaseHindIII#HDL-CwiththeHþallele[49,75] N291S#HDL-C[50 ] S447X"HDL-C[48,75]0.8%[64 ]3%[35] PON1Paraoxonase1À107T>C"HDL-C[76-78] Q192R"HDL-C[77,79 ];#HDL-C[79 ] PPARDPeroxisomeproliferatorsactivatedreceptordelta294T>C#HDL-C[80] PPARGPeroxisomeproliferatorsactivatedreceptorgammaPro12Ala"HDL-C[81,82] SCARB1ScavengerreceptorclassB,member1A350A"HDL-C[64 ,83]1.3%[64 ] IVS5/A350A(/IVS10)haplotype#HDL-C[84 ] a Citationsrepresentaselectionofavailablestudiesprioritizedbasedonmeta-analysesofassociationresultsinnumerousstudygroups,andrecentstudiescontainingcomprehensivereviewsofpreviously reportedassociations.
X
ABCA1 p.Val825Ile 17556888:81:678
status: NEW
PMID: 17412755
[PubMed]
Kyriakou T et al: "Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patients."
No.
Sentence
Comment
8
Functional analyses of the coding polymorphisms showed an effect of the V825I substitution on ABCA1 function, with the 825I variant having higher activity in mediating cholesterol efflux than the wild-type (825V).
X
ABCA1 p.Val825Ile 17412755:8:72
status: NEW53 The relationships were still observed after adjusting for age, gender, smoking, body mass index, hypertension, type 1 diabetes, type 2 diabetes and family history of CAD (P ¼ 0.048 for V825I and P ¼ 0.001 for I883M).
X
ABCA1 p.Val825Ile 17412755:53:190
status: NEW54 Gender ratio, percentage of smokers, body mass index, total cholesterol and triglyceride levels, hypertension, type 1 and type 2 diabetes and family history of CAD did not significantly differ among the different genotypes of the V825I and I883M SNPs. No significant association was observed between HDL level and the other SNPs studied.
X
ABCA1 p.Val825Ile 17412755:54:230
status: NEW74 Coefficients (D 0 ) of pair-wise linkage disequilibrium between ABCA1 SNPs 21801 21652 21506 21395 21252 21217 21034 2940 2803 2565 2407 2302 2278 299 214 R219K V825I I883M 21652A.G 20.97 Ã 21506G.C 20.97 Ã 20.86 Ã 21395C.T 0.94 Ã 20.94 Ã 20.91 Ã 21252G.A 20.90 Ã 0.89 Ã 20.64 † 20.95 Ã 21217C.T 21.00 Ã 0.96 Ã 20.94 Ã 20.97 Ã 20.91 † 21034ATins/del 20.91 Ã 20.90 Ã 0.89 Ã 20.94 Ã 20.80 Ã 20.94 Ã 2940T.G 20.95 Ã 0.40 Ã 0.90 Ã 20.95 Ã 20.79 Ã 0.96 Ã 0.84 Ã 2803G.A 0.93 Ã 20.91 Ã 20.95 Ã 0.96 Ã 20.83 † 21.00 Ã 20.95 Ã 20.98 Ã 2565C.T 20.95 Ã 20.42 Ã 0.71 Ã 20.97 Ã 20.81 Ã 1.00 Ã 0.74 Ã 0.92 Ã 20.98 Ã 2407G.C 20.87 Ã 0.39 Ã 0.71 Ã 20.86 Ã 20.74 Ã 0.88 Ã 0.73 Ã 0.86 Ã 20.95 Ã 0.92 Ã 2302C.T 20.85 Ã 20.90 Ã 0.87 Ã 20.88 Ã 20.77 Ã 20.87 Ã 0.90 Ã 0.84 Ã 20.89 Ã 0.94 Ã 0.98 Ã 2278G.C 20.94 Ã 0.41 Ã 0.72 Ã 20.94 Ã 20.83 Ã 0.96 Ã 0.77 Ã 0.93 Ã 20.98 Ã 0.99 Ã 0.91 Ã 0.92 Ã 299G.C 0.79 Ã 20.81 Ã 20.84 Ã 0.82 Ã 20.96 Ã 20.88 Ã 20.80 Ã 20.82 Ã 20.96 Ã 20.85 Ã 20.75 Ã 20.88 Ã 20.85 Ã 214C.T 20.93 Ã 0.10 † 0.78 Ã 20.94 Ã 20.81 Ã 20.89 Ã 0.77 Ã 0.91 Ã 21.00 Ã 0.98 Ã 0.90 Ã 0.84 Ã 0.98 Ã 20.86 Ã R219K 0.14 † 20.17 † 20.18 ‡ 0.14 † 20.62 Ã 0.01 ‡ 20.16 ‡ 0.00 ‡ 0.09 ‡ 20.11 † 0.10 ‡ 20.17 ‡ 0.11 ‡ 0.04 ‡ 0.05 ‡ V825I 20.03 ‡ 20.39 † 0.14 † 0.19 ‡ 20.35 ‡ 20.62 ‡ 0.17 † 20.06 ‡ 0.02 ‡ 0.12 ‡ 0.15 ‡ 0.03 ‡ 20.12 ‡ 0.09 ‡ 0.04 ‡ 20.88 Ã I883M 0.08 ‡ 20.38 † 0.09 † 0.05 ‡ 20.24 ‡ 20.18 ‡ 0.11 † 0.02 ‡ 20.05 ‡ 0.04 ‡ 20.04 ‡ 0.04 ‡ 0.02 ‡ 20.12 ‡ 0.01 ‡ 0.25 Ã 0.81 Ã R1587K 0.00 ‡ 0.03 ‡ 20.04 ‡ 20.05 ‡ 0.06 ‡ 0.00 ‡ 0.01 ‡ 20.04 ‡ 20.08 ‡ 20.07 ‡ 20.08 ‡ 20.08 † 20.06 ‡ 0.01 ‡ 20.03 ‡ 0.14 † 20.27 ‡ 20.01 ‡ Ã P , 0.001.
X
ABCA1 p.Val825Ile 17412755:74:161
status: NEWX
ABCA1 p.Val825Ile 17412755:74:1845
status: NEW85 The V825I and I883M SNPs were found to be in strong LD in our sample and other European populations (14,15).
X
ABCA1 p.Val825Ile 17412755:85:4
status: NEW86 In the in vitro assays, we found that the rate of cholesterol efflux in cells expressing the 825I variant was higher than in cells expressing the ABCA1 wild-type (825V), indicating a potential effect of V825I on ABCA1 function in facilitating cellular cholesterol efflux, which could potentially explain its association with HDL level.
X
ABCA1 p.Val825Ile 17412755:86:4
status: NEWX
ABCA1 p.Val825Ile 17412755:86:203
status: NEW92 It is plausible that the relationship of this SNP with plasma HDL level might have arisen from its LD with other SNPs such as V825I.
X
ABCA1 p.Val825Ile 17412755:92:126
status: NEW95 A G/G 59.94 (9.79), 708 0.57 299G.C (rs2740483) G/G 60.41 (9.90), 505 0.12 G/A 59.80 (9.88), 180 G/C 59.41 (9.68), 363 A/A 57.80 (8.82), 15 C/C 59.18 (9.35), 78 21217C.T (rs10991420) C/C 59.47 (9.82), 769 0.05 214C.T (rs1800977) C/C 59.80 (9.69), 460 0.54 C/T 61.11 (9.48), 209 C/T 59.74 (9.80), 401 T/T 59.82 (11.39), 11 T/T 60.68 (10.5), 113 21034ATins/del (rs34669957) AT/AT 59.63 (9.71), 621 0.37 R219K (rs2230806) R/R 60.07 (9.94), 503 0.52 AT/ 2 60.14 (9.73), 350 R/K 59.82 (9.84), 392 2/2 60.49 (11.13), 43 K/K 59.33 (8.81), 78 2940T.G (rs2980083) T/T 59.11 (9.51), 273 0.03 V825I (rs28587567) V/V 59.70 (9.86), 866 0.24 T/G 59.85 (9.68), 430 V/I 60.75 (9.52), 100 G/G 61.07 (9.86), 200 I/I 63.46 (9.07), 4 2803G.A (rs10991419) G/G 59.83 (9.74), 812 0.79 I883M (rs4149313) I/I 60.38 (9.66), 644 0.23 G/A 59.73 (9.91), 192 I/M 59.10 (9.65), 217 A/A 58.94 (10.85), 14 M/M 62.12 (6.36), 19 R1587K (rs2230808) R/R 60.23 (9.95), 496 0.30 R/K 58.90 (9.50), 301 K/K 60.93 (9.12), 41 1416 association was detected between the R219K SNP and plasma level of HDL.
X
ABCA1 p.Val825Ile 17412755:95:582
status: NEW119 Plasma HDL levels (mmol/L) according to ABCA1 genotypes Polymorphism Genotype Mean (SD), n P-value Polymorphism Genotype Mean (SD), n P-value 21801C.T (rs2487046) C/C 1.26 (0.31), 93 0.88 2565C.T (rs2422493) C/C 1.25 (0.32), 81 0.78 C/T 1.23 (0.31), 122 C/T 1.24 (0.30), 137 T/T 1.29 (0.33), 40 T/T 1.23 (0.28), 54 21652A.G (rs10124728) A/A 1.22 (0.29), 99 0.37 2407G.C (rs2246293) G/G 1.24 (0.32), 76 0.80 A/G 1.25 (0.31), 131 G/C 1.23 (0.30), 123 G/G 1.29 (0.35), 30 C/C 1.24 (0.27), 52 21506G.C (rs2487047) G/G 1.26 (0.33), 156 0.47 2302C.T (rs2246298) C/C 1.26 (0.32), 165 0.67 G/C 1.21 (0.28), 90 C/T 1.21 (0.27), 68 C/C 1.24 (0.29), 14 T/T 1.27 (0.26), 13 21395C.T (rs2487048) C/C 1.26 (0.31), 96 0.83 2278G.C (rs1800976) G/G 1.25 (0.32), 80 0.79 C/T 1.22 (0.29), 115 G/C 1.24 (0.30), 126 T/T 1.26 (0.32), 45 C/C 1.23 (0.28), 51 21252G.A G/G 1.23 (0.29), 193 0.13 299G.C (rs2740483) G/G 1.25 (0.29), 139 0.83 G/A 1.27 (0.29), 44 G/C 1.23 (0.31), 93 A/A 1.27 (0.34), 7 C/C 1.30 (0.28), 21 21217C.T (rs10991420) C/C 1.25 (0.32), 202 0.64 214C.T (rs1800977) C/C 1.25 (0.31), 126 0.59 C/T 1.23 (0.28), 56 C/T 1.25 (0.32), 99 T/T 0.97 (2), 1 T/T 1.20 (0.23), 30 21034ATins/del (rs34669957) AT/AT 1.27 (0.33), 157 0.36 R219K (rs2230806) R/R 1.26 (0.30), 129 0.58 AT/ 2 1.21 (0.26), 89 R/K 1.23 (0.30), 104 2/2 1.24 (0.29), 14 K/K 1.25 (0.34), 18 2940T.G (rs2980083) T/T 1.24 (0.32), 70 0.77 V825I (rs28587567) V/V 1.23 (0.30), 232 0.01 T/G 1.24 (0.31), 117 V/I 1.34 (0.31), 26 G/G 1.22 (0.29), 53 I/I 1.54 (0.07), 3 2803G.A (rs10991419) G/G 1.26 (0.31), 208 0.40 I883M (rs4149313) I/I 1.20 (0.27), 172 0.0004 G/A 1.20 (0.28), 51 I/M 1.39 (0.36), 56 A/A 1.32 (0.47), 4 M/M 1.34 (0.34), 9 R1587K (rs2230808) R/R 1.27 (0.31), 142 0.39 R/K 1.24 (0.30), 84 K/K 1.18 (0.20), 9 Figure 2.
X
ABCA1 p.Val825Ile 17412755:119:1391
status: NEW126 Single nucleotide polymorphism selection and determination of genotypes The subjects of this study were genotyped for 15 common SNPs in the proximal promoter region, i.e. 21801C.T (rs2487046), 21652A.G (rs10124728), 21506G.C (rs2487047), 21395C.T (rs2487048), 21252G.A (rs number unavailable), 21217C.T (rs10991420), 21034A Tins/del (rs34669957), 2940T.G (rs2980083), 2803G.A (rs10991419), 2565C.T (rs2422493), 2407G.C (rs2246293), 2302C.T (rs2246298), 2278G.C (rs1800976), 299G.C (rs2740483) and 214C.T (rs1800977), respectively, and four common non-synonymous SNPs, i.e. R219K (rs2230806), V825I (rs28587567), I883M (rs4149313) and R1587K (rs2230808) (Fig. 1).
X
ABCA1 p.Val825Ile 17412755:126:592
status: NEW55 The relationships were still observed after adjusting for age, gender, smoking, body mass index, hypertension, type 1 diabetes, type 2 diabetes and family history of CAD (P &#bc; 0.048 for V825I and P &#bc; 0.001 for I883M).
X
ABCA1 p.Val825Ile 17412755:55:189
status: NEW56 Gender ratio, percentage of smokers, body mass index, total cholesterol and triglyceride levels, hypertension, type 1 and type 2 diabetes and family history of CAD did not significantly differ among the different genotypes of the V825I and I883M SNPs. No significant association was observed between HDL level and the other SNPs studied.
X
ABCA1 p.Val825Ile 17412755:56:230
status: NEW76 Coefficients (D 0 ) of pair-wise linkage disequilibrium between ABCA1 SNPs 21801 21652 21506 21395 21252 21217 21034 2940 2803 2565 2407 2302 2278 299 214 R219K V825I I883M 21652A.G 20.97 21506G.C 20.97 20.86 21395C.T 0.94 20.94 20.91 21252G.A 20.90 0.89 20.64 ߤ 20.95 21217C.T 21.00 0.96 20.94 20.97 20.91 ߤ 21034ATins/del 20.91 20.90 0.89 20.94 20.80 20.94 2940T.G 20.95 0.40 0.90 20.95 20.79 0.96 0.84 2803G.A 0.93 20.91 20.95 0.96 20.83 ߤ 21.00 20.95 20.98 2565C.T 20.95 20.42 0.71 20.97 20.81 1.00 0.74 0.92 20.98 2407G.C 20.87 0.39 0.71 20.86 20.74 0.88 0.73 0.86 20.95 0.92 2302C.T 20.85 20.90 0.87 20.88 20.77 20.87 0.90 0.84 20.89 0.94 0.98 2278G.C 20.94 0.41 0.72 20.94 20.83 0.96 0.77 0.93 20.98 0.99 0.91 0.92 299G.C 0.79 20.81 20.84 0.82 20.96 20.88 20.80 20.82 20.96 20.85 20.75 20.88 20.85 214C.T 20.93 0.10 ߤ 0.78 20.94 20.81 20.89 0.77 0.91 21.00 0.98 0.90 0.84 0.98 20.86 R219K 0.14 ߤ 20.17 ߤ 20.18 ߥ 0.14 ߤ 20.62 0.01 ߥ 20.16 ߥ 0.00 ߥ 0.09 ߥ 20.11 ߤ 0.10 ߥ 20.17 ߥ 0.11 ߥ 0.04 ߥ 0.05 ߥ V825I 20.03 ߥ 20.39 ߤ 0.14 ߤ 0.19 ߥ 20.35 ߥ 20.62 ߥ 0.17 ߤ 20.06 ߥ 0.02 ߥ 0.12 ߥ 0.15 ߥ 0.03 ߥ 20.12 ߥ 0.09 ߥ 0.04 ߥ 20.88 I883M 0.08 ߥ 20.38 ߤ 0.09 ߤ 0.05 ߥ 20.24 ߥ 20.18 ߥ 0.11 ߤ 0.02 ߥ 20.05 ߥ 0.04 ߥ 20.04 ߥ 0.04 ߥ 0.02 ߥ 20.12 ߥ 0.01 ߥ 0.25 0.81 R1587K 0.00 ߥ 0.03 ߥ 20.04 ߥ 20.05 ߥ 0.06 ߥ 0.00 ߥ 0.01 ߥ 20.04 ߥ 20.08 ߥ 20.07 ߥ 20.08 ߥ 20.08 ߤ 20.06 ߥ 0.01 ߥ 20.03 ߥ 0.14 ߤ 20.27 ߥ 20.01 ߥ P , 0.001.
X
ABCA1 p.Val825Ile 17412755:76:161
status: NEWX
ABCA1 p.Val825Ile 17412755:76:1317
status: NEW87 In the in vitro assays, we found that the rate of cholesterol efflux in cells expressing the 825I variant was higher than in cells expressing the ABCA1 wild-type (825V), indicating a potential effect of V825I on ABCA1 function in facilitating cellular cholesterol efflux, which could potentially explain its association with HDL level.
X
ABCA1 p.Val825Ile 17412755:87:203
status: NEW93 It is plausible that the relationship of this SNP with plasma HDL level might have arisen from its LD with other SNPs such as V825I.
X
ABCA1 p.Val825Ile 17412755:93:126
status: NEW96 A G/G 59.94 (9.79), 708 0.57 299G.C (rs2740483) G/G 60.41 (9.90), 505 0.12 G/A 59.80 (9.88), 180 G/C 59.41 (9.68), 363 A/A 57.80 (8.82), 15 C/C 59.18 (9.35), 78 21217C.T (rs10991420) C/C 59.47 (9.82), 769 0.05 214C.T (rs1800977) C/C 59.80 (9.69), 460 0.54 C/T 61.11 (9.48), 209 C/T 59.74 (9.80), 401 T/T 59.82 (11.39), 11 T/T 60.68 (10.5), 113 21034ATins/del (rs34669957) AT/AT 59.63 (9.71), 621 0.37 R219K (rs2230806) R/R 60.07 (9.94), 503 0.52 AT/ 2 60.14 (9.73), 350 R/K 59.82 (9.84), 392 2/2 60.49 (11.13), 43 K/K 59.33 (8.81), 78 2940T.G (rs2980083) T/T 59.11 (9.51), 273 0.03 V825I (rs28587567) V/V 59.70 (9.86), 866 0.24 T/G 59.85 (9.68), 430 V/I 60.75 (9.52), 100 G/G 61.07 (9.86), 200 I/I 63.46 (9.07), 4 2803G.A (rs10991419) G/G 59.83 (9.74), 812 0.79 I883M (rs4149313) I/I 60.38 (9.66), 644 0.23 G/A 59.73 (9.91), 192 I/M 59.10 (9.65), 217 A/A 58.94 (10.85), 14 M/M 62.12 (6.36), 19 R1587K (rs2230808) R/R 60.23 (9.95), 496 0.30 R/K 58.90 (9.50), 301 K/K 60.93 (9.12), 41 association was detected between the R219K SNP and plasma level of HDL.
X
ABCA1 p.Val825Ile 17412755:96:582
status: NEW120 Plasma HDL levels (mmol/L) according to ABCA1 genotypes Polymorphism Genotype Mean (SD), n P-value Polymorphism Genotype Mean (SD), n P-value 21801C.T (rs2487046) C/C 1.26 (0.31), 93 0.88 2565C.T (rs2422493) C/C 1.25 (0.32), 81 0.78 C/T 1.23 (0.31), 122 C/T 1.24 (0.30), 137 T/T 1.29 (0.33), 40 T/T 1.23 (0.28), 54 21652A.G (rs10124728) A/A 1.22 (0.29), 99 0.37 2407G.C (rs2246293) G/G 1.24 (0.32), 76 0.80 A/G 1.25 (0.31), 131 G/C 1.23 (0.30), 123 G/G 1.29 (0.35), 30 C/C 1.24 (0.27), 52 21506G.C (rs2487047) G/G 1.26 (0.33), 156 0.47 2302C.T (rs2246298) C/C 1.26 (0.32), 165 0.67 G/C 1.21 (0.28), 90 C/T 1.21 (0.27), 68 C/C 1.24 (0.29), 14 T/T 1.27 (0.26), 13 21395C.T (rs2487048) C/C 1.26 (0.31), 96 0.83 2278G.C (rs1800976) G/G 1.25 (0.32), 80 0.79 C/T 1.22 (0.29), 115 G/C 1.24 (0.30), 126 T/T 1.26 (0.32), 45 C/C 1.23 (0.28), 51 21252G.A G/G 1.23 (0.29), 193 0.13 299G.C (rs2740483) G/G 1.25 (0.29), 139 0.83 G/A 1.27 (0.29), 44 G/C 1.23 (0.31), 93 A/A 1.27 (0.34), 7 C/C 1.30 (0.28), 21 21217C.T (rs10991420) C/C 1.25 (0.32), 202 0.64 214C.T (rs1800977) C/C 1.25 (0.31), 126 0.59 C/T 1.23 (0.28), 56 C/T 1.25 (0.32), 99 T/T 0.97 (2), 1 T/T 1.20 (0.23), 30 21034ATins/del (rs34669957) AT/AT 1.27 (0.33), 157 0.36 R219K (rs2230806) R/R 1.26 (0.30), 129 0.58 AT/ 2 1.21 (0.26), 89 R/K 1.23 (0.30), 104 2/2 1.24 (0.29), 14 K/K 1.25 (0.34), 18 2940T.G (rs2980083) T/T 1.24 (0.32), 70 0.77 V825I (rs28587567) V/V 1.23 (0.30), 232 0.01 T/G 1.24 (0.31), 117 V/I 1.34 (0.31), 26 G/G 1.22 (0.29), 53 I/I 1.54 (0.07), 3 2803G.A (rs10991419) G/G 1.26 (0.31), 208 0.40 I883M (rs4149313) I/I 1.20 (0.27), 172 0.0004 G/A 1.20 (0.28), 51 I/M 1.39 (0.36), 56 A/A 1.32 (0.47), 4 M/M 1.34 (0.34), 9 R1587K (rs2230808) R/R 1.27 (0.31), 142 0.39 R/K 1.24 (0.30), 84 K/K 1.18 (0.20), 9 Figure 2.
X
ABCA1 p.Val825Ile 17412755:120:1391
status: NEW127 Single nucleotide polymorphism selection and determination of genotypes The subjects of this study were genotyped for 15 common SNPs in the proximal promoter region, i.e. 21801C.T (rs2487046), 21652A.G (rs10124728), 21506G.C (rs2487047), 21395C.T (rs2487048), 21252G.A (rs number unavailable), 21217C.T (rs10991420), 21034A Tins/del (rs34669957), 2940T.G (rs2980083), 2803G.A (rs10991419), 2565C.T (rs2422493), 2407G.C (rs2246293), 2302C.T (rs2246298), 2278G.C (rs1800976), 299G.C (rs2740483) and 214C.T (rs1800977), respectively, and four common non-synonymous SNPs, i.e. R219K (rs2230806), V825I (rs28587567), I883M (rs4149313) and R1587K (rs2230808) (Fig. 1).
X
ABCA1 p.Val825Ile 17412755:127:592
status: NEW
PMID: 17303779
[PubMed]
Kiss RS et al: "Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects."
No.
Sentence
Comment
47
In ABCA1, a total of 19 nonsynonymous coding sequence variants; some of these we reported previously.22 Of these, 9 sequence variants were common polymorphisms (ie, reported in the literature as common or of similar prevalence in control subjects): P85L, P85A, R219K, V399A, V771M, V825I, I883M, E1172D, R1587K.14,32-35 Another 5 sequence variants, identified here, were previously reported to be disease causing: W590L (reported as W590S)14; C1477F (reported as C1477R)13; S1731C (only found in French-Canadian populations)36; N1800H32; and 1851X.37 Five sequence variants were novel: K199F, H551D, R965C, E1386Q, and D1706N.
X
ABCA1 p.Val825Ile 17303779:47:282
status: NEW42 In ABCA1, a total of 19 nonsynonymous coding sequence variants; some of these we reported previously.22 Of these, 9 sequence variants were common polymorphisms (ie, reported in the literature as common or of similar prevalence in control subjects): P85L, P85A, R219K, V399A, V771M, V825I, I883M, E1172D, R1587K.14,32-35 Another 5 sequence variants, identified here, were previously reported to be disease causing: W590L (reported as W590S)14; C1477F (reported as C1477R)13; S1731C (only found in French-Canadian populations)36; N1800H32; and 1851X.37 Five sequence variants were novel: K199F, H551D, R965C, E1386Q, and D1706N.
X
ABCA1 p.Val825Ile 17303779:42:282
status: NEW
PMID: 17430597
[PubMed]
Wahrle SE et al: "Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms."
No.
Sentence
Comment
40
In particular, studies have implicated the following SNPs in affecting levels of plasma HDL-C: rs2230806 (R219K) [33], rs2066718 (V771M) [31,32], rs2066715 (V825I) [31], rs4149313 (I883M) [34], rs2230808 (R1587K) [31].
X
ABCA1 p.Val825Ile 17430597:40:157
status: NEW70 The subjects for whom we had CSF apoE data were genotyped for the following ABCA1 SNPs: rs2230806 (R219K), rs2066718 (V771M), rs2066715 (V825I), rs4149313 (I883M), rs2230808 (R1587K), rs1883025 (intron), rs2275544 (intron), rs2777799 (intron), rs3904999 (intron) and rs6479283 (intron).
X
ABCA1 p.Val825Ile 17430597:70:137
status: NEW149 Genotyping The following SNPS in ABCA1 were genotyped in the Washington University sample of 168 subjects: rs2230806 (R219K), rs2066718 (V771M), rs2066715 (V825I), rs4149313 (I883M), rs2230808 (R1587K), rs1883025 (intron), rs2275544 (intron), rs2777799 (intron), rs3904999 (intron) and rs6479283 (intron).
X
ABCA1 p.Val825Ile 17430597:149:156
status: NEW
PMID: 17383594
[PubMed]
Mantaring M et al: "Genotypic variation in ATP-binding cassette transporter-1 (ABCA1) as contributors to the high and low high-density lipoprotein-cholesterol (HDL-C) phenotype."
No.
Sentence
Comment
3
Carrier frequencies of common ABCA1 polymorphisms, R219K, V771M, V825I, I883M, E1172D, and R1587K were also assessed.
X
ABCA1 p.Val825Ile 17383594:3:65
status: NEW36 DNA was PCR amplified and digested using standard methods and the frequency of the 6 common polymorphisms (R219K, V771M, V825I, I883M, E1172D, and R1587K) in ABCA1, which was determined as described by Clee et al.8 Sequencing of PCR-amplified DNA.
X
ABCA1 p.Val825Ile 17383594:36:121
status: NEW54 The prevalence of 6 common ABCA1 polymorphisms, R219K, V771M, V825I, I883M, E1172D, and R1587K was also evaluated.
X
ABCA1 p.Val825Ile 17383594:54:62
status: NEW77 Genotype and allele frequencies for 6 common ABCA1 polymorphisms in subgroups with HDL-C defined as very high (n ϭ 22), high (n ϭ 34), average (n ϭ 36), or low (n ϭ 32) R219K Genotype frequencies P value Allele frequencies P valueR/R R/K K/K R K Very high 31.8% 45.5% 22.7% 0.04 0.55 0.45 0.20 High 45.7% 51.4% 2.9% 0.71 0.29 Average 43.2% 56.8% 0.0% 0.72 0.28 Low 50.0% 40.0% 10.0% 0.70 0.30 V771M V/V V/M M/M V M Very high 59.0% 36.0% 4.5% 0.11 0.77 0.23 0.04 High 85.7% 14.3% 0.0% 0.93 0.07 Average 86.1% 13.9% 0.0% 0.93 0.07 Low 80.0% 20.0% 0.0% 0.90 0.10 V825I V/V V/I I/I V I Very high 77.3% 22.7% 0.0% 0.58 0.89 0.11 0.62 High 88.6% 11.4% 0.0% 0.94 0.06 Average 88.9% 11.1% 0.0% 0.94 0.06 Low 82.8% 17.2% 0.0% 0.92 0.08 I883M I/I I/M M/M I M Very high 40.9% 45.5% 13.6% 0.29 0.64 0.36 0.05 High 60.0% 34.3% 5.7% 0.78 0.22 Average 73.0% 24.3% 2.7% 0.85 0.15 Low 66.7% 26.7% 6.7% 0.80 0.20 E1172D E/E E/D D/D E D Very high 68.2% 31.8% 0.0% 0.0004 0.82 0.18 0.0002 High 94.3% 5.7% 0.0% 0.97 0.03 Average 94.6% 5.4% 0.0% 0.97 0.03 Low 100.00% 0.0% 0.0% 1.00 0.00 R1587K R/R R/K K/K R K Very high 31.8% 50.0% 18.2% 0.16 0.57 0.43 0.07 High 65.6% 25.0% 9.4% 0.78 0.22 Average 55.6% 41.7% 2.8% 0.76 0.24 Low 51.9% 33.3% 14.8% 0.69 0.31 of R219K may have a basis for reduced CVD risk as previously suggested.8-11,24 CONCLUSION The data extend previous findings that novel mutations in ABCA1 are associated with the low rather than the high HDL-C (FHA) phenotype.
X
ABCA1 p.Val825Ile 17383594:77:584
status: NEW35 DNA was PCR amplified and digested using standard methods and the frequency of the 6 common polymorphisms (R219K, V771M, V825I, I883M, E1172D, and R1587K) in ABCA1, which was determined as described by Clee et al.8 Sequencing of PCR-amplified DNA.
X
ABCA1 p.Val825Ile 17383594:35:121
status: NEW53 The prevalence of 6 common ABCA1 polymorphisms, R219K, V771M, V825I, I883M, E1172D, and R1587K was also evaluated.
X
ABCA1 p.Val825Ile 17383594:53:62
status: NEW
PMID: 16704350
[PubMed]
Brunham LR et al: "Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis."
No.
Sentence
Comment
612
The V825I and V771M SNPs were associated with increased HDL cholesterol in one, but not both, genders.
X
ABCA1 p.Val825Ile 16704350:612:4
status: NEW
PMID: 16372134
[PubMed]
Katzov H et al: "Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta 1-42 and plasma apolipoprotein levels."
No.
Sentence
Comment
127
The number of individuals in each category is shown in parenthesis. Comparisons were performed by ANOVATC total cholesterol, LDL-C low density lipoprotein cholesterol Traits KK RK RR F value P value APOA1a (g/l) 1.46±0.02 (157) 1.48±0.01 (966) 1.47±0.01 (1,439) 0.23 0.79 APOB (g/l) 1.64±0.03 (157) 1.53±0.01 (966) 1.55±0.01 (1,439) 5.4 0.0046 HDL-C (mmol/l) 1.16±0.26 (156) 1.20±0.01 (961) 1.20±0.01 (1,427) 1.1 0.34 LDL-C (mmol/l) 4.26±0.86 (154) 4.08±0.03 (951) 4.05±0.03 (1,415) 0.26 0.038 TC (mmol/l) 6.24±0.09 (157) 6.04±0.04 (969) 6.01±0.03 (1,439) 3.02 0.049 TGa (mmol/l) 1.87±0.11 (157) 1.71±0.04 (969) 1.72±0.03 (1,441) 1.38 0.25 a Log-transformed traits k.embl-heidelberg.de/PolyPhen/) (Ramensky et al. 2002) for five coding SNPs (cSNPs) in ABCA1 (R219K rs2230806; V771M rs2066718; V825I rs4149312; I883M rs2066714; R1587K rs2230808) (Frikke-Schmidt et al. 2004).
X
ABCA1 p.Val825Ile 16372134:127:885
status: NEW129 The number of individuals in each category is shown in parenthesis. Comparisons were performed by ANOVATC total cholesterol, LDL-C low density lipoprotein cholesterol Traits KK RK RR F value P value APOA1a (g/l) 1.46&#b1;0.02 (157) 1.48&#b1;0.01 (966) 1.47&#b1;0.01 (1,439) 0.23 0.79 APOB (g/l) 1.64&#b1;0.03 (157) 1.53&#b1;0.01 (966) 1.55&#b1;0.01 (1,439) 5.4 0.0046 HDL-C (mmol/l) 1.16&#b1;0.26 (156) 1.20&#b1;0.01 (961) 1.20&#b1;0.01 (1,427) 1.1 0.34 LDL-C (mmol/l) 4.26&#b1;0.86 (154) 4.08&#b1;0.03 (951) 4.05&#b1;0.03 (1,415) 0.26 0.038 TC (mmol/l) 6.24&#b1;0.09 (157) 6.04&#b1;0.04 (969) 6.01&#b1;0.03 (1,439) 3.02 0.049 TGa (mmol/l) 1.87&#b1;0.11 (157) 1.71&#b1;0.04 (969) 1.72&#b1;0.03 (1,441) 1.38 0.25 a Log-transformed traits k.embl-heidelberg.de/PolyPhen/) (Ramensky et al. 2002) for five coding SNPs (cSNPs) in ABCA1 (R219K rs2230806; V771M rs2066718; V825I rs4149312; I883M rs2066714; R1587K rs2230808) (Frikke-Schmidt et al. 2004).
X
ABCA1 p.Val825Ile 16372134:129:867
status: NEW
PMID: 15935359
[PubMed]
Hodoglugil U et al: "Common polymorphisms of ATP binding cassette transporter A1, including a functional promoter polymorphism, associated with plasma high density lipoprotein cholesterol levels in Turks."
No.
Sentence
Comment
24
Recently, it was shown that some polymorphisms of ABCA1 were associated with increases (V771M and V825I) or decreases (R1587K) in HDL-C in women and with some consistent trends in men in a large random Danish population [17].
X
ABCA1 p.Val825Ile 15935359:24:98
status: NEW104 The G-803A Table 2 ABCA1 polymorphisms Nucleotide changea Carrier of rare allele (%) Rare allele (%) nb Referencesc Frequency in 5 and promoter regions G-803A ~10 92/141 [19] T-564C 72.7 47.7 728/1268 [18] G-407C 62.5 40.7 220/233 [18] G-99C 42.2 24.2 875/1130 [46] C-14T 61.2 37.7 916/1416 [46] InsG 319 26.6 14.2 848/1288 [46] Nucleotide changed Amino acid change Exon Carrier of rare allele (%) Rare allele (%) nb Referencesc Frequency in coding sequence Nonsynonymous G(70943)A R219K 7 62.3 38.5 996/1466 db 2230806 G(102555)A V771M 16 10.0 5.1 981/1477 db 2066718 G(103777)A V825I 17 12.3 6.2 960/1145 db 4149312 A(105057)G I883M 18 38.1 21.8 1084/1448 db 4149313 G(112177)C E1172D 24 9.0 4.6 1001/1237 [12,13] A(116887)G Q1328R 28 0.003e 0.0015 172/156 NR G(129004)A R1587K 35 55.1 33.0 937/1351 db 2230808 T(133402)C Y1767H 39 ~1.0e 40/55 NR G(133420)A V1773M 39 ~1.0e 40/55 NR Synonymous C(100538)A I620I 15 ~4.0 40/55 NR C(109469)T V990V 21 ~3.0 87/90 [17] T(109861)G V1053V 22 ~1.0 90/90 [12] C(109868)T L1056L 22 ~5.0 90/90 NR C(109906)T R1068R 22 ~3.0 90/90 NR A(113280)G E1211E 25 ~4.0 40/55 [17] A(116879)G T1325T 28 ~1.0 40/55 NR T(137043)C Y1921Y 43 ~1.0 40/55 NR Nucleotide changed Intron Carrier of rare allele (%) Intronic location nb Referencesc Frequency in noncoding sequence G(23816)A 1 ~1.0 11 bp 5 exon 1b 94 NR G(23819)C 1 42 8 bp 5 exon 1b 94 NR A(22997)T 1 46 90 bp 5 exon 1d 91 NR A(23004)G 1 ~1.0 83 bp 5 exon 1d 91 NR G(23058)C 1 46 29 bp 5 exon 1d 91 NR G(40504)A 3 2.6 26 bp 3 of exon 3 192 NR C(45217)T 4 0.7 64 bp 3 of exon 4 142 NR T(98628)A 14 35-40 24 bp 3 of exon 14 190 db 4743763 C(100332)T 14 4.3 59 bp 5 of exon 15 90 db 2066717 C(108020)T 19 0.7 3 bp 5 of exon 20 144 NR DelTTT(134503-6) 39 7.0 20-23 bp 5 of exon 40 90 NR C(142026)T 46 8.6 34 bp 5 of exon 47 116 NR A(142751)G 48 15.9 13 bp 3 of exon 48 107 NR a Relative to transcriptional start.
X
ABCA1 p.Val825Ile 15935359:104:580
status: NEW109 Table 3 ABCA1 polymorphisms and mean plasma HDL-C levels (mg/dl ± S.D.) in a random Turkish population Females Males AAa AB BB AAa AB BB Promoter and 5 region T-564C 40.4 ± 8.4 (205) 41.0 ± 7.9 (365) 39.9 ± 7.6 (158) 35.6 ± 7.4 (339) 35.5 ± 6.5 (635) 34.9 ± 6.5 (294) G-407C 41.3 ± 11.2 (82) 40.7 ± 7.7 (101) 40.7 ± 12.2 (37) 35.7 ± 6.9 (88) 35.3 ± 6.7 (96) 35.4 ± 7.4 (49) G-99C 40.7 ± 7.5 (505) 41.0 ± 7.2 (317) 41.3 ± 8.4 (53) 35.1 ± 6.5 (654) 35.0 ± 6.3 (405) 34.9 ± 6.5 (71) C-14T 41.3 ± 9.0 (361) 41.0 ± 9.0 (417) 41.0 ± 9.4 (138) 34.8 ± 7.0b (547) 35.5 ± 7.5 (675) 36.7 ± 8.1b (194) InsG 319 41.3 ± 8.1 (641) 40.5 ± 7.7 (193) 43.1 ± 8.0 (14) 35.3 ± 6.4 (933) 34.7 ± 6.4 (332) 34.5 ± 6.5 (23) Nonsynonymous R219K 41.2 ± 9.4 (364) 40.8 ± 8.6 (480) 41.2 ± 10 (152) 35.2 ± 7.3 (574) 35.3 ± 7.3 (688) 35.2 ± 7.6 (204) V771M 40.9 ± 9.2 (896) 42.8 ± 9.3 (82) 38.7 ± 10 (3) 35.1 ± 7.2c (1330) 37.1 ± 8.0c (144) 45.7 ± 10.7 (3) V825I 40.6 ± 9.4 (842) 38.9 ± 8.5 (117) 42 (1) 35.8 ± 8.7 (1005) 37.1 ± 9.5 (140) (-) I883M 41.1 ± 9.5 (643) 40.8 ± 8.4 (372) 41.4 ± 9.1 (69) 35.0 ± 7.0 (922) 35.7 ± 8.0 (457) 35.6 ± 7.4 (69) E1172D 40.5 ± 8.8 (907) 40.5 ± 7.6 (93) 29 (1) 34.6 ± 7.3 (1129) 35.4 ± 7.6 (105) 30.7 ± 8.7 (3) R1587K 41.1 ± 9.4 (410) 40.8 ± 9.6 (433) 41.0 ± 10.1 (94) 35.9 ± 8.1 (617) 35.1 ± 7.6 (579) 35.3 ± 8.6 (155) Numbers of subjects are shown in parenthesis.
X
ABCA1 p.Val825Ile 15935359:109:1141
status: NEW204 However, further analysis Table 5 Allele frequency and significant (P < 0.01) pair-wise linkage disequilibrium coefficients between the ABCA1 polymorphisms in a random Turkish population Position Allele % T-564C G-99C C-14T InsG 319 R219K V771M V825I I883M E1172D R1587K T-564C 52.3/47.7 - G-99C 75.8/24.2 0.36 - C-14T 62.3/37.7 -0.96 -0.98 - InsG 319 85.8/14.2 - - - - R219K 61.5/38.5 - - - - V771M 94.9/5.1 - - - 0.99 - V825I 93.8/6.2 -0.40 -0.69 - - -0.76 - - I883M 78.2/21.8 - -0.42 - - 0.20 -0.79 0.91 - E1172D 95.4/4.6 - - - - - 0.34 - - - R1587K 67.0/33.0 - - -0.23 - - 0.56 - - 0.87 - Table 6 Common haplotypes of promoter and coding regions of ABCA1 gene in a random Turkish population Promoter region haplotypes % T-564C G-99C C-14T InsG 319 1 31.7 0 0 1 0 2 20.1 1 1 0 0 3 19.9 1 0 0 0 4 12.7 0 0 0 0 5 4.6 0 0 1 1 6 4.2 1 1 0 1 7 3.2 1 0 0 1 8 2.5 0 0 0 1 Sum 98.9 Coding region haplotypes % R219K V771M V825I I883M E1172D R1587K 1 39.3 0 0 0 0 0 0 2 12.6 1 0 0 0 0 0 3 12.0 0 0 0 0 0 1 4 8.7 1 0 0 1 0 0 5 8.3 1 0 0 0 0 1 6 4.0 0 0 1 1 0 0 7 3.4 0 0 0 0 1 1 8 1.6 1 0 0 1 0 1 9 1.3 1 1 0 0 0 0 10 1.3 0 1 0 0 1 1 11 1.3 0 0 1 1 0 1 12 1.1 1 1 0 0 0 1 Sum 95.1 0: common allele; 1: rare allele.
X
ABCA1 p.Val825Ile 15935359:204:245
status: NEWX
ABCA1 p.Val825Ile 15935359:204:422
status: NEWX
ABCA1 p.Val825Ile 15935359:204:919
status: NEW215 Haplotype structure and haplotype-phenotype association of polymorphisms in the coding region of ABCA1 When the haplotype structure of the coding region was constructed using six polymorphisms (R219K, V771M, V825I, I883M, E1172D, and R1587K; Table 6), 12 haplotypes with a frequency >1% accounted for 95.1% of all haplotypes.
X
ABCA1 p.Val825Ile 15935359:215:208
status: NEW230 (rare allele in LD with rare allele) was observed between pairs of V771M and InsG 319, V825I and I883M, and R1587K and E1172D.
X
ABCA1 p.Val825Ile 15935359:230:87
status: NEW302 The association with V825I and R1587K on plasma HDL-C levels were found in a large general Danish population [17]; however, it was not observed in Dutch men with CAD [18] or in our population.
X
ABCA1 p.Val825Ile 15935359:302:21
status: NEW103 The G-803A Table 2 ABCA1 polymorphisms Nucleotide changea Carrier of rare allele (%) Rare allele (%) nb Referencesc Frequency in 5 and promoter regions G-803A ~10 92/141 [19] T-564C 72.7 47.7 728/1268 [18] G-407C 62.5 40.7 220/233 [18] G-99C 42.2 24.2 875/1130 [46] C-14T 61.2 37.7 916/1416 [46] InsG 319 26.6 14.2 848/1288 [46] Nucleotide changed Amino acid change Exon Carrier of rare allele (%) Rare allele (%) nb Referencesc Frequency in coding sequence Nonsynonymous G(70943)A R219K 7 62.3 38.5 996/1466 db 2230806 G(102555)A V771M 16 10.0 5.1 981/1477 db 2066718 G(103777)A V825I 17 12.3 6.2 960/1145 db 4149312 A(105057)G I883M 18 38.1 21.8 1084/1448 db 4149313 G(112177)C E1172D 24 9.0 4.6 1001/1237 [12,13] A(116887)G Q1328R 28 0.003e 0.0015 172/156 NR G(129004)A R1587K 35 55.1 33.0 937/1351 db 2230808 T(133402)C Y1767H 39 ~1.0e 40/55 NR G(133420)A V1773M 39 ~1.0e 40/55 NR Synonymous C(100538)A I620I 15 ~4.0 40/55 NR C(109469)T V990V 21 ~3.0 87/90 [17] T(109861)G V1053V 22 ~1.0 90/90 [12] C(109868)T L1056L 22 ~5.0 90/90 NR C(109906)T R1068R 22 ~3.0 90/90 NR A(113280)G E1211E 25 ~4.0 40/55 [17] A(116879)G T1325T 28 ~1.0 40/55 NR T(137043)C Y1921Y 43 ~1.0 40/55 NR Nucleotide changed Intron Carrier of rare allele (%) Intronic location nb Referencesc Frequency in noncoding sequence G(23816)A 1 ~1.0 11 bp 5 exon 1b 94 NR G(23819)C 1 42 8 bp 5 exon 1b 94 NR A(22997)T 1 46 90 bp 5 exon 1d 91 NR A(23004)G 1 ~1.0 83 bp 5 exon 1d 91 NR G(23058)C 1 46 29 bp 5 exon 1d 91 NR G(40504)A 3 2.6 26 bp 3 of exon 3 192 NR C(45217)T 4 0.7 64 bp 3 of exon 4 142 NR T(98628)A 14 35-40 24 bp 3 of exon 14 190 db 4743763 C(100332)T 14 4.3 59 bp 5 of exon 15 90 db 2066717 C(108020)T 19 0.7 3 bp 5 of exon 20 144 NR DelTTT(134503-6) 39 7.0 20-23 bp 5 of exon 40 90 NR C(142026)T 46 8.6 34 bp 5 of exon 47 116 NR A(142751)G 48 15.9 13 bp 3 of exon 48 107 NR a Relative to transcriptional start.
X
ABCA1 p.Val825Ile 15935359:103:581
status: NEW108 Table 3 ABCA1 polymorphisms and mean plasma HDL-C levels (mg/dl &#b1; S.D.) in a random Turkish population Females Males AAa AB BB AAa AB BB Promoter and 5 region T-564C 40.4 &#b1; 8.4 (205) 41.0 &#b1; 7.9 (365) 39.9 &#b1; 7.6 (158) 35.6 &#b1; 7.4 (339) 35.5 &#b1; 6.5 (635) 34.9 &#b1; 6.5 (294) G-407C 41.3 &#b1; 11.2 (82) 40.7 &#b1; 7.7 (101) 40.7 &#b1; 12.2 (37) 35.7 &#b1; 6.9 (88) 35.3 &#b1; 6.7 (96) 35.4 &#b1; 7.4 (49) G-99C 40.7 &#b1; 7.5 (505) 41.0 &#b1; 7.2 (317) 41.3 &#b1; 8.4 (53) 35.1 &#b1; 6.5 (654) 35.0 &#b1; 6.3 (405) 34.9 &#b1; 6.5 (71) C-14T 41.3 &#b1; 9.0 (361) 41.0 &#b1; 9.0 (417) 41.0 &#b1; 9.4 (138) 34.8 &#b1; 7.0b (547) 35.5 &#b1; 7.5 (675) 36.7 &#b1; 8.1b (194) InsG 319 41.3 &#b1; 8.1 (641) 40.5 &#b1; 7.7 (193) 43.1 &#b1; 8.0 (14) 35.3 &#b1; 6.4 (933) 34.7 &#b1; 6.4 (332) 34.5 &#b1; 6.5 (23) Nonsynonymous R219K 41.2 &#b1; 9.4 (364) 40.8 &#b1; 8.6 (480) 41.2 &#b1; 10 (152) 35.2 &#b1; 7.3 (574) 35.3 &#b1; 7.3 (688) 35.2 &#b1; 7.6 (204) V771M 40.9 &#b1; 9.2 (896) 42.8 &#b1; 9.3 (82) 38.7 &#b1; 10 (3) 35.1 &#b1; 7.2c (1330) 37.1 &#b1; 8.0c (144) 45.7 &#b1; 10.7 (3) V825I 40.6 &#b1; 9.4 (842) 38.9 &#b1; 8.5 (117) 42 (1) 35.8 &#b1; 8.7 (1005) 37.1 &#b1; 9.5 (140) (-) I883M 41.1 &#b1; 9.5 (643) 40.8 &#b1; 8.4 (372) 41.4 &#b1; 9.1 (69) 35.0 &#b1; 7.0 (922) 35.7 &#b1; 8.0 (457) 35.6 &#b1; 7.4 (69) E1172D 40.5 &#b1; 8.8 (907) 40.5 &#b1; 7.6 (93) 29 (1) 34.6 &#b1; 7.3 (1129) 35.4 &#b1; 7.6 (105) 30.7 &#b1; 8.7 (3) R1587K 41.1 &#b1; 9.4 (410) 40.8 &#b1; 9.6 (433) 41.0 &#b1; 10.1 (94) 35.9 &#b1; 8.1 (617) 35.1 &#b1; 7.6 (579) 35.3 &#b1; 8.6 (155) Numbers of subjects are shown in parenthesis.
X
ABCA1 p.Val825Ile 15935359:108:1099
status: NEW203 However, further analysis Table 5 Allele frequency and significant (P < 0.01) pair-wise linkage disequilibrium coefficients between the ABCA1 polymorphisms in a random Turkish population Position Allele % T-564C G-99C C-14T InsG 319 R219K V771M V825I I883M E1172D R1587K T-564C 52.3/47.7 - G-99C 75.8/24.2 0.36 - C-14T 62.3/37.7 -0.96 -0.98 - InsG 319 85.8/14.2 - - - - R219K 61.5/38.5 - - - - V771M 94.9/5.1 - - - 0.99 - V825I 93.8/6.2 -0.40 -0.69 - - -0.76 - - I883M 78.2/21.8 - -0.42 - - 0.20 -0.79 0.91 - E1172D 95.4/4.6 - - - - - 0.34 - - - R1587K 67.0/33.0 - - -0.23 - - 0.56 - - 0.87 - Table 6 Common haplotypes of promoter and coding regions of ABCA1 gene in a random Turkish population Promoter region haplotypes % T-564C G-99C C-14T InsG 319 1 31.7 0 0 1 0 2 20.1 1 1 0 0 3 19.9 1 0 0 0 4 12.7 0 0 0 0 5 4.6 0 0 1 1 6 4.2 1 1 0 1 7 3.2 1 0 0 1 8 2.5 0 0 0 1 Sum 98.9 Coding region haplotypes % R219K V771M V825I I883M E1172D R1587K 1 39.3 0 0 0 0 0 0 2 12.6 1 0 0 0 0 0 3 12.0 0 0 0 0 0 1 4 8.7 1 0 0 1 0 0 5 8.3 1 0 0 0 0 1 6 4.0 0 0 1 1 0 0 7 3.4 0 0 0 0 1 1 8 1.6 1 0 0 1 0 1 9 1.3 1 1 0 0 0 0 10 1.3 0 1 0 0 1 1 11 1.3 0 0 1 1 0 1 12 1.1 1 1 0 0 0 1 Sum 95.1 0: common allele; 1: rare allele.
X
ABCA1 p.Val825Ile 15935359:203:245
status: NEWX
ABCA1 p.Val825Ile 15935359:203:422
status: NEWX
ABCA1 p.Val825Ile 15935359:203:919
status: NEW214 Haplotype structure and haplotype-phenotype association of polymorphisms in the coding region of ABCA1 When the haplotype structure of the coding region was constructed using six polymorphisms (R219K, V771M, V825I, I883M, E1172D, and R1587K; Table 6), 12 haplotypes with a frequency >1% accounted for 95.1% of all haplotypes.
X
ABCA1 p.Val825Ile 15935359:214:208
status: NEW229 (rare allele in LD with rare allele) was observed between pairs of V771M and InsG 319, V825I and I883M, and R1587K and E1172D.
X
ABCA1 p.Val825Ile 15935359:229:87
status: NEW301 The association with V825I and R1587K on plasma HDL-C levels were found in a large general Danish population [17]; however, it was not observed in Dutch men with CAD [18] or in our population.
X
ABCA1 p.Val825Ile 15935359:301:21
status: NEW
PMID: 16429166
[PubMed]
Brunham LR et al: "Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene."
No.
Sentence
Comment
48
This SNP has been reported to be associated with decreased HDL cholesterol and increased severity of atherosclerosis in Table 1. subPSEC Scores and Probability of Functional Impairment (Pdeleterious) for ABCA1 Mutations and SNPs Mutations SNPs Variant SubPSEC Pdeleterious Variant subPSEC Pdeleterious P85L À4.62 0.83 R219K À0.57 0.08 H160F À2.79 0.45 V399A À2.26 0.32 R230C À4.27 0.78 V771M À2.86 0.46 A255T À1.81 0.23 T774P À1.99 0.27 E284K À;2.34 0.34 K776N À3.53 0.63 Y482C À4.21 0.77 V825I À1.06 0.13 R587W À6.04 0.95 I883M À1.38 0.17 W590S À5.19 0.9 E1172D À1.96 0.26 W590L À4.48 0.82 R1587K À0.58 0.08 Q597R À7.15 0.98 S1731C À4.21 0.77 T929I À4.29 0.78 N935H À8.54 1 N935S À7.53 0.99 A937V À6.6 0.97 A1046D À7.52 0.99 M1091T À3.56 0.64 D1099Y À6.09 0.96 D1289N À2.48 0.37 L1379F À3.81 0.69 C1477R À5.44 0.92 S1506L À5.17 0.9 N1611D À5.69 0.94 R1680W À6.02 0.95 V1704D À3.21 0.55 N1800H À4.23 0.77 R1901S À5.06 0.89 F2009S À2.73 0.43 R2081W À8.08 0.99 P2150L À2.88 0.47 Q2196H À2.74 0.43 DOI: 10.1371/journal.pgen.0010083.t001 PLoS Genetics | www.plosgenetics.org December 2005 | Volume 1 | Issue 6 | e83 0740 Accurate Prediction of ABCA1 Variants Synopsis A major goal of human genetics research is to understand how genetic variation leads to differences in the function of genes.
X
ABCA1 p.Val825Ile 16429166:48:488
status: NEWX
ABCA1 p.Val825Ile 16429166:48:543
status: NEW
PMID: 16226177
[PubMed]
Frikke-Schmidt R et al: "Mutation in ABCA1 predicted risk of ischemic heart disease in the Copenhagen City Heart Study Population."
No.
Sentence
Comment
107
However, at the individual level, K776N appears to have a marked impact on risk.
X
ABCA1 p.Val825Ile 16226177:107:965
status: NEW109 However, several arguments favor a true observation: 1) the involved amino acid residue is completely conserved between species and relatively conserved between 12 ABCAs with very different transport functions; 2) the amino acid substitution changes the charge of the side-chain, potentially leading to structural alterations of the protein, and consequently to altered protein interactions or transport properties; 3) in the CFTR (or ABCC7), a disease-causing mutation (R347P) has been identified at a site that corresponds to residue 764 in ABCA1 (15), and thus in close vicinity to K776N; 4) the present study is of a large cohort, and therefore includes only incident cases, avoiding the normal pitfalls of case reports and case-control studies (30); 5) we observed a similar trend on risk of IHD in a separate case-control study; 6) we have previously determined effects on lipids and lipoproteins of all non-synonymous SNPs identified in ABCA1 (R219K, V771M, V825I, I883M, E1172D, R1587K).
X
ABCA1 p.Val825Ile 16226177:109:965
status: NEW
PMID: 16183915
[PubMed]
Oram JF et al: "ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease."
No.
Sentence
Comment
431
The most studied of these SNPs is the R219K variant, with the K allele being associated with higher levels of HDL (255).
X
ABCA1 p.Val825Ile 16183915:431:10
status: NEW432 V771M and V825I SNPs have also been reported to be associated with increased HDL levels, whereas R1587K is associated with low levels of HDL (78, 255).
X
ABCA1 p.Val825Ile 16183915:432:10
status: NEW
PMID: 15528481
[PubMed]
Kyriakou T et al: "Genotypic effect of the -565C>T polymorphism in the ABCA1 gene promoter on ABCA1 expression and severity of atherosclerosis."
No.
Sentence
Comment
87
An interaction between another ABCA1 gene polymorphism (ie, R219K) and smoking has been reported previously, although the underlying mechanisms remain unknown.16 TABLE 2.
X
ABCA1 p.Val825Ile 15528481:87:148
status: NEW93 For example, the R219K polymorphism has been shown to be associated with risk of myocardial infarction and/or severity of atherosclerosis,15-19 the V825I, M883I, and R1587K polymorphisms with various cardiovascular traits,17,20,21 the -191GϾC, -17CϾG, and 69CϾT polymorphisms with risk of coronary events in patients with coronary atherosclerosis,22 and the 319insG polymorphism with severity of atherosclerosis.22 Taken together, these data suggest that the development and outcome of atherosclerosis might be influenced by a qualitative change of the ABCA1 protein caused by coding region variants and a quantitative change in ABCA1 expression caused by regulatory region variants.
X
ABCA1 p.Val825Ile 15528481:93:148
status: NEW
PMID: 14962947
[PubMed]
Tregouet DA et al: "In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction."
No.
Sentence
Comment
79
Strong LD was also present in the coding region for 1 cluster of polymorphisms (R219K, G316G, I680I, V771 M, V825I, I883 M) located in exons 8 to 17.
X
ABCA1 p.Val825Ile 14962947:79:109
status: NEW84 Description and Frequency of ABCA1 Gene Polymorphisms in the 2 Centers From the United Kingdom Sequence Allele Frequency† Name 5Ј Flanking Nucleotide Change 3Ј Flanking Belfast (Nϭ888) Glasgow (Nϭ725) A-1814G CAGCCTCCTG A/g GATAACAGGC 0.339 0.366 C-1801T TAACAGGCGC C/t CGCCACCACA 0.443 0.433 A-1652G CACTGCGCCC A/g GCTCAGATCC 0.350 0.364 G-1506C CTCTTCTATG G/c GTCTGTCCTG 0.203 0.205 C-1395T TGAATGTCTG C/t ATGCAGGTGG 0.428 0.425 G-1252A TGCCCTTCAA G/a GTGGCTACAA 0.095 0.088 C-1217T AGGTAGGAGA C/t CTTGTGGCCT 0.120 0.121 -1034ins/del ATATTTAGAC ϮAT ATGGTGTGTA 0.210 0.220 T-940G GGCAAACAGA T/g AAGTTGGAGG 0.486 0.483 G-803A AAATTAAAAG G/a GGGCTGGTCC 0.108 0.093 -777rpt/23nt* CTGTGTTTTTGTTTGTTTGTTTC 0.527 0.518 -777rpt/28nt CTGTGTTTTTGTTTGTTTTGTTTGTTTC 0.267 0.272 -777rpt/32nt CTGTGTTTTTGTTTGTTTGTTTTGTTTGTTTC 0.206 0.210 C-564T GAGGACTGTC C/t GCCTTCCCCT 0.456 0.472 G-407C GCGGAAAGCA G/c GATTTAGAGG 0.455 0.459 C-302T CGTCTTAGGC C/t GGCGGGCCCG 0.196 0.189 G-278C GGGGGAAGGG G/c ACGCAGACCG 0.435 0.424 C-14T GGAACTAGTC C/t CGGCAAAAAC 0.335 0.346 R219K GGCCTACCAA G/a GGAGAAACTG 0.283 0.278 G316G AGGGAGGGGG G/a CTGAAGATCA 0.114 0.095 I680I ACAACAGCAT C/a CTCTGGTTTA 0.129 0.118 V771 M GCAGGACTAC G/a TGGGCTTCAC 0.029 0.034 V825I CACCACTTCG G/a TCTCCATGAT 0.056 0.060 I883 M AGAAGAGAAT A/g TCAGAAAGTA 0.137 0.126 L1122L GAAGAACCAG C/t TGGGAACAGG 0.023 0.017 E1172D GCGACCATGA G/c AGTGACACGC 0.026 0.027 T1427T GCAGAGACAC G/a CCCTGCCAGG 0.069 0.083 R1587K CTGGACACCA G/a AAATAATGTC 0.216 0.226 *1 subject carried an additional GTTT deletion, leading to an allele of 19 nucleotides.
X
ABCA1 p.Val825Ile 14962947:84:1264
status: NEW124 Discussion Much attention has been focused on the association of ABCA1 gene polymorphisms with different phenotypes including lipid variables and clinical endpoints.23,25-29,39 Several studies have consistently reported an association between the R219K polymorphism and coronary artery disease.23,26,27 This polymorphism has been shown to be associated with triglycerides23 but not with HDL-C.26,27 Inconsistent results were also observed for other ABCA1 gene polymorphisms including V825I, I883 M, and E1172D.
X
ABCA1 p.Val825Ile 14962947:124:484
status: NEW133 Haplotype Structure Defined by the Polymorphisms of the ABCA1 Gene Coding Region (N)6921؍ Polymorphisms Estimated Haplotype Frequencies R219K G316G (G/A) I680I (C/A) V771 M V825I I883 M L1122L (C/T) E1172D T1427T (G/A) R1587K Controls (Nϭ639) Cases (Nϭ657) R G C V V I C E G R 0.470 0.522 R G C V V I C E G K 0.089 0.085 R G C V V I C E A R 0.026 0.031 R G C V V I C D G K 0.018 0.019 R G C V V I T E G R 0.016 0.017 R G A V I M C E G R 0.015 0.015 R G A V I M C E G K 0.015 0.015 R G A V I M C E A R 0.028 0.026 K G C V V I C E G R 0.077 0.063 K G C V V I C E G K 0.041 0.037 K G A V V M C E G R 0.026 0.020 K G A V V M C E G K 0.014 0.012 K G A V V M C E A R 0.016 0.019 K A C V V I C E G R 0.042 0.035 K A C V V I C E G K 0.034 0.027 K A C M V I C E G R 0.028 0.027 The haplotype structure of the coding region of the ABCA1 gene can be completely defined by a minimal subset of 8 "tag" polymorphisms indicated in boxes.
X
ABCA1 p.Val825Ile 14962947:133:195
status: NEW75 Strong LD was also present in the coding region for 1 cluster of polymorphisms (R219K, G316G, I680I, V771 M, V825I, I883 M) located in exons 8 to 17.
X
ABCA1 p.Val825Ile 14962947:75:109
status: NEW80 Description and Frequency of ABCA1 Gene Polymorphisms in the 2 Centers From the United Kingdom Sequence Allele Frequencyߤ Name 5b18; Flanking Nucleotide Change 3b18; Flanking Belfast (Nafd;888) Glasgow (Nafd;725) A-1814G CAGCCTCCTG A/g GATAACAGGC 0.339 0.366 C-1801T TAACAGGCGC C/t CGCCACCACA 0.443 0.433 A-1652G CACTGCGCCC A/g GCTCAGATCC 0.350 0.364 G-1506C CTCTTCTATG G/c GTCTGTCCTG 0.203 0.205 C-1395T TGAATGTCTG C/t ATGCAGGTGG 0.428 0.425 G-1252A TGCCCTTCAA G/a GTGGCTACAA 0.095 0.088 C-1217T AGGTAGGAGA C/t CTTGTGGCCT 0.120 0.121 afa;1034ins/del ATATTTAGAC afe;AT ATGGTGTGTA 0.210 0.220 T-940G GGCAAACAGA T/g AAGTTGGAGG 0.486 0.483 G-803A AAATTAAAAG G/a GGGCTGGTCC 0.108 0.093 afa;777rpt/23nt* CTGTGTTTTTGTTTGTTTGTTTC 0.527 0.518 afa;777rpt/28nt CTGTGTTTTTGTTTGTTTTGTTTGTTTC 0.267 0.272 afa;777rpt/32nt CTGTGTTTTTGTTTGTTTGTTTTGTTTGTTTC 0.206 0.210 C-564T GAGGACTGTC C/t GCCTTCCCCT 0.456 0.472 G-407C GCGGAAAGCA G/c GATTTAGAGG 0.455 0.459 C-302T CGTCTTAGGC C/t GGCGGGCCCG 0.196 0.189 G-278C GGGGGAAGGG G/c ACGCAGACCG 0.435 0.424 C-14T GGAACTAGTC C/t CGGCAAAAAC 0.335 0.346 R219K GGCCTACCAA G/a GGAGAAACTG 0.283 0.278 G316G AGGGAGGGGG G/a CTGAAGATCA 0.114 0.095 I680I ACAACAGCAT C/a CTCTGGTTTA 0.129 0.118 V771 M GCAGGACTAC G/a TGGGCTTCAC 0.029 0.034 V825I CACCACTTCG G/a TCTCCATGAT 0.056 0.060 I883 M AGAAGAGAAT A/g TCAGAAAGTA 0.137 0.126 L1122L GAAGAACCAG C/t TGGGAACAGG 0.023 0.017 E1172D GCGACCATGA G/c AGTGACACGC 0.026 0.027 T1427T GCAGAGACAC G/a CCCTGCCAGG 0.069 0.083 R1587K CTGGACACCA G/a AAATAATGTC 0.216 0.226 *1 subject carried an additional GTTT deletion, leading to an allele of 19 nucleotides.
X
ABCA1 p.Val825Ile 14962947:80:1287
status: NEW120 Discussion Much attention has been focused on the association of ABCA1 gene polymorphisms with different phenotypes including lipid variables and clinical endpoints.23,25-29,39 Several studies have consistently reported an association between the R219K polymorphism and coronary artery disease.23,26,27 This polymorphism has been shown to be associated with triglycerides23 but not with HDL-C.26,27 Inconsistent results were also observed for other ABCA1 gene polymorphisms including V825I, I883 M, and E1172D.
X
ABCA1 p.Val825Ile 14962947:120:484
status: NEW129 Haplotype Structure Defined by the Polymorphisms of the ABCA1 Gene Coding Region (Nd1d;1296) Polymorphisms Estimated Haplotype Frequencies R219K G316G (G/A) I680I (C/A) V771 M V825I I883 M L1122L (C/T) E1172D T1427T (G/A) R1587K Controls (Nafd;639) Cases (Nafd;657) R G C V V I C E G R 0.470 0.522 R G C V V I C E G K 0.089 0.085 R G C V V I C E A R 0.026 0.031 R G C V V I C D G K 0.018 0.019 R G C V V I T E G R 0.016 0.017 R G A V I M C E G R 0.015 0.015 R G A V I M C E G K 0.015 0.015 R G A V I M C E A R 0.028 0.026 K G C V V I C E G R 0.077 0.063 K G C V V I C E G K 0.041 0.037 K G A V V M C E G R 0.026 0.020 K G A V V M C E G K 0.014 0.012 K G A V V M C E A R 0.016 0.019 K A C V V I C E G R 0.042 0.035 K A C V V I C E G K 0.034 0.027 K A C M V I C E G R 0.028 0.027 The haplotype structure of the coding region of the ABCA1 gene can be completely defined by a minimal subset of 8 "tag" polymorphisms indicated in boxes.
X
ABCA1 p.Val825Ile 14962947:129:179
status: NEW
PMID: 15024730
[PubMed]
Katzov H et al: "Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism."
No.
Sentence
Comment
74
Details of ABCA1 SNPs, and Oligos for PCR and DASHn Variant dbSNP rsID Base change Forward primer sequence (50 ^30 ) Reverse primer sequence (30 ^50 ) Probe sequence (50 ^30 ) p.R219K rs2230806 c.658G4A g.10300705G4A b-TTTCTGAGCTTTGTGGCCTACC GCTCTGCTGCAGCCAGTTTCTC GTTTCTCCCTTGGTAGG p.V771M rs2066718 c.2314G4A g.102969093G4A b-TGTGTGTGGCATGGCAGGACTA GCGAAGATCTTGAGTGTGAAGC GAAGCCCACGTAGTCCT p.V825I rs4149312 c.2476G4A g.102967871G4A b-ATGGCTTCAATCTCACCACTTG GGTGTCAAACAGCATCATGGAG CATGGAGACCCAAGTGG p.I883M rs4149313 c.2650A4G g.102966591A4G b-GAGGTCAACAGCACTTACTTTCT AGAAGAGCCACCCTTGTTCCAA AAGAGAATGTCAGAAAG p.R1587K rs2230808 c.4762G4A g.102942642G4A b-ATTTATGACAGGACTGGACACC AGCGGTTTACCTTGACATTATT CATTATTTCTGGTGTCC n Genotyping of SNPs was performed using dynamic allele speci'c hybridization (DASH) [Prince et al., 2001].
X
ABCA1 p.Val825Ile 15024730:74:394
status: NEW86 Marker rs4149312 (c.2476G4A, p.V825I) was found to be monomorphic in set B.
X
ABCA1 p.Val825Ile 15024730:86:31
status: NEW93 Single MarkerAssociations forABCA1and Alzheimer Diseasew p.R219K (rs2230806) G/G G/A A/A P value Set A AD 238 (.62) 125 (.33) 21 (.05) 0.014n Controls 102 (.58) 51 (.29) 22 (.13) Set B AD 58 (.48) 53 (.44) 9 (.08) 0.76 Controls 76 (.53) 59 (.41) 9 (.06) Set C AD 82 (.57) 53 (.37) 8 (.06) 0.66 Controls 183 (.56) 117 (.36) 26 (.08) Set D AD 183 (.56) 122 (.37) 22 (.07) 0.93 Controls 60 (.57) 40 (.38) 6 (.06) p.I883M (rs4149313) C/C C/T T/T Set A AD 2 (.01) 81 (.21) 301 (.78) 0.39 Controls 0 (.00) 31 (.18) 145 (.82) Set B AD 0 (.00) 29 (.24) 91 (.76) 0.27 Controls 3 (.02) 32 (.21) 115 (.77) Set C AD 2 (.01) 27 (.19) 116 (.80) 0.84 Controls 3 (.01) 53 (.17) 256 (.82) Set D AD 3 (.01) 68 (.21) 253 (.78) 0.61 Controls 2 (.02) 19 (.19) 83 (.80) p.R1587K (rs2230808) G/G G/A A/A Set A AD 253 (.66) 114 (.30) 15 (.04) 0.13 Controls 101 (.57) 66 (.38) 9 (.05) Set B AD 56 (.46) 58 (.48) 7 (.06) 0.016n Controls 96 (.64) 48 (.32) 7 (.05) Set C AD 80 (.55) 56 (.39) 9 (.06) 0.70 Controls 189 (.58) 121 (.37) 15 (.05) Det D AD 185 (.57) 118 (.36) 24 (.07) 0.18 Controls 68 (.64) 28 (.26) 10 (.09) p.V771M (rs2066718) G/G G/A A/A Set A AD 365 (.95) 20 (.05) 0 (.00) 0.28 Controls 167 (.95) 7 (.04) 1 (.01) Set B AD 109 (.98) 2 (.02) 0 (.00) 0.029n Controls 126 (.92) 11 (.08) 0 (.00) p.V825I (rs4149312) G/G G/A A/A Set A AD 341 (.93) 20 (.05) 4 (.01) 0.17 Controls 164 (.92) 15 (.08) 0 (.00) w Genotype frequencies for all studied SNPs in ABCA1 are presented.
X
ABCA1 p.Val825Ile 15024730:93:1282
status: NEW
PMID: 14767869
[PubMed]
Yamakawa-Kobayashi K et al: "Associations between serum high-density lipoprotein cholesterol or apolipoprotein AI levels and common genetic variants of the ABCA1 gene in Japanese school-aged children."
No.
Sentence
Comment
39
Missense Polymorphisms in the Coding Region To date, in the coding region of the ABCA1 gene, 9 SNPs inducing amino acid changes have been reported in the dbSNP database; we have ascertained that at least 5 of these missense mutations (K219R, V771M, V825I, M883I, and R1587K) are polymorphic in Japanese populations.
X
ABCA1 p.Val825Ile 14767869:39:249
status: NEW40 Tight linkage disequilib- liums were observed between the V771M polymorphism and the M883I polymorphism, and the V825I polymorphism and the M883I polymorphism (data not shown).
X
ABCA1 p.Val825Ile 14767869:40:113
status: NEW54 *Statistical tests for TG levels were calculated on log-transformed values. Table 4. Relations Between Genotypes of Missense Polymorphisms and the Serum Levels of HDL-C, TG, and apoAI Genotype n HDL-C (mg/dL) P TG (mg/dL)* P apoAI (mg/dL) P K219R KK 97 56.9 Ϯ 11.3 .016 74.3 Ϯ 36.6 .43 136.0 Ϯ 18.8 .012 KR 160 52.2 Ϯ 10.3 77.2 Ϯ 32.3 128.7 Ϯ 17.3 RR 70 54.3 Ϯ 9.7 71.8 Ϯ 31.9 131.2 Ϯ 15.7 V771M VV 265 53.4 Ϯ 10.5 .13 74.4 Ϯ 32.3 .76 130.1 Ϯ 17.5 .035 VM 59 56.8 Ϯ 10.5 79.3 Ϯ 39.2 137.5 Ϯ 17.3 MM 3 57.7 Ϯ 18.2 71.0 Ϯ 14.0 133.3 Ϯ 23.5 V825I VV 134 53.2 Ϯ 10.9 .53 76.3 Ϯ 35.3 .77 130.7 Ϯ 18.3 .54 VI 156 54.9 Ϯ 10.3 74.8 Ϯ 31.6 132.5 Ϯ 17.2 II 37 53.8 Ϯ 11.2 73.1 Ϯ 35.4 129.5 Ϯ 17.4 M8831 MM 120 53.9 Ϯ 11.4 .73 75.3 Ϯ 35.1 .24 131.2 Ϯ 18.0 .90 MI 162 53.8 Ϯ 10.2 76.5 Ϯ 32.3 131.1 Ϯ 18.1 II 45 55.3 Ϯ 10.6 70.6 Ϯ 33.7 133.0 Ϯ 15.7 R1587K RR 114 54.5 Ϯ 10.7 .52 75.2 Ϯ 34.8 .063 131.7 Ϯ 16.9 .49 RK 154 54.0 Ϯ 10.3 78.1 Ϯ 34.3 131.9 Ϯ 17.5 KK 59 53.4 Ϯ 11.7 67.7 Ϯ 27.7 129.5 Ϯ 19.7 NOTE. Values are shown as mean Ϯ SD. P values were calculated by multiple linear regression analyses incorporating sex, age, and BMI as covariates.
X
ABCA1 p.Val825Ile 14767869:54:646
status: NEW59 However, no significant associations were observed between the remaining 3 missense polymorphisms (V825I, M883I, and R1587K) and serum HDL-C, TG, and apoAI levels (Table 4).
X
ABCA1 p.Val825Ile 14767869:59:99
status: NEW55 *Statistical tests for TG levels were calculated on log-transformed values. Table 4. Relations Between Genotypes of Missense Polymorphisms and the Serum Levels of HDL-C, TG, and apoAI Genotype n HDL-C (mg/dL) P TG (mg/dL)* P apoAI (mg/dL) P K219R KK 97 56.9 afe; 11.3 .016 74.3 afe; 36.6 .43 136.0 afe; 18.8 .012 KR 160 52.2 afe; 10.3 77.2 afe; 32.3 128.7 afe; 17.3 RR 70 54.3 afe; 9.7 71.8 afe; 31.9 131.2 afe; 15.7 V771M VV 265 53.4 afe; 10.5 .13 74.4 afe; 32.3 .76 130.1 afe; 17.5 .035 VM 59 56.8 afe; 10.5 79.3 afe; 39.2 137.5 afe; 17.3 MM 3 57.7 afe; 18.2 71.0 afe; 14.0 133.3 afe; 23.5 V825I VV 134 53.2 afe; 10.9 .53 76.3 afe; 35.3 .77 130.7 afe; 18.3 .54 VI 156 54.9 afe; 10.3 74.8 afe; 31.6 132.5 afe; 17.2 II 37 53.8 afe; 11.2 73.1 afe; 35.4 129.5 afe; 17.4 M8831 MM 120 53.9 afe; 11.4 .73 75.3 afe; 35.1 .24 131.2 afe; 18.0 .90 MI 162 53.8 afe; 10.2 76.5 afe; 32.3 131.1 afe; 18.1 II 45 55.3 afe; 10.6 70.6 afe; 33.7 133.0 afe; 15.7 R1587K RR 114 54.5 afe; 10.7 .52 75.2 afe; 34.8 .063 131.7 afe; 16.9 .49 RK 154 54.0 afe; 10.3 78.1 afe; 34.3 131.9 afe; 17.5 KK 59 53.4 afe; 11.7 67.7 afe; 27.7 129.5 afe; 19.7 NOTE. Values are shown as mean afe; SD. P values were calculated by multiple linear regression analyses incorporating sex, age, and BMI as covariates.
X
ABCA1 p.Val825Ile 14767869:55:646
status: NEW60 However, no significant associations were observed between the remaining 3 missense polymorphisms (V825I, M883I, and R1587K) and serum HDL-C, TG, and apoAI levels (Table 4).
X
ABCA1 p.Val825Ile 14767869:60:99
status: NEW
PMID: 12763760
[PubMed]
Singaraja RR et al: "Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene."
No.
Sentence
Comment
136
Single Nucleotide Polymorphisms in the ABCA1 Gene Nucleotide Amino Acid Exon -1095A/G Promoter ⅐ ⅐ ⅐ -477C/T Promoter ⅐ ⅐ ⅐ -419A/C Promoter ⅐ ⅐ ⅐ -320G/C Promoter ⅐ ⅐ ⅐ -191G/C Promoter ⅐ ⅐ ⅐ C69T 5ЈUTR 1 C117G 5ЈUTR 1 InsG319 5ЈUTR 2 G378C 5ЈUTR 2 G1051A R219K 7 T1591C V399A 11 G2706A V771M 16 A2715C T774P 16 G2723C K776N 16 G2826A V825I 17 A3044G I883M 18 G3911C E1172D 24 G5255A R1587K 35 C5587G S1731C 38 markers, namely, increased arterial wall thickness and ABCA1-mediated cholesterol efflux, was performed.73 The study group consisted of 30 individuals heterozygous for 4 different missense mutations in the ABCA1 gene, C1477R, M1091T, P2150L, and T929I.
X
ABCA1 p.Val825Ile 12763760:136:465
status: NEW148 In TABLE 4. Conservation of Amino Acids Polymorphic in Humans cSNP H. sapiens M. musculus G. gallus D. melanogaster C. elegans R219K R R K ⅐ ⅐ ⅐ L V399A V V V A I V771M V V V L Y T774P T S S S G K776N K K K K R V825I V V A M L I883M I V P R A E1172D E E E ⅐ ⅐ ⅐ ⅐ ⅐ ⅐ R1587K R K K E V S1731C S S S T H Five of 10 (50%) amino acids at which cSNPs occur are conserved with G. gallus, indicating a relatively less crucial functional role of these residues compared with those at which mutations occur (Figure 2).
X
ABCA1 p.Val825Ile 12763760:148:232
status: NEW153 The V825I, I883M, and E1172D SNPs have also been associated with increased clinical events and severity of atherosclerosis.75,77 The R219K Variant The R219K SNP has been most studied and highlights many of the difficulties associated with the study of SNPs in general.
X
ABCA1 p.Val825Ile 12763760:153:4
status: NEW162 Functional Effects of cSNPs and Regulatory SNPs in the ABCA1 Gene Nucleotide Amino Acid/Position Lipids CAD/Atherosclerosis Antiatherogenic SNPs C-17G Promoter No change 2 InsG319 5ЈUTR No change 2 G1051A R219K 2 TG, 1 HDL, 1 ApoA-1, 1 ApoB, 1 LDL 2 A3044G I883M 2 TG, 1 HDL 1 Proatherogenic SNPs -191C/-320C/-477T haplotype Promoter No change 1 G-191C Promoter No change 1 A-1095G Promoter No change 1 C117G 5ЈUTR 1 TG No change G2706A V771M No change 1 G2868A V825I No change 1 G3911C E1172D 2 HDL, 2 ApoB 1 G5155A R1587K 2 HDL No change Associations with lipid levels and CAD are shown by arrows to represent the direction of association.
X
ABCA1 p.Val825Ile 12763760:162:474
status: NEW171 The noncoding SNPs G-191C, C-69T, C-17G, and InsG319 and the cSNPs R219K, V771M, and V825I have all been found to be associated with differences in severity of atherosclerosis but not with changes in HDL-C levels in at least 1 study.
X
ABCA1 p.Val825Ile 12763760:171:85
status: NEW128 Single Nucleotide Polymorphisms in the ABCA1 Gene Nucleotide Amino Acid Exon afa;1095A/G Promoter ዼ ዼ ዼ afa;477C/T Promoter ዼ ዼ ዼ afa;419A/C Promoter ዼ ዼ ዼ afa;320G/C Promoter ዼ ዼ ዼ afa;191G/C Promoter ዼ ዼ ዼ C69T 5b18;UTR 1 C117G 5b18;UTR 1 InsG319 5b18;UTR 2 G378C 5b18;UTR 2 G1051A R219K 7 T1591C V399A 11 G2706A V771M 16 A2715C T774P 16 G2723C K776N 16 G2826A V825I 17 A3044G I883M 18 G3911C E1172D 24 G5255A R1587K 35 C5587G S1731C 38 Singaraja et al Clinical and Biochemical Impact of ABCA1 Variants markers, namely, increased arterial wall thickness and ABCA1-mediated cholesterol efflux, was performed.73 The study group consisted of 30 individuals heterozygous for 4 different missense mutations in the ABCA1 gene, C1477R, M1091T, P2150L, and T929I.
X
ABCA1 p.Val825Ile 12763760:128:480
status: NEW140 In TABLE 4. Conservation of Amino Acids Polymorphic in Humans cSNP H. sapiens M. musculus G. gallus D. melanogaster C. elegans R219K R R K ዼ ዼ ዼ L V399A V V V A I V771M V V V L Y T774P T S S S G K776N K K K K R V825I V V A M L I883M I V P R A E1172D E E E ዼ ዼ ዼ ዼ ዼ ዼ R1587K R K K E V S1731C S S S T H Five of 10 (50%) amino acids at which cSNPs occur are conserved with G. gallus, indicating a relatively less crucial functional role of these residues compared with those at which mutations occur (Figure 2).
X
ABCA1 p.Val825Ile 12763760:140:229
status: NEW145 The V825I, I883M, and E1172D SNPs have also been associated with increased clinical events and severity of atherosclerosis.75,77 The R219K Variant The R219K SNP has been most studied and highlights many of the difficulties associated with the study of SNPs in general.
X
ABCA1 p.Val825Ile 12763760:145:4
status: NEW154 Functional Effects of cSNPs and Regulatory SNPs in the ABCA1 Gene Nucleotide Amino Acid/Position Lipids CAD/Atherosclerosis Antiatherogenic SNPs C-17G Promoter No change 2 InsG319 5b18;UTR No change 2 G1051A R219K 2 TG, 1 HDL, 1 ApoA-1, 1 ApoB, 1 LDL 2 A3044G I883M 2 TG, 1 HDL 1 Proatherogenic SNPs afa;191C/afa;320C/afa;477T haplotype Promoter No change 1 G-191C Promoter No change 1 A-1095G Promoter No change 1 C117G 5b18;UTR 1 TG No change G2706A V771M No change 1 G2868A V825I No change 1 G3911C E1172D 2 HDL, 2 ApoB 1 G5155A R1587K 2 HDL No change Associations with lipid levels and CAD are shown by arrows to represent the direction of association.
X
ABCA1 p.Val825Ile 12763760:154:492
status: NEW163 The noncoding SNPs G-191C, C-69T, C-17G, and InsG319 and the cSNPs R219K, V771M, and V825I have all been found to be associated with differences in severity of atherosclerosis but not with changes in HDL-C levels in at least 1 study.
X
ABCA1 p.Val825Ile 12763760:163:85
status: NEW
PMID: 12709788
[PubMed]
Tan JH et al: "ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore."
No.
Sentence
Comment
6
While genotype-phenotype associations were not reproduced across populations and loci, V825I and M883I were clearly associated with CAD status in Malays with no effects on HDL-C or apoA1.
X
ABCA1 p.Val825Ile 12709788:6:87
status: NEW17 The ABCA1 SNPs studied were: -14C>T, located in the proximal promoter (Pullinger et al. 2000; Zwarts et al. 2002); 237indelG, an insertion/deletion of one G nucleotide in the 5'-untranslated region (UTR) (Pullinger et al. 2000; Zwarts et al. 2002); the missense SNPs, V825I in exon 17 (GTC→ATC) and M883I (ATG→ATA) in exon 18, both located upstream of the first nucleotide binding domain (Wang et al. 2000; Clee et al. 2001; Brousseau et al. 2001); and 8994A>G, a novel 3'UTR SNP discovered in the course of this study.
X
ABCA1 p.Val825Ile 12709788:17:268
status: NEW20 The data from Malays showed a strong association of V825I and M883I with the CAD phenotype, especially when the two SNPs were considered simultaneously, and the association was not accompanied by changes in plasma HDL-C or apoA1 levels in the controls.
X
ABCA1 p.Val825Ile 12709788:20:52
status: NEW24 The five SNPs and their alleles in this study were: -14C>T, 237indelG (2g, 3g alleles), V825I (GTC→ATC), M883I (ATG→ATA) (Pullinger et al. 2000; Wang et al. 2000; Clee et al. 2001; Brousseau et al. 2001; Zwarts et al. 2002), and 8994A>G, for which an association study is reported here for the first time.
X
ABCA1 p.Val825Ile 12709788:24:88
status: NEW44 SNPs -14C>T, 237indelG, V825I and I883M were genotyped by restriction fragment length polymorphism (RFLP) assays.
X
ABCA1 p.Val825Ile 12709788:44:24
status: NEW78 In Chinese and Malays, 108 Table 1 Genotyping methods Location SNP Forward primer, PCR size Genotyping reverse primer (bp)c Proximal promoter -14C>T 5'-CGGCTCCACGTGCTTTC-3', 177 BsmA1 5'-CCACTCACTCTCGTCCGCAATTAC-3' 2.5% agarose gel C: 177 bp T: 25, 144 bp Exon 2a 237indelG 5'-GCTGGATTAGCAGTCCTCATTG-3', 301, 302 Bsl1 5'UTR (2g/3g) 5'-CCCCAACTCAAAACCACAAAG-3' 10% polyacrylamide gel 2g: 148, 153 bp 3g: 93, 56, 153 bp Exon 17 V825I 5'-GGTAGCCCACCACTCCCCTAAAG-3', 525 DpnII 5'-ATCAGCTGCCTGTCCTTGGACTA-3' 2.5% agarose gel G: 62, 423, 40 bp A: 62, 241, 182, 40 bp Exon 18b M883I 5'-ATGATGCTGAGCTTGGCTCATAC-3', 171 BsmI 5'-AGGTCAACAGCACTTACTTTCTGG-3' 3% agarose gel A: 171 bp G: 150, 21 bp Exon 50 3'UTR 8994A>G 5'-ATGAGAGAACTATTGTTTGGG-3', 109 SSCP 5'-CTGAAGTCTTACACCTTTAGCG-3' 20% polyacrylamide + 5% glycerol native gel.
X
ABCA1 p.Val825Ile 12709788:78:426
status: NEW82 There were strong ethnic contrasts in allele frequencies at V825I and M883I (Table 3).
X
ABCA1 p.Val825Ile 12709788:82:60
status: NEW87 237indelG and V825I Comparisons of allele and genotype distributions at 237indelG and V825I loci did not indicate any association with CAD status in all three ethnic groups.
X
ABCA1 p.Val825Ile 12709788:87:14
status: NEWX
ABCA1 p.Val825Ile 12709788:87:86
status: NEW104 Genomic distances separating the five SNPs are: -14C>T and 237indelG, 24 kb; 237indelG and V825I, 78 kb; V825I and M883I, 1.3 kb; and M883I and 8994A>G, 42 kb.
X
ABCA1 p.Val825Ile 12709788:104:91
status: NEWX
ABCA1 p.Val825Ile 12709788:104:105
status: NEW105 With the exception of the pair V825I and M883I, the magnitude of LD was generally low (r2<0.06), although statistical significance was noted in some situations.
X
ABCA1 p.Val825Ile 12709788:105:31
status: NEW106 Strong and statistical 110 Table 3 Genotype and allele frequency distributions of ABCA1 SNPs (n number of individuals, n.s. not significant) SNP Chinese males Malay males Indian males CAD Controls CAD Controls CAD Controls -14C>T CC 203 (41.4%) 90 (40.5%) 44 (40%) 52 (41.3%) 45 (28.3%) 78 (37%) CT 242 (49.4%) 107 (48.2%) 60 (54.5%) 68 (54%) 87 (54.7%) 117 (55.5%) TT 45 (9.2%) 25 (11.3%) 6 (5.5%) 6 (4.8%) 27 (17%) 16 (7.6%) n 490 222 110 126 159 211 HWE exact P 0.027 n.s. 0.003 0.001 n.s. 0.001 Frequency C 0.661 0.646 0.673 0.683 0.557* 0.647* 237indelG 2g2g 367 (71.1%) 181 (73%) 70 (61.9%) 126 (71.6%) 92 (57.5%) 115 (49.8%) 2g3g 133 (25.8%) 57 (23%) 40 (35.4%) 44 (25%) 51 (31.9%) 93 (40.3%) 3g3g 16 (3.1%) 10 (4%) 3 (2.7%) 6 (3.4%) 17 (10.6%) 23 (10%) n 516 248 113 176 160 231 HWE exact P n.s. n.s. n.s. n.s. n.s. n.s. Frequency 2g 0.840 0.845 0.796 0.841 0.734 0.699 V825I (GTC>ATC) GG 92 (31.3%) 34 (31.5%) 37 (48.1%) 62 (50.4%) 71 (85.5%) 97 (89%) GA 142 (48.3%) 58 (53.7%) 31 (40.3%) 52 (42.3%) 10 (12%) 12 (11%) AA 60 (20.4%) 16 (14.8%) 9 (11.7%) 9 (7.3%) 2 (2.4%) 0 (0%) n 294 108 77 123 83 109 HWE exact P n.s. n.s. n.s. n.s. n.s. n.s. Frequency G 0.554 0.583 0.682 0.715 0.916 0.945 M883I (ATG>ATA) GG 168 (46.2%) 97 (38.8%) 26 (26%) 22 (13.2%) 6 (3.9%) 3 (1.3%) GA 169 (46.4%) 134 (53.6%) 45 (45%) 87 (52.1%) 20 (13.2%) 34 (15.2%) AA 27 (7.4%) 19 (7.6%) 29 (29%) 58 (34.7%) 126 (82.9%) 186 (83.4%) n 364 250 100 167 152 223 HWE exact P n.s. 0.002 n.s. n.s. n.s. n.s. Frequency G 0.694 0.656 0.485* 0.392* 0.105 0.090 8994A>G AA 342 (66.4%) 193 (71%) 84 (75%) 130 (72.6%) 117 (70.5%) 162 (69.5%) AG 152 (29.5%) 75 (27.6%) 22 (19.6%) 39 (21.8%) 45 (27.1%) 66 (28.3%) GG 21 (4.1%) 4 (1.5%) 6 (5.4%) 10 (5.6%) 4 (2.4%) 5 (2.1%) n 515 272 112 179 166 233 HWE exact P n.s. n.s. n.s. n.s. n.s. n.s. Frequency A 0.812* 0.847* 0.848 0.835 0.840 0.837 *P<0.05, allele frequencies that are statistically different between cases and controls by Fisher`s exact test (one-sided) significant LD was detected between V825I and M883I in both Chinese and Indian case-control samples, as well as in Malay cases, but not in Malay controls (data not shown).
X
ABCA1 p.Val825Ile 12709788:106:878
status: NEWX
ABCA1 p.Val825Ile 12709788:106:2021
status: NEW118 All configurations that omitted both V825I and M883I, or included the former but not the latter, gave insignificant test results, whereas those that included both produced consistently significant outcomes.
X
ABCA1 p.Val825Ile 12709788:118:37
status: NEW119 Furthermore there may be a stronger association with M883I compared with V825I because some haplotype configurations involving M883I, but not V825I, were sufficient to detect a positive association.
X
ABCA1 p.Val825Ile 12709788:119:73
status: NEWX
ABCA1 p.Val825Ile 12709788:119:142
status: NEW120 Hence, based on the results of the haplotype analysis, both V825I and M883I were necessary to be strongly associated with the CAD phenotype in the Malay population, and studying the effect of either SNP alone, in particular V825I, might weaken the association.
X
ABCA1 p.Val825Ile 12709788:120:60
status: NEWX
ABCA1 p.Val825Ile 12709788:120:224
status: NEW121 The reason is that V825I and M883I were not in perfect LD.
X
ABCA1 p.Val825Ile 12709788:121:19
status: NEW127 In Malay cases, for all the eight locus combinations that involved both V825I and M883I, all of them tested positive for disequilibria, whereas in the corresponding controls, every locus combination remained in HWE (Table 6).
X
ABCA1 p.Val825Ile 12709788:127:72
status: NEW133 Notably, the seven significant disequilibria (out of a possible eight) in the Chinese CAD group involved both V825I and I883M; however, two of these disequilibria were also found in the Chinese control group and therefore it was hard to deduce the effects of V825I and I883M on the CAD status in Chinese.
X
ABCA1 p.Val825Ile 12709788:133:110
status: NEWX
ABCA1 p.Val825Ile 12709788:133:259
status: NEW146 V825I Significant trends in lipids between V825I genotypes were not observed in any population.
X
ABCA1 p.Val825Ile 12709788:146:0
status: NEWX
ABCA1 p.Val825Ile 12709788:146:43
status: NEW151 Codes for loci: 1 -14C>T, 2 237indelG, 3 V825I, 4 M883I, 5 8994A>G.
X
ABCA1 p.Val825Ile 12709788:151:41
status: NEW160 The case-control analysis in the Malay population revealed that V825I and M883I are potential markers for the CAD phenotype, but this positive association was not accompanied by changes in plasma HDL-C or apoA1 concentrations in Malay controls.
X
ABCA1 p.Val825Ile 12709788:160:64
status: NEW167 In our study, several lines of evidence implicate V825I and M883I in CAD susceptibility for the Malay population.
X
ABCA1 p.Val825Ile 12709788:167:50
status: NEW169 However, the case-control analysis for V825I did not detect a significant difference, a result that could partly be explained by the smaller number of individuals genotyped for V825I, in which case there would be a higher chance of making a false negative inference or type II error.
X
ABCA1 p.Val825Ile 12709788:169:39
status: NEWX
ABCA1 p.Val825Ile 12709788:169:177
status: NEW170 Also, the LD between V825I and M883I might have partially dissipated.
X
ABCA1 p.Val825Ile 12709788:170:21
status: NEW171 While single-locus frequency comparison was ambiguous in assigning an effect to V825I, analyses using multiple SNPs clearly indicate that both V825I and M883I were associated with CAD status in Malays.
X
ABCA1 p.Val825Ile 12709788:171:80
status: NEWX
ABCA1 p.Val825Ile 12709788:171:143
status: NEW173 Specifically, V825I and M883I were in strong LD in Malay cases but not in Malay controls.
X
ABCA1 p.Val825Ile 12709788:173:14
status: NEW178 The association of both V825I and M883I in CAD susceptibility in Malays was revealed definitively in haplotype frequency and multi-locus disequilibria tests.
X
ABCA1 p.Val825Ile 12709788:178:24
status: NEW180 Based on these observations, it seems that 8994A>G is inconsequential to the CAD phenotype, while the effects of -14C>T and 237indelG are inconclusive; but there is an obvious association of V825I and M883I with CAD status. Moreover, multi-locus HWE tests showed that any combinations that involved both V825I and M883I were always in disequilibria in Malay cases but not in the corresponding controls, thus reinforcing the haplotype association result.
X
ABCA1 p.Val825Ile 12709788:180:191
status: NEWX
ABCA1 p.Val825Ile 12709788:180:304
status: NEW181 Since V825I and M883I code for missense SNPs and are sited near the critical nucleotide-binding domain of the ABCA1 protein, these allelic variants may potentially modulate the biological function of the transporter.
X
ABCA1 p.Val825Ile 12709788:181:6
status: NEW186 In any case, it may be premature at this stage to do a functional analysis of V825I and M883I.
X
ABCA1 p.Val825Ile 12709788:186:78
status: NEW189 Although the data in Malay case-control samples indicated a combined association of V825I and M883I with the CAD phenotype, genotypes of either SNP did not show changes in HDL-C or apoA1 in the controls.
X
ABCA1 p.Val825Ile 12709788:189:84
status: NEW192 Genotypes of V825I showed no association with any lipids in the Malay controls.
X
ABCA1 p.Val825Ile 12709788:192:13
status: NEW197 Existing literature on the associations of V825I and M883I with CAD agree with our findings in the Malay case-control study.
X
ABCA1 p.Val825Ile 12709788:197:43
status: NEW199 Among male CAD participants in a Dutch cohort prospective study, obvious differences in CAD event rate were also detected for V825I or M883I, again without any change in HDL-C (Clee et al. 2001).
X
ABCA1 p.Val825Ile 12709788:199:126
status: NEW221 In summary, our data showed a strong association of V825I and M883I with CAD susceptibility that was specific to the Malay population.
X
ABCA1 p.Val825Ile 12709788:221:52
status: NEW
No.
Sentence
Comment
66
TD 1591 T/C 11 V399A extracellular [68] TD 1979 (110bpAlu Ins) 12 truncated truncation [60] TD/FHA 2154 C/T 14 R587W extracellular [67,69] TD 2164 G/C 14 W590S extracellular [61] TD 2185 A/G 14 Q597R extracellular [59,67] TD 2219 G/del 14 truncated, 635X truncated [60,61] FHA 2472-2474 3bp del 15 Del L693 TM domain #3 [59] phosphorylation 2706 G/A 16 V771M extracellular [68] 2715 A/C 16 T774P extracellular [68] 2723 G/C 16 K776N extracellular [68] 2868 G/A 17 V825I TM domain #6 [67,68] TD/FHA 3044 A/G 18 I883M cytoplasmic [68] phosphorylat site FHA 3120 C/T 19 R909X truncation [63,71] TD 3181 C/T 19 T929I cytoplasmic [62] TD 3199 A/G 19 N935S Walker A [61] TD 3205 C/T 19 A937V Walker A [61] TD 3532 C/A 22 A1046D cytoplasmic, Walker A/B [70] FHA 3667 T/C 23 M1091T cytoplasmic [63] 3690 G/T 23 D1099Y cytoplasmic [9] TD 3738 2bp del 23 1145X truncation [66] FHA 3911 G/C 24 E1172D linker/cytoplasmic [68] FHA 4242 4bp del 27 1297X truncated [64] TD 4260 G/A 27 D1289N linker cytoplasm [64,65] TD 4824 T/C 31 C1477R extracellular [59] TD 4912 C/T 32 S1506L extracellular loop #2 [71] TD 5025 ins A 34 A1544S?1552X truncation [70] 5059 T/C 34 I1555T extracellular loop #2 [67] 5155 G/A 35 R1587K extracellular loop #2 [68] FHA 5226 A/G 36 N1611D extracellular loop #2 [75..] 5338 T/C 36 L1648P extracellular loop #2 [67] TD 5443 C/T 37 R1680W cytoplasmic [74.]
X
ABCA1 p.Val825Ile 12840658:66:464
status: NEW
PMID: 11238261
[PubMed]
Clee SM et al: "Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease."
No.
Sentence
Comment
48
Methods for Restriction Fragment Length Polymorphism Screening of ABCA1 cSNPs Variant pmol of Each Oligo Forward Oligo (5Ј33Ј)* Reverse Oligo (5Ј33Ј)* Annealing Temperature, °C Enzyme Product, bp Wild-type Allele Variant Allele % Agarose Gel for Resolution G1051A 20 GTATTTTTGCAAGGCTACCAGTTACATTTGACAA 60 EcoN I 177 1.5 (R219K) GATTGGCTTCAGGATGTCCATGTTGGAA 107, 70 T1591C 27.5 GCTGCTGTGATGGGGTATCT 57 Hph I 117, 103, 48, 33 1.5 (V399A) ACCTCACTCACACCTGGGAA 220, 48, 33 G2706A 27.5 CAAGTGAGTGCTTGGGATTG 57 BsaA I 98, 252 2 (V771M) TGCTTTTATTCAGGGACTCCA 350 A2715C 27.5 GTGATCCCAGCGTGGTGTTTGTCTT 55 Hph I 56, 69, 95 2 (T774P) GAAAGGCCAGAGGTACTCACAGCGAAGATCTTGAGGG 56, 161 G2723C 12 TCGTTTTATTCAGGGACTCCA 55 Bgl II 269, 80 2 (K776N) CAAGTGAGTGCTTGGGATTG 349 G2868A 27.5 CCCATGCACTGCAGAGATTC 57 Bsa I 149, 237 2 (V825I) GCAAATTCAAATTTCTCCAGG 386 A3044G 27.5 GAGAAGAGCCACCCTGGTTCCAACCAGAAGAGGAT 55 EcoR V 94, 35 2.5 (I883M) AAGGCAGGAGACATCGCTT 129 G3911C 27.5 GAGCAGTTCTGATGCTGGCCTGGGCAGCGACCACGA 55 BssS I 104, 37 2 (E1172D) TCTGCACCTCTCCTCCTCTG 141 G5155A 27.5 CAGCTTGGGAAGATTTATGACAGGACTGGACACGA 55 BssS I 114, 31 2 (R1587K) ATGCCCCTGCCAACTTAC 145 C5587G 20 GTGCAATTACGTTGTCCCTGCCACACT 60 Mnl I 82, 35 3 (S1731C) CCATACAGCAAAAGTAGAAGGGCTAGCACA 117 *Bold indicates mismatch in oligo to create restriction site.
X
ABCA1 p.Val825Ile 11238261:48:838
status: NEW85 Frequencies of ABCA1 cSNPs Nucleotide Change Amino Acid Change Exon REGRESS Carrier Frequency Allele Frequency n* Nonsynonymous G1051A R219K 7 46.3 0.254 1588 T1591C V399A 11 1.6 0.008 1098 G2706A V771M 16 5.8 0.029 1270 A2715C T774P 16 0.6 0.003 1250 G2723C K776N 16 0.5 0.003 1106 G2868A V825I 17 15.7 0.081 1364 A3044G I883M 18 23.8 0.136 840 G3911C E1172D 24 5.3 0.026 1288 G5155A R1587K 35 44.3 0.259 1566 C5587G† S1731C 38 0 0 558 Synonymous From sequencing G869A None 6 62.5 0.38 32 C1331T None 9 31.3 0.19 32 G1343A None 9 25 0.133 32 T3554G None 22 12.5 0.059 32 G4676A None 30 6.3 0.06 32 C6842T None 49 6.3 0.033 32 *Number of alleles screened.
X
ABCA1 p.Val825Ile 11238261:85:290
status: NEW111 Other ABCA1 cSNPs Influence Plasma Lipid Levels and Risk of CAD Carriers of the V825I cSNP (nϭ103 VI ϩ 4 II) had no obvious differences in lipid levels or baseline MSD or MOD (Table 6), but they did have a significantly increased number of events during the trial (44% versus 33% in noncarriers, Pϭ0.0008; odds ratio, 2.31; 95% CI, 1.41 to 3.83).
X
ABCA1 p.Val825Ile 11238261:111:80
status: NEW145 If all V771M and K776N carriers are excluded, the results are unaltered, with increased MOD (1.80Ϯ0.35 versus 1.73Ϯ0.35 mm, Pϭ0.006) and MSD (2.76Ϯ0.36 versus 2.70Ϯ0.37 mm, Pϭ0.02) and lower mean TG levels (1.71Ϯ0.75 versus 1.84Ϯ0.77 mmol/L, Pϭ0.02) in carriers of R219K (nϭ329) compared with noncarriers (nϭ422).
X
ABCA1 p.Val825Ile 11238261:145:4
status: NEW146 The I883M and R1587K cSNPs are also often seen in carriers of R219K.
X
ABCA1 p.Val825Ile 11238261:146:25
status: NEW147 We identified R219K carriers who do not also carry either the I883M or R1587K genotype (nϭ62) and compared them with the group of individuals who do not carry any of the 3 variants (nϭ116).
X
ABCA1 p.Val825Ile 11238261:147:136
status: NEW150 The V825I cSNP was found to be in linkage disequilibrium with I883M.
X
ABCA1 p.Val825Ile 11238261:150:4
status: NEW151 The relative risk of the V825I carriers adjusted for I883M genotype was 2.31 (95% CI, 0.78 to 6.85).
X
ABCA1 p.Val825Ile 11238261:151:25
status: NEW152 Because the effects of the I883M variant were only evident in homozygous carriers, the number of individuals was too few to correct for V825I genotype.
X
ABCA1 p.Val825Ile 11238261:152:136
status: NEW156 No significant differences in lipid levels or CAD were observed for E1172D carriers compared with R1587K heterozygotes without E1172D.
X
ABCA1 p.Val825Ile 11238261:156:147
status: NEW161 ABCA cSNPs in REGRESS MOD, mm MSD, mm HDL-C, mmol/L TG, mmol/L Carrier Noncarrier P Carrier Noncarrier P Carrier Noncarrier P Carrier Noncarrier P V825I 1.74Ϯ0.37 (107) 1.77Ϯ0.35 (575) 0.39 2.70Ϯ0.38 2.75Ϯ0.38 0.21 0.91Ϯ0.23 0.93Ϯ0.22 0.42 1.86Ϯ0.84 1.80Ϯ0.76 0.49 I883M 1.74Ϯ0.38 (100) 1.75Ϯ0.36 (320) 0.71 2.69Ϯ0.38 2.73Ϯ0.36 0.41 0.91Ϯ0.22 0.91Ϯ0.21 0.97 1.75Ϯ0.77 1.82Ϯ0.75 0.42 R1587K 1.77Ϯ0.34 (346) 1.76Ϯ0.37 (433) 0.75 2.73Ϯ0.39 2.74Ϯ0.36 0.64 0.90Ϯ0.22 0.94Ϯ0.23 0.03 1.79Ϯ0.76 1.81Ϯ0.78 0.77 V399A 1.92Ϯ0.32 (9) 1.73Ϯ0.35 (540) 0.13 2.73Ϯ0.40 2.71Ϯ0.37 0.89 1.03Ϯ0.28 0.92Ϯ0.23 0.15 1.71Ϯ0.63 1.82Ϯ0.78 0.68 V771M 1.89Ϯ0.38 (37) 1.76Ϯ0.35 (598) 0.045 2.83Ϯ0.49 2.73Ϯ0.37 0.13 0.91Ϯ0.20 0.92Ϯ0.22 0.58 1.98Ϯ0.79 1.78Ϯ0.76 0.11 T774P 1.63Ϯ0.31 (4) 1.76Ϯ0.36 (621) 0.47 2.85Ϯ0.34 2.73Ϯ0.37 0.52 0.85Ϯ0.07 0.93Ϯ0.22 0.50 1.90Ϯ1.04 1.82Ϯ0.77 0.84 K776N 1.92Ϯ0.33 (3) 1.78Ϯ0.34 (546) 0.48 2.95Ϯ0.48 2.76Ϯ0.37 0.36 0.94Ϯ0.28 0.93Ϯ0.22 0.93 2.25Ϯ0.94 1.76Ϯ0.76 0.26 E117SD 1.80Ϯ0.39 (34) 1.77Ϯ0.36 (610) 0.67 2.78Ϯ0.35 2.74Ϯ0.37 0.42 0.93Ϯ0.23 0.94Ϯ0.23 0.89 1.80Ϯ0.90 1.77Ϯ0.76 0.80 Values are meanϮSD (n).
X
ABCA1 p.Val825Ile 11238261:161:147
status: NEW43 Methods for Restriction Fragment Length Polymorphism Screening of ABCA1 cSNPs Variant pmol of Each Oligo Forward Oligo (5b18;33b18;)* Reverse Oligo (5b18;33b18;)* Annealing Temperature, &#b0;C Enzyme Product, bp Wild-type Allele Variant Allele % Agarose Gel for Resolution G1051A 20 GTATTTTTGCAAGGCTACCAGTTACATTTGACAA 60 EcoN I 177 1.5 (R219K) GATTGGCTTCAGGATGTCCATGTTGGAA 107, 70 T1591C 27.5 GCTGCTGTGATGGGGTATCT 57 Hph I 117, 103, 48, 33 1.5 (V399A) ACCTCACTCACACCTGGGAA 220, 48, 33 G2706A 27.5 CAAGTGAGTGCTTGGGATTG 57 BsaA I 98, 252 2 (V771M) TGCTTTTATTCAGGGACTCCA 350 A2715C 27.5 GTGATCCCAGCGTGGTGTTTGTCTT 55 Hph I 56, 69, 95 2 (T774P) GAAAGGCCAGAGGTACTCACAGCGAAGATCTTGAGGG 56, 161 G2723C 12 TCGTTTTATTCAGGGACTCCA 55 Bgl II 269, 80 2 (K776N) CAAGTGAGTGCTTGGGATTG 349 G2868A 27.5 CCCATGCACTGCAGAGATTC 57 Bsa I 149, 237 2 (V825I) GCAAATTCAAATTTCTCCAGG 386 A3044G 27.5 GAGAAGAGCCACCCTGGTTCCAACCAGAAGAGGAT 55 EcoR V 94, 35 2.5 (I883M) AAGGCAGGAGACATCGCTT 129 G3911C 27.5 GAGCAGTTCTGATGCTGGCCTGGGCAGCGACCACGA 55 BssS I 104, 37 2 (E1172D) TCTGCACCTCTCCTCCTCTG 141 G5155A 27.5 CAGCTTGGGAAGATTTATGACAGGACTGGACACGA 55 BssS I 114, 31 2 (R1587K) ATGCCCCTGCCAACTTAC 145 C5587G 20 GTGCAATTACGTTGTCCCTGCCACACT 60 Mnl I 82, 35 3 (S1731C) CCATACAGCAAAAGTAGAAGGGCTAGCACA 117 *Bold indicates mismatch in oligo to create restriction site.
X
ABCA1 p.Val825Ile 11238261:43:837
status: NEW80 Frequencies of ABCA1 cSNPs Nucleotide Change Amino Acid Change Exon REGRESS Carrier Frequency Allele Frequency n* Nonsynonymous G1051A R219K 7 46.3 0.254 1588 T1591C V399A 11 1.6 0.008 1098 G2706A V771M 16 5.8 0.029 1270 A2715C T774P 16 0.6 0.003 1250 G2723C K776N 16 0.5 0.003 1106 G2868A V825I 17 15.7 0.081 1364 A3044G I883M 18 23.8 0.136 840 G3911C E1172D 24 5.3 0.026 1288 G5155A R1587K 35 44.3 0.259 1566 C5587Gߤ S1731C 38 0 0 558 Synonymous From sequencing G869A None 6 62.5 0.38 32 C1331T None 9 31.3 0.19 32 G1343A None 9 25 0.133 32 T3554G None 22 12.5 0.059 32 G4676A None 30 6.3 0.06 32 C6842T None 49 6.3 0.033 32 *Number of alleles screened.
X
ABCA1 p.Val825Ile 11238261:80:290
status: NEW106 Other ABCA1 cSNPs Influence Plasma Lipid Levels and Risk of CAD Carriers of the V825I cSNP (nafd;103 VI af9; 4 II) had no obvious differences in lipid levels or baseline MSD or MOD (Table 6), but they did have a significantly increased number of events during the trial (44% versus 33% in noncarriers, Pafd;0.0008; odds ratio, 2.31; 95% CI, 1.41 to 3.83).
X
ABCA1 p.Val825Ile 11238261:106:80
status: NEW
PMID: 11558901
[PubMed]
Iida A et al: "High-density single-nucleotide polymorphism (SNP) map of the 150-kb region corresponding to the human ATP-binding cassette transporter A1 (ABCA1) gene."
No.
Sentence
Comment
15
Therefore, information concerning naturally occurring genetic variants in human transporter genes such as ABCA1 Fig.1.Single-nucleotidepolymorphism(SNP)mapspanningthe150-kbregioncontainingtheABCA1gene.Exonsarerepresentedbyopenrectanglesandintronsbyhorizontallines.SNPs areindicatedabovethelinesaccordingtonumber(correspondingtothenumbersinthefar-leftcolumnofTable1);thepositionsofeightinsertion-deletionpolymorphismsareindicatedbelow thelines(seeTable2).Microsatellitesequencesarealsoshown Table 1. Characterization of 162 single-nucleotide polymorphisms (SNPs) within the ABCA1 locus Repetitive Identity Number Location Exon SNP (5Ј to 3Ј) Substituion sequence to dbSNP Reference 1 -278 G Ͼ C 5Ј flanking region gggcccgggcgggggaaggg G/C acgcagaccgcggaccctaa rs1800976 2 -99 G Ͼ C 5Ј flanking region acataaacagaggccgggaa G/C ggggcggggaggagggagag 3 159 G Ͼ T intron 1 gcggtgttaaatggggagac G/T atgtcctagtacgagctctg 4 506 G Ͼ C intron 1 gaattggctatatgctcccc G/C ggactggagcggcacagtcc 5 5897 T Ͼ G intron 1 gtacaaaaccctttagcttt T/G gcaaacctcctttaagaccc 6 5929 C Ͼ T intron 1 ttaagacccgatttaaatgc C/T tccctcctcatgaagctctt 7 5962 T Ͼ C intron 1 aagctcttctggatccactc T/C ttcccatcactaagttgaaa 8 5985 A Ͼ C intron 1 cccatcactaagttgaaagt A/C agatccccttctctttactt 9 11416 G Ͼ A intron 1 ttacagtgccctttatagga G/A agaaagaagaaattgtgtct 10 11935 G Ͼ A intron 1 tctctgtggagcaaatagag G/A gctgtctgacacttggttcc 11 12281 T Ͼ A intron 1 gaatgtttgatttgtgaaaa T/A cttaataacagtagtttttt 12 12924 T Ͼ C intron 1 gtgctgacaatcttatactc T/C aggttgaacctccggggaag 13 13002 C Ͼ G intron 1 gagcctcaatcacagattct C/G tctagctcacatgaagttaa 14 17715 C Ͼ T intron 1 ggagcatgactttgtggaag C/T ctctcctcttccacccagag 15 17848 T Ͼ C intron 1 gagggctgactgtcaccctt T/C gataggagcccagcactaaa 16 21384 G Ͼ C intron 1 gtgggtgggaggaattggag G/C aggaagcttgcctaagtgtg 17 22145 C Ͼ G intron 1 gtagcttctaaatcaacgaa C/G tgattcctggagagcagctt rs1340361 18 23063 G Ͼ A intron 1 ggaggcacctgtgacaccca G/A cggagtaggggggcggtgtg 19 23131 G Ͼ A intron 1 agtgtgcatatgtgctgacc G/A tgggagcttgtttgtcggtt 20 156 T Ͼ C intron 2 ggacacaggactgtgtggtc T/C ggatatggcatgtggcttat rs1078143 21 384 A Ͼ G intron 2 gctgtgggtgaagtgagtta A/G tggccccactcttagagatc rs1078144 22 1081 G Ͼ A intron 2 agtgcagccaaaattgcaaa G/A tcataccattcaaattaata rs752187 23 2801 A Ͼ G intron 2 aagaaaagtgatttatttca A/G gttgctgatgcttagattgt 24 2830 C Ͼ G intron 2 tgcttagattgttagagttg C/G aaagatctggcttgcatctt 25 2856 A Ͼ G intron 2 tctggcttgcatcttgtaca A/G ctgacagaactggggctcag 26 3187 A Ͼ G intron 2 tgatagctgttgcctgcagc A/G tacggacgttcattgcgcag 27 3190 C Ͼ T intron 2 tagctgttgcctgcagcata C/T ggacgttcattgcgcagttc 28 3194 C Ͼ T intron 2 tgttgcctgcagcatacgga C/T gttcattgcgcagttcctgt 29 3204 G Ͼ A intron 2 agcatacggacgttcattgc G/A cagttcctgtctcctgagat 30 3401 T Ͼ C intron 2 acataaagcctgtgtgctgc T/C gccaggaagactagaaacgc 31 13927 A Ͼ G intron 2 gtcaccacatacctggcact A/G tgctaaggctgggaatgcag L2 32 4163 G Ͼ A intron 3 ccagcccacttcatcttacc G/A tagttacctccttagagtat 33 4262 T Ͼ C intron 3 tgtcaaagaggaactaagga T/C gccagggactttctgcttag 34 4306 C Ͼ T intron 3 ccctctcatcacttctccaa C/T gctggtatcatgaaccccat 35 240 G Ͼ A intron 5 gacagaagaaaagtccccag G/A gaagaatactacagacttgg rs1107281 36 490 G Ͼ A intron 5 gatgggcatttgaacttgtt G/A tctttaaaaagtgaaatctt 37 583 T Ͼ G intron 5 tatctggggagtgggcattt T/G ctgactgaggcattggctgc 38 1051 C Ͼ T inton 5 ggctacaaaactgtgctttc C/T ttgggcagtaaaagaggcaa 39 3051 G Ͼ A intron 5 tagagaacaagtctaattct G/A ttttccttgaaatagtcgaa 40 3127 A Ͼ G intron 5 aagtccatgattttttaggc A/G aaatggcctcctttcctctt 41 5924 C Ͼ T intron 5 ctttctttcacaaaattgcc C/T cccagagctttctggaaggg 42 6831 T Ͼ C intron 5 ccagtccctcagccttgcca T/C tgcttatgctggtctggaaa 43 12678 G Ͼ C intron 5 gctcaccgctctgctcaccc G/C accctctggccatctcctct 44 14214 G Ͼ A intron 5 cagcttggtcccagaggcct G/A gacctgggtcccagaggtcc 45 14257 C Ͼ T intron 5 gctggttccccggcttggtc C/T cagaggcctggatgtgtggc 46 18078 C Ͼ T intron 5 cctaccacaccatgcacgtg C/T acagccaagggttgttgact 47 18795 G Ͼ A intron 5 ctgggctcttcctggacctg G/A ccagctaaaaggaaatctcc 48 18948 G Ͼ A intron 5 gcattggtggtactaagaac G/A catattccctatcctatagg L2 49 19053 T Ͼ C intron 5 ctcccccaacattaaaagtg T/C aagggatgcttattcaaatg MER5A 50 19148 C Ͼ A intron 5 ggcccaagaaactgcatttt C/A gcatgctccctaaatgaagc MER5A 51 19229 C Ͼ T intron 5 atgctaacagtgtagagtca C/T atgtgatgggaagcatcagg 52 19405 T Ͼ C intron 5 cttgctcaatttattctgtc T/C atataactcaatattactga 53 19534 G Ͼ A intron 5 catgtgaccctcttagctcc G/A cggattaactcctgtcctca 54 474 G Ͼ A coding region 6 gaaaccttctctgggttcct G/A tatcacaacctctctctccc Leu 158 Leu 55 210 A Ͼ C intron 6 gcaacctggcgtcatgggcc A/C gctggttaaaataaaattga 56 334 G Ͼ A intron 6 acagttctgaggcaataacc G/A tggttaagggttattgatct 57 2288 C Ͼ T intron 6 cttctttcaaagcttgtggt C/T cactggaccacgtatgaagt 58 2322 T Ͼ C intron 6 atgaagtagaatagtttagg T/C ccagaaaggcaattaagtaa 59 2820 T Ͼ G intron 6 gtgctttgatacattctgag T/G ttcagtaaagagacctgatg 60 656 G Ͼ A coding region 7 tgagctttgtggcctaccaa G/A ggagaaactggctgcagcag Arg 219 Lys Clee et al. 2001 61 416 G Ͼ A intron 7 catcataaagatgacattgt G/A ggctgtcacagttggaaggc 62 471 C Ͼ T intron 7 agaccacactatttagctta C/T ttagtaataacattgcaaag 63 504 G Ͼ A intron 7 ttgcaaagaaaaattccgac G/A aagttttttcagcctaggaa 64 679 G Ͼ C intron 7 gctctggtgaaattcctctc G/C ctaccccaaacatcatcatt 65 1740 C Ͼ T intron 7 acaaatgctcaccctttcag C/T tggaatgattgaaattttgg 66 2122 A Ͼ G intron 7 tgattaaggtggctactacc A/G ggtgctttctgcatatctcg 67 7753 T Ͼ C intrion 7 taggaattccaagctgtgaa T/C tttttactgaagctctttgg 68 8973 A Ͼ T intron 7 atggaaatttgtttatattg A/T ctacagattgccaatattat 69 8976 A Ͼ G intron 7 gaaatttgtttatattgact A/G cagattgccaatattattag Table 1. Continued Repetitive Identity Number Location Exon SNP (5Ј to 3Ј) Substituion sequence to dbSNP Reference 70 11327 G Ͼ C intron 7 ctaacaatcttatttccatt G/C agtccttataaaagaagtgg 71 11738 C Ͼ T intron 7 ctgacgtttaagggagaccg C/T gtaggtccctttgaggactg 72 12295 T Ͼ A intron 7 agtctgtaaattattgttct T/A ttttttctttagcttatgct 73 387 C Ͼ G intron 8 tagcaaggccaatcatttta C/G caacacacatgcttgctaac 74 697 A Ͼ T intron 8 ggaactgtctggtgtccccc A/T gcataggaagctgagccagg 75 1312 G Ͼ A intron 8 attgctctgcagatcccctc G/A cagccctctgtcccttgttc rs1175929 76 3036 T Ͼ G intron 8 ctttatgtgggaagaaattt T/G tttttttgattggggagtgg 77 3176 C Ͼ A intron 8 aaatggcctggttctctgtc C/A cctttctgtctgtatgcctc 78 3364 A Ͼ T intron 8 ggcagaaggcaaagcttagg A/T cctagagagtgctggaccac 79 3373 G Ͼ A intron 8 caaagcttaggacctagaga G/A tgctggaccacgccactcac 80 3561 C Ͼ A intron 8 cagggatttattaatgattt C/A ttgtgaaatgtttggaaata 81 3654 T Ͼ C intron 8 agtgccggaatacatttgca T/C gtaagacagaacgctgcctg 82 4715 C Ͼ T intron 8 ggcagaggggtctcagaatc C/T gcatttccaacaatgtctcc 83 936 C Ͼ T coding region 9 cgtattgtctgcgggcatcc C/T gagggaggggggctgaagat Pro 312 Pro 84 2309 A Ͼ G intron 9 cccctcaagagtcagtttaa A/G tgttggtcatgttagttgtc 85 2392 T Ͼ C intron 9 atgggagggcttgtgcttca T/C gaaaacatttttccagatca 86 228 A Ͼ G intron 10 tggggatggggaggactggc A/G cagggctgctgtgatggggt 87 319 C Ͼ T intron 10 ttctgcggtccctggctccc C/T acctgactccaggtgaacaa 88 377 A Ͼ C intron 11 gaaagaagtgtgggagcaaa A/C gcatgatgttacatgtagac 89 521 G Ͼ A intron 11 agtgctctagagacaattgg G/A ttcaaatgtggagcaggctg 90 2850 G Ͼ C intron 11 ctctatacaatcattatgct G/C ccattgaaataataaataca 91 2976 A Ͼ G intron 11 ctccaattcggtagaaccag A/G gcttcatcttctctgtcgaa 92 3056 C Ͼ T intron 11 gtttgcagctgctgtttttc C/T ggcagcacatctgtgcaggc 93 340 T Ͼ C intron 12 ggcattatttgtgaaactta T/C ctaaaatcgaattcgggtcc 94 381 A Ͼ G intron 12 aattaaatttttgaaatttt A/G tattaaaaattatattagta 95 1728 C Ͼ T intron 14 caggctcagaggccttggcc C/T atcaccctggctcacgtgtg 96 2040 C Ͼ A coding region 15 atgggcctggacaacagcat C/A ctctggtttagctggttcat Ile 680 Ile 97 1382 G Ͼ A intron 15 cttttagacagaaaagttac G/A tgggatattatctcccacag 98 1453 G Ͼ A intron 15 tatataaggagaaaccagtt G/A aaattacctattgaagaaac 99 1567 G Ͼ A intron 15 ttctgcgtagttttgggtaa G/A tcacttatcttctttaggat MIR 100 1617 T Ͼ A intron 15 cagttgcctcatcagaaaga T/A gaacagcattacgcctctgc MIR 101 95 T Ͼ A intron 16 agttgagaacagaagatgat T/A gtcttttccaatgggacatg 102 452 G Ͼ A intron 16 tggtgttttgcttgagtaat G/A ttttctgaactaagcacaac 103 657 T Ͼ C intron 16 ctgttgcctcagtctgggct T/C cataggcatcagcagcccca 104 2473 G Ͼ A coding region 17 gcttcaatctcaccacttcg G/A tctccatgatgctgtttgac Val 825 Ile Clee et al. 2001 105 2649 A Ͼ G coding region 18 ggttccaaccagaagagaat A/G tcagaaagtaagtgctgttg Ile 883 Met Clee et al. 2001 106 1730 C Ͼ G intron 18 tgaaagttcaagcgcagtgc C/G ctgtgtccttacactccact 107 426 A Ͼ G intron 19 aggaccttacagtgggtagt A/G tcaggaggggtcaggggctg 108 468 A Ͼ G intron 19 aaagcaccagcgttagcctc A/G gtggcttccagcacgattcc 109 876 C Ͼ T intron 20 ccctcctcatctaaagtgaa C/T acatggggctcatgtgcagg 110 118 T Ͼ G intron 22 catgggatactcttctgtta T/G cacagaagagataaagggca 111 560 G Ͼ A intron 22 aaagctttgccattctaggg G/A tcatagccatacagggtgaa 112 102 A Ͼ G intron 23 accccttttgccatgttgaa A/G ccaccatctccctgctctgt 113 287 C Ͼ T intron 23 gtcaaagaaaagagacttgt C/T aagaggtaagagccttggct 114 1063 G Ͼ A intron 23 acctttcaccctcaggaagc G/A aggctgttcacacggcacac 115 321 T Ͼ G intron 25 ctctttacttaagtacagtg T/G gaggaacagcggcatcagga MER5A 116 376 G Ͼ C intron 25 gttagaaattcagcaacttg G/C gcccagctcagacctactga MER5A 117 478 C Ͼ T intron 25 catacataggaaatgacaaa C/T gtttatggatggatagtcta 118 579 G Ͼ T intron 25 tcatttaattctcaaaaaaa G/T atgaaaaaatgaacactcag 119 153 C Ͼ T intron 27 aatggtaaaagccacttgtt C/T tttgcagcatcgtgcatgtg 120 1058 C Ͼ T intron 28 actatcatgggagataatga C/T tatggttgtccatgattgga 121 1317 C Ͼ T intron 28 caggacccagtgttctgagt C/T accctgaatgtgagcactat 122 372 T Ͼ C intron 30 tatatgatttttaggttttg T/C ttatcagcttcttcgctttt 123 506 A Ͼ G intron 30 ccttttaaaaagtaagcagt A/G gataaataaattcagtgaag 124 1033 G Ͼ C intron 30 ctggatttcatggtgccttt G/C attttccacatgaaggttgt 125 4281 G Ͼ A coding region 31 tcttccctttgcagagacac G/A ccctgccaggcaggggagga Thr 1427 Thr 126 626 C Ͼ T intron 33 ggctccttgttactgatttc C/T gtcttttctctctgcctttt 127 719 G Ͼ A intron 33 taatagccctcatgctagaa G/A ggagccggagcctgtgtata 128 726 G Ͼ A intron 33 cctcatgctagaagggagcc G/A gagcctgtgtataaggccag 129 889 A Ͼ G intron 33 ctttcctcaatgtctcagct A/G tctaactgtgtgtgtaatca 130 1097 G Ͼ C intron 33 ctgtgcaccccactgtctgg G/C ttttaatgtcaggctgttct 131 4760 G Ͼ A coding region 35 tatgacaggactggacacca G/A aaataatgtcaaggtaaacc Arg 1587 Lys Clee et al. 2001 132 234 T Ͼ C intron 35 aacctatctaaacctcagtt T/C cctcatctgtgaaatggaga MIR 133 411 C Ͼ T intron 37 aactctgtacattttatcag C/T agcttatccatccattgcaa 134 1224 A Ͼ G intron 37 caggcataggtgattcagag A/G tgaaaggtcaagtccctgaa L2 135 1720 G Ͼ T intron 37 aaattaaaattactctgact G/T ggaatccatcgttcagtaag 136 251 T Ͼ G intron 40 tgaaggtaaggaaaatagtg T/G tatttgcttggatccactgg 137 252 T Ͼ C intron 40 gaaggtaaggaaaatagtgt T/C atttgcttggatccactggc 138 319 A Ͼ G intron 40 agcactggaaaagtcaaacc A/G taactttgagaattaggtga Table 2. Characterization of insertion/deletion polymorphisms at the ABCA1 locus Number Location Variations (5Ј to 3Ј) 1 (-1033)-(-1032) ins AT 5Ј flanking region tgacttaaatatttagacat (AT/ϩ) ggtgtgtaggcctgcattcc 2 6368 del C intron 5 ttctgatggggttgttgctg (C/-) tgagaatcatgactgggtgg 3 9709 del T intron 5 cattttctgtctgaaccccc (T/-) cacccattcaggcagctgct 4 13816 del T intron 5 tccctacttctccttttttt (T/-) catttgcctcctccacccac 5 270-271 ins G intron 10 cttttcagggaggagccaaa (G/ϩ) cgctcattgtctgtgcttct 6 611-612 ins C intron 20 tttagcccatcctctccccc (C/ϩ) gccaccctccttattgaggc 7 391-392 ins T intron 32 gagtgccttgggtactctct (T/ϩ) gatgggggactccatgataa 8 847 del C intron 37 gctgtatattgtgaatgtcc (C/-) gttttcaaaagcaaagccaa Nucleotide numbering is according to the mutation nomenclature (den Dunnen and Antonarakis, 2000) (ϩ), insertion polymorphism; (-), deletion polymorphism Table 1. Continued Repetitive Identity Number Location Exon SNP (5Ј to 3Ј) Substituion sequence to dbSNP Reference 139 957 G Ͼ C intron 40 cttgttactcttttttcctt G/C tcatgggtgatagccatttg 140 146 C Ͼ T intron 41 tgatgtgggcatcccgcagc C/T ccctccctgcccatcctgga 141 239 A Ͼ C intron 42 cattggttttatatgcttac A/C tttatgtgttagttattaaa 142 321 T Ͼ A intron 42 aataaatggttgattttgag T/A ttgagtttcatagtccaaaa 143 322 T Ͼ C intron 42 ataaatggttgattttgagt T/C tgagtttcatagtccaaaaa 144 533 G Ͼ A intron 42 agatgaaaaattatgtagat G/A ataatgaatgatacggttct 145 546 A Ͼ G intron 42 tgtagatgataatgaatgat A/G cggttctaaaaagacaggtt 146 739 T Ͼ A intron 43 tacagccacacttaaaatgg T/A cccattatgaaatacatatt 147 18 T Ͼ C intron 44 taggtgagaaaagaagtggc T/C tgtattttgctgcaaagact 148 264 T Ͼ C intron 44 acaatataatttgcttgttt T/C ttaagagtataatttagtga L1MB8 149 279 T Ͼ C intron 44 tgttttttaagagtataatt T/C agtgatttttggtaaattga L1MB8 150 508 C Ͼ T intron 44 tttacattgctacataaaat C/T cccctatgtacatgtaccta 151 1477 A Ͼ T intron 44 gatctcctctcctgtctctt A/T catttttgcagtagcaatgt 152 1665 G Ͼ A intron 44 tggttgtaagaactgatttg G/A ttggtatagctgtgagggcc 153 1956 T Ͼ G intron 44 gtgttgctcacactcaaaat T/G tctgggccttctcatttggt 154 68 T Ͼ C intron 45 aatatataccttatggcttt T/C ccacacgcattgacttcagg 155 608 G Ͼ C intron 46 ttatactgacttcaatagag G/C tttcagacaaaaagttgttt 156 336 T Ͼ C intron 47 ttcacaattgtaaacaccac T/C acactgaacagcatcatccc L1MD2 157 55 G Ͼ C intron 49 agggtgtggattcctgcccc G/C acactcccgcccataggtcc rs1331924 158 7479 C Ͼ T 3Ј untranslated region 50 aacaaaaatgtgggtgtctc C/T aggcacgggaaacttggttc 159 8226 C Ͼ T 3Ј untranslated region 50 aggagcccactgtaacaata C/T tgggcagccttttttttttt 160 8682 G Ͼ A 3Ј untranslated region 50 aacttcttccactttttcca G/A aatttgaatattaacgctaa rs363717 161 8697 C Ͼ T 3Ј untranslated region 50 ttccagaatttgaatattaa C/T gctaaaggtgtaagacttca 162 9097 A Ͼ G 3Ј untranslated region 50 aactattttgaagaaaacac A/G acattttaatacagattgaa Nucleotide numbering is according to the mutation nomenclature (den Dunnen and Antonarakis, 2000) is an important resource for understanding not only the etiology and risk of some diseases, but also the pharmacokinetics or pharmacodyamics of drugs used to treat them.
X
ABCA1 p.Val825Ile 11558901:15:8867
status: NEW19 Microsatellite sequences are also shown Table 1. Characterization of 162 single-nucleotide polymorphisms (SNPs) within the ABCA1 locus Repetitive Identity Number Location Exon SNP (5b18; to 3b18;) Substituion sequence to dbSNP Reference 1 afa;278 G b0e; C 5b18; flanking region gggcccgggcgggggaaggg G/C acgcagaccgcggaccctaa rs1800976 2 afa;99 G b0e; C 5b18; flanking region acataaacagaggccgggaa G/C ggggcggggaggagggagag 3 159 G b0e; T intron 1 gcggtgttaaatggggagac G/T atgtcctagtacgagctctg 4 506 G b0e; C intron 1 gaattggctatatgctcccc G/C ggactggagcggcacagtcc 5 5897 T b0e; G intron 1 gtacaaaaccctttagcttt T/G gcaaacctcctttaagaccc 6 5929 C b0e; T intron 1 ttaagacccgatttaaatgc C/T tccctcctcatgaagctctt 7 5962 T b0e; C intron 1 aagctcttctggatccactc T/C ttcccatcactaagttgaaa 8 5985 A b0e; C intron 1 cccatcactaagttgaaagt A/C agatccccttctctttactt 9 11416 G b0e; A intron 1 ttacagtgccctttatagga G/A agaaagaagaaattgtgtct 10 11935 G b0e; A intron 1 tctctgtggagcaaatagag G/A gctgtctgacacttggttcc 11 12281 T b0e; A intron 1 gaatgtttgatttgtgaaaa T/A cttaataacagtagtttttt 12 12924 T b0e; C intron 1 gtgctgacaatcttatactc T/C aggttgaacctccggggaag 13 13002 C b0e; G intron 1 gagcctcaatcacagattct C/G tctagctcacatgaagttaa 14 17715 C b0e; T intron 1 ggagcatgactttgtggaag C/T ctctcctcttccacccagag 15 17848 T b0e; C intron 1 gagggctgactgtcaccctt T/C gataggagcccagcactaaa 16 21384 G b0e; C intron 1 gtgggtgggaggaattggag G/C aggaagcttgcctaagtgtg 17 22145 C b0e; G intron 1 gtagcttctaaatcaacgaa C/G tgattcctggagagcagctt rs1340361 18 23063 G b0e; A intron 1 ggaggcacctgtgacaccca G/A cggagtaggggggcggtgtg 19 23131 G b0e; A intron 1 agtgtgcatatgtgctgacc G/A tgggagcttgtttgtcggtt 20 156 T b0e; C intron 2 ggacacaggactgtgtggtc T/C ggatatggcatgtggcttat rs1078143 21 384 A b0e; G intron 2 gctgtgggtgaagtgagtta A/G tggccccactcttagagatc rs1078144 22 1081 G b0e; A intron 2 agtgcagccaaaattgcaaa G/A tcataccattcaaattaata rs752187 23 2801 A b0e; G intron 2 aagaaaagtgatttatttca A/G gttgctgatgcttagattgt 24 2830 C b0e; G intron 2 tgcttagattgttagagttg C/G aaagatctggcttgcatctt 25 2856 A b0e; G intron 2 tctggcttgcatcttgtaca A/G ctgacagaactggggctcag 26 3187 A b0e; G intron 2 tgatagctgttgcctgcagc A/G tacggacgttcattgcgcag 27 3190 C b0e; T intron 2 tagctgttgcctgcagcata C/T ggacgttcattgcgcagttc 28 3194 C b0e; T intron 2 tgttgcctgcagcatacgga C/T gttcattgcgcagttcctgt 29 3204 G b0e; A intron 2 agcatacggacgttcattgc G/A cagttcctgtctcctgagat 30 3401 T b0e; C intron 2 acataaagcctgtgtgctgc T/C gccaggaagactagaaacgc 31 13927 A b0e; G intron 2 gtcaccacatacctggcact A/G tgctaaggctgggaatgcag L2 32 4163 G b0e; A intron 3 ccagcccacttcatcttacc G/A tagttacctccttagagtat 33 4262 T b0e; C intron 3 tgtcaaagaggaactaagga T/C gccagggactttctgcttag 34 4306 C b0e; T intron 3 ccctctcatcacttctccaa C/T gctggtatcatgaaccccat 35 240 G b0e; A intron 5 gacagaagaaaagtccccag G/A gaagaatactacagacttgg rs1107281 36 490 G b0e; A intron 5 gatgggcatttgaacttgtt G/A tctttaaaaagtgaaatctt 37 583 T b0e; G intron 5 tatctggggagtgggcattt T/G ctgactgaggcattggctgc 38 1051 C b0e; T inton 5 ggctacaaaactgtgctttc C/T ttgggcagtaaaagaggcaa 39 3051 G b0e; A intron 5 tagagaacaagtctaattct G/A ttttccttgaaatagtcgaa 40 3127 A b0e; G intron 5 aagtccatgattttttaggc A/G aaatggcctcctttcctctt 41 5924 C b0e; T intron 5 ctttctttcacaaaattgcc C/T cccagagctttctggaaggg 42 6831 T b0e; C intron 5 ccagtccctcagccttgcca T/C tgcttatgctggtctggaaa 43 12678 G b0e; C intron 5 gctcaccgctctgctcaccc G/C accctctggccatctcctct 44 14214 G b0e; A intron 5 cagcttggtcccagaggcct G/A gacctgggtcccagaggtcc 45 14257 C b0e; T intron 5 gctggttccccggcttggtc C/T cagaggcctggatgtgtggc 46 18078 C b0e; T intron 5 cctaccacaccatgcacgtg C/T acagccaagggttgttgact 47 18795 G b0e; A intron 5 ctgggctcttcctggacctg G/A ccagctaaaaggaaatctcc 48 18948 G b0e; A intron 5 gcattggtggtactaagaac G/A catattccctatcctatagg L2 49 19053 T b0e; C intron 5 ctcccccaacattaaaagtg T/C aagggatgcttattcaaatg MER5A 50 19148 C b0e; A intron 5 ggcccaagaaactgcatttt C/A gcatgctccctaaatgaagc MER5A 51 19229 C b0e; T intron 5 atgctaacagtgtagagtca C/T atgtgatgggaagcatcagg 52 19405 T b0e; C intron 5 cttgctcaatttattctgtc T/C atataactcaatattactga 53 19534 G b0e; A intron 5 catgtgaccctcttagctcc G/A cggattaactcctgtcctca 54 474 G b0e; A coding region 6 gaaaccttctctgggttcct G/A tatcacaacctctctctccc Leu 158 Leu 55 210 A b0e; C intron 6 gcaacctggcgtcatgggcc A/C gctggttaaaataaaattga 56 334 G b0e; A intron 6 acagttctgaggcaataacc G/A tggttaagggttattgatct 57 2288 C b0e; T intron 6 cttctttcaaagcttgtggt C/T cactggaccacgtatgaagt 58 2322 T b0e; C intron 6 atgaagtagaatagtttagg T/C ccagaaaggcaattaagtaa 59 2820 T b0e; G intron 6 gtgctttgatacattctgag T/G ttcagtaaagagacctgatg 60 656 G b0e; A coding region 7 tgagctttgtggcctaccaa G/A ggagaaactggctgcagcag Arg 219 Lys Clee et al. 2001 61 416 G b0e; A intron 7 catcataaagatgacattgt G/A ggctgtcacagttggaaggc 62 471 C b0e; T intron 7 agaccacactatttagctta C/T ttagtaataacattgcaaag 63 504 G b0e; A intron 7 ttgcaaagaaaaattccgac G/A aagttttttcagcctaggaa 64 679 G b0e; C intron 7 gctctggtgaaattcctctc G/C ctaccccaaacatcatcatt 65 1740 C b0e; T intron 7 acaaatgctcaccctttcag C/T tggaatgattgaaattttgg 66 2122 A b0e; G intron 7 tgattaaggtggctactacc A/G ggtgctttctgcatatctcg 67 7753 T b0e; C intrion 7 taggaattccaagctgtgaa T/C tttttactgaagctctttgg 68 8973 A b0e; T intron 7 atggaaatttgtttatattg A/T ctacagattgccaatattat 69 8976 A b0e; G intron 7 gaaatttgtttatattgact A/G cagattgccaatattattag Table 1. Continued Repetitive Identity Number Location Exon SNP (5b18; to 3b18;) Substituion sequence to dbSNP Reference 70 11327 G b0e; C intron 7 ctaacaatcttatttccatt G/C agtccttataaaagaagtgg 71 11738 C b0e; T intron 7 ctgacgtttaagggagaccg C/T gtaggtccctttgaggactg 72 12295 T b0e; A intron 7 agtctgtaaattattgttct T/A ttttttctttagcttatgct 73 387 C b0e; G intron 8 tagcaaggccaatcatttta C/G caacacacatgcttgctaac 74 697 A b0e; T intron 8 ggaactgtctggtgtccccc A/T gcataggaagctgagccagg 75 1312 G b0e; A intron 8 attgctctgcagatcccctc G/A cagccctctgtcccttgttc rs1175929 76 3036 T b0e; G intron 8 ctttatgtgggaagaaattt T/G tttttttgattggggagtgg 77 3176 C b0e; A intron 8 aaatggcctggttctctgtc C/A cctttctgtctgtatgcctc 78 3364 A b0e; T intron 8 ggcagaaggcaaagcttagg A/T cctagagagtgctggaccac 79 3373 G b0e; A intron 8 caaagcttaggacctagaga G/A tgctggaccacgccactcac 80 3561 C b0e; A intron 8 cagggatttattaatgattt C/A ttgtgaaatgtttggaaata 81 3654 T b0e; C intron 8 agtgccggaatacatttgca T/C gtaagacagaacgctgcctg 82 4715 C b0e; T intron 8 ggcagaggggtctcagaatc C/T gcatttccaacaatgtctcc 83 936 C b0e; T coding region 9 cgtattgtctgcgggcatcc C/T gagggaggggggctgaagat Pro 312 Pro 84 2309 A b0e; G intron 9 cccctcaagagtcagtttaa A/G tgttggtcatgttagttgtc 85 2392 T b0e; C intron 9 atgggagggcttgtgcttca T/C gaaaacatttttccagatca 86 228 A b0e; G intron 10 tggggatggggaggactggc A/G cagggctgctgtgatggggt 87 319 C b0e; T intron 10 ttctgcggtccctggctccc C/T acctgactccaggtgaacaa 88 377 A b0e; C intron 11 gaaagaagtgtgggagcaaa A/C gcatgatgttacatgtagac 89 521 G b0e; A intron 11 agtgctctagagacaattgg G/A ttcaaatgtggagcaggctg 90 2850 G b0e; C intron 11 ctctatacaatcattatgct G/C ccattgaaataataaataca 91 2976 A b0e; G intron 11 ctccaattcggtagaaccag A/G gcttcatcttctctgtcgaa 92 3056 C b0e; T intron 11 gtttgcagctgctgtttttc C/T ggcagcacatctgtgcaggc 93 340 T b0e; C intron 12 ggcattatttgtgaaactta T/C ctaaaatcgaattcgggtcc 94 381 A b0e; G intron 12 aattaaatttttgaaatttt A/G tattaaaaattatattagta 95 1728 C b0e; T intron 14 caggctcagaggccttggcc C/T atcaccctggctcacgtgtg 96 2040 C b0e; A coding region 15 atgggcctggacaacagcat C/A ctctggtttagctggttcat Ile 680 Ile 97 1382 G b0e; A intron 15 cttttagacagaaaagttac G/A tgggatattatctcccacag 98 1453 G b0e; A intron 15 tatataaggagaaaccagtt G/A aaattacctattgaagaaac 99 1567 G b0e; A intron 15 ttctgcgtagttttgggtaa G/A tcacttatcttctttaggat MIR 100 1617 T b0e; A intron 15 cagttgcctcatcagaaaga T/A gaacagcattacgcctctgc MIR 101 95 T b0e; A intron 16 agttgagaacagaagatgat T/A gtcttttccaatgggacatg 102 452 G b0e; A intron 16 tggtgttttgcttgagtaat G/A ttttctgaactaagcacaac 103 657 T b0e; C intron 16 ctgttgcctcagtctgggct T/C cataggcatcagcagcccca 104 2473 G b0e; A coding region 17 gcttcaatctcaccacttcg G/A tctccatgatgctgtttgac Val 825 Ile Clee et al. 2001 105 2649 A b0e; G coding region 18 ggttccaaccagaagagaat A/G tcagaaagtaagtgctgttg Ile 883 Met Clee et al. 2001 106 1730 C b0e; G intron 18 tgaaagttcaagcgcagtgc C/G ctgtgtccttacactccact 107 426 A b0e; G intron 19 aggaccttacagtgggtagt A/G tcaggaggggtcaggggctg 108 468 A b0e; G intron 19 aaagcaccagcgttagcctc A/G gtggcttccagcacgattcc 109 876 C b0e; T intron 20 ccctcctcatctaaagtgaa C/T acatggggctcatgtgcagg 110 118 T b0e; G intron 22 catgggatactcttctgtta T/G cacagaagagataaagggca 111 560 G b0e; A intron 22 aaagctttgccattctaggg G/A tcatagccatacagggtgaa 112 102 A b0e; G intron 23 accccttttgccatgttgaa A/G ccaccatctccctgctctgt 113 287 C b0e; T intron 23 gtcaaagaaaagagacttgt C/T aagaggtaagagccttggct 114 1063 G b0e; A intron 23 acctttcaccctcaggaagc G/A aggctgttcacacggcacac 115 321 T b0e; G intron 25 ctctttacttaagtacagtg T/G gaggaacagcggcatcagga MER5A 116 376 G b0e; C intron 25 gttagaaattcagcaacttg G/C gcccagctcagacctactga MER5A 117 478 C b0e; T intron 25 catacataggaaatgacaaa C/T gtttatggatggatagtcta 118 579 G b0e; T intron 25 tcatttaattctcaaaaaaa G/T atgaaaaaatgaacactcag 119 153 C b0e; T intron 27 aatggtaaaagccacttgtt C/T tttgcagcatcgtgcatgtg 120 1058 C b0e; T intron 28 actatcatgggagataatga C/T tatggttgtccatgattgga 121 1317 C b0e; T intron 28 caggacccagtgttctgagt C/T accctgaatgtgagcactat 122 372 T b0e; C intron 30 tatatgatttttaggttttg T/C ttatcagcttcttcgctttt 123 506 A b0e; G intron 30 ccttttaaaaagtaagcagt A/G gataaataaattcagtgaag 124 1033 G b0e; C intron 30 ctggatttcatggtgccttt G/C attttccacatgaaggttgt 125 4281 G b0e; A coding region 31 tcttccctttgcagagacac G/A ccctgccaggcaggggagga Thr 1427 Thr 126 626 C b0e; T intron 33 ggctccttgttactgatttc C/T gtcttttctctctgcctttt 127 719 G b0e; A intron 33 taatagccctcatgctagaa G/A ggagccggagcctgtgtata 128 726 G b0e; A intron 33 cctcatgctagaagggagcc G/A gagcctgtgtataaggccag 129 889 A b0e; G intron 33 ctttcctcaatgtctcagct A/G tctaactgtgtgtgtaatca 130 1097 G b0e; C intron 33 ctgtgcaccccactgtctgg G/C ttttaatgtcaggctgttct 131 4760 G b0e; A coding region 35 tatgacaggactggacacca G/A aaataatgtcaaggtaaacc Arg 1587 Lys Clee et al. 2001 132 234 T b0e; C intron 35 aacctatctaaacctcagtt T/C cctcatctgtgaaatggaga MIR 133 411 C b0e; T intron 37 aactctgtacattttatcag C/T agcttatccatccattgcaa 134 1224 A b0e; G intron 37 caggcataggtgattcagag A/G tgaaaggtcaagtccctgaa L2 135 1720 G b0e; T intron 37 aaattaaaattactctgact G/T ggaatccatcgttcagtaag 136 251 T b0e; G intron 40 tgaaggtaaggaaaatagtg T/G tatttgcttggatccactgg 137 252 T b0e; C intron 40 gaaggtaaggaaaatagtgt T/C atttgcttggatccactggc 138 319 A b0e; G intron 40 agcactggaaaagtcaaacc A/G taactttgagaattaggtga Table 2. Characterization of insertion/deletion polymorphisms at the ABCA1 locus Number Location Variations (5b18; to 3b18;) 1 (afa;1033)-(afa;1032) ins AT 5b18; flanking region tgacttaaatatttagacat (AT/af9;) ggtgtgtaggcctgcattcc 2 6368 del C intron 5 ttctgatggggttgttgctg (C/afa;) tgagaatcatgactgggtgg 3 9709 del T intron 5 cattttctgtctgaaccccc (T/afa;) cacccattcaggcagctgct 4 13816 del T intron 5 tccctacttctccttttttt (T/afa;) catttgcctcctccacccac 5 270-271 ins G intron 10 cttttcagggaggagccaaa (G/af9;) cgctcattgtctgtgcttct 6 611-612 ins C intron 20 tttagcccatcctctccccc (C/af9;) gccaccctccttattgaggc 7 391-392 ins T intron 32 gagtgccttgggtactctct (T/af9;) gatgggggactccatgataa 8 847 del C intron 37 gctgtatattgtgaatgtcc (C/afa;) gttttcaaaagcaaagccaa Nucleotide numbering is according to the mutation nomenclature (den Dunnen and Antonarakis, 2000) (af9;), insertion polymorphism; (afa;), deletion polymorphism Table 1. Continued Repetitive Identity Number Location Exon SNP (5b18; to 3b18;) Substituion sequence to dbSNP Reference 139 957 G b0e; C intron 40 cttgttactcttttttcctt G/C tcatgggtgatagccatttg 140 146 C b0e; T intron 41 tgatgtgggcatcccgcagc C/T ccctccctgcccatcctgga 141 239 A b0e; C intron 42 cattggttttatatgcttac A/C tttatgtgttagttattaaa 142 321 T b0e; A intron 42 aataaatggttgattttgag T/A ttgagtttcatagtccaaaa 143 322 T b0e; C intron 42 ataaatggttgattttgagt T/C tgagtttcatagtccaaaaa 144 533 G b0e; A intron 42 agatgaaaaattatgtagat G/A ataatgaatgatacggttct 145 546 A b0e; G intron 42 tgtagatgataatgaatgat A/G cggttctaaaaagacaggtt 146 739 T b0e; A intron 43 tacagccacacttaaaatgg T/A cccattatgaaatacatatt 147 18 T b0e; C intron 44 taggtgagaaaagaagtggc T/C tgtattttgctgcaaagact 148 264 T b0e; C intron 44 acaatataatttgcttgttt T/C ttaagagtataatttagtga L1MB8 149 279 T b0e; C intron 44 tgttttttaagagtataatt T/C agtgatttttggtaaattga L1MB8 150 508 C b0e; T intron 44 tttacattgctacataaaat C/T cccctatgtacatgtaccta 151 1477 A b0e; T intron 44 gatctcctctcctgtctctt A/T catttttgcagtagcaatgt 152 1665 G b0e; A intron 44 tggttgtaagaactgatttg G/A ttggtatagctgtgagggcc 153 1956 T b0e; G intron 44 gtgttgctcacactcaaaat T/G tctgggccttctcatttggt 154 68 T b0e; C intron 45 aatatataccttatggcttt T/C ccacacgcattgacttcagg 155 608 G b0e; C intron 46 ttatactgacttcaatagag G/C tttcagacaaaaagttgttt 156 336 T b0e; C intron 47 ttcacaattgtaaacaccac T/C acactgaacagcatcatccc L1MD2 157 55 G b0e; C intron 49 agggtgtggattcctgcccc G/C acactcccgcccataggtcc rs1331924 158 7479 C b0e; T 3b18; untranslated region 50 aacaaaaatgtgggtgtctc C/T aggcacgggaaacttggttc 159 8226 C b0e; T 3b18; untranslated region 50 aggagcccactgtaacaata C/T tgggcagccttttttttttt 160 8682 G b0e; A 3b18; untranslated region 50 aacttcttccactttttcca G/A aatttgaatattaacgctaa rs363717 161 8697 C b0e; T 3b18; untranslated region 50 ttccagaatttgaatattaa C/T gctaaaggtgtaagacttca 162 9097 A b0e; G 3b18; untranslated region 50 aactattttgaagaaaacac A/G acattttaatacagattgaa Nucleotide numbering is according to the mutation nomenclature (den Dunnen and Antonarakis, 2000) is an important resource for understanding not only the etiology and risk of some diseases, but also the pharmacokinetics or pharmacodyamics of drugs used to treat them.
X
ABCA1 p.Val825Ile 11558901:19:8426
status: NEW
PMID: 19341173
[PubMed]
Ksiazek J et al: "Is dyslipidemia sustained during remission of nephrotic syndrome genetically determined? Evaluation of genetic polymorphisms of proteins involved in lipoprotein metabolism in children and adolescents with nephrotic syndrome."
No.
Sentence
Comment
8
We evalauated associations between lipid profile and genetic polymorphisms, V771M, V825I, and R1587K of the gene encoding the cassette ABCA1 (adenosine triphosphate binding cassette transporter A1) protein synthesis, a b5;3 polymorphism of the gene encoding the type b5; of apolipoprotein E (apoE) synthesis and that of the gene encoding the cholesterol ester transfer protein (CETP) synthesis.
X
ABCA1 p.Val825Ile 19341173:8:83
status: NEW9 Resultsߓ Dyslipidemia was observed in 10/13 (76.9%) patients with V825I polymorphism vs. 27/37 (73%) of nonߛcarriers, and in 16/21 (76.2%) patients with R1587K polymorphism vs. 21/29 (72.4%) in the remaining subjects.
X
ABCA1 p.Val825Ile 19341173:9:72
status: NEW36 Some investigators have suggestߛ ed higher incidence of specific genotypes in paߛ tients with nephritic syndrome and endߛstage Table 1ߓ Characteristics of patients Patients Total Males Females Steroidߛresistant Number (n) % ߗ 50 100 35 70 15 30 12 24 Mean age (years) SD ߗ 10.45 ߗߗ 3.04 10.5 ߗ 3.13 10.35 ߗ 2.82 Duration of treatment (years) SD ߗߗ 7.09 ߗߗ 2.88 ߗ 6.88 ߗ 3.14 ߗ 7.55 ߗ 2.19 Histological diagnosis MCNS ߗ 21 14 ߗ 7 ߗ 1 MPGN ߗ 26 19 ߗ 7 ߗ 9 FSGS ߗߗ 3 ߗ 1 ߗ 2 ߗ 2 Abbreviations: FSGS - focal segmental glomerulosclerosis, MCNS - minimal change nephrotic syndrome, MPGN - mesangial proliferative glomerulonephritis, SD - standard deviation of the ABCA1 gene (V771M, V825I and R1587K), a polymorphism of the CETP gene and polymorߛ phisms of the apoE gene.
X
ABCA1 p.Val825Ile 19341173:36:860
status: NEW39 Three single nuߛ cleotide variants of guanine (G) > adenine (A) transition of the ABCA1 gene such as V771M, V825I i R1587K that determine the HDLߛC plasma level were genotyped by the selfߛdevelߛ oped method, using the restriction enzyme Tail for determining polymorphism V771M, the reߛ striction enzyme MboI for polymorphism V825I and the restriction enzyme Bgl II for R1587K polymorphism.
X
ABCA1 p.Val825Ile 19341173:39:114
status: NEWX
ABCA1 p.Val825Ile 19341173:39:355
status: NEW41 Transition G to A in posiߛ tion 2472 cDNA caused substitution of valine to isoleucine in position 825 of the polypepߛ tide chain of ABCA1 protein (polymorphism V825IߛG2472A).
X
ABCA1 p.Val825Ile 19341173:41:71
status: NEW56 The results were assessed in comparison with normal reference values coming from the evaluߛ ation of the healthy Warszawa population aged between 6 and 20, published previously by inߛ vestigators from the Children`s Memorial Health Institute.14 In all subjects the following genetic polyߛ morphisms were evaluated: - three nonߛsynonߛ ymous single nucleotide polymorphisms variants Table 2ߓ Median values of lipid profile parameters in patients with dyslipidemia (nߙ=ߙ37) and normolipidemia (nߙ=ߙ13) during remission of nephrotic syndrome Parameter mg/dl nߙ=ߙ13 nߙ=ߙ37 pa TC (mg/dl) 175.8 232 <0.0001 HDLߛC (mg/dl) ߗ 55 ߗ 49 NS LDLߛC (mg/dl) 100.66 163.29 <0.0001 VLDLߛC (mg/dl) ߗ 14.2308 ߗ 21.6 0.0015 TG (mg/dl) ߗ 77.2222 156.25 0.00007 ApoB (g/dl) ߗߗ 0.8067 ߗߗ 1.22 0.000004 ApoA1 (g/dl) ߗߗ 1.52 ߗߗ 1.51 NS OxyߛLDL (mU/ml) 278.28 504.9 0.0022 GPX (u/gHb) ߗ 32.30 ߗ 30.71 0.0016 Lp(a) (mg/dl) ߗ 10.20 ߗ 15.62 0.0184 Albumin (g/l) ߗ 40.73 ߗ 37.52 0.0014 aߓ MannߛWhitney`s test Abbreviations: apoA1 - apolipoprotein A1, apoB - apolipoprotein B, GPX - glutathione peroxidase, HDLߛC - highߛdensity lipoprotein cholesterol, LDLߛC - lowߛdensity lipoprotein cholesterol, Lp (a) - lipoprotein (a), NS - not significant, oxyߛLDLߛC - oxidized LDLߛcholesterol, TC - total cholesterol, TG - triglycerides, VLDLߛC - very lowߛdensity lipoprotein cholesterol Table 3ߓ Number of patients with ABCA1 genetic polymorphisms Patients Polymorphic variants V771M V825I R1587K V825 Iߙ+ߙR1587K GA GA AA GA AA GAߛGA GAߛAA s - d. ns nߙ=ߙ38 2 ߗ 9 1 11 2 5 1 s - r. ns nߙ=ߙ12 - ߗ 3 - ߗ 6 2 2 1 Overall nߙ=ߙ50 2 (4%) 13 (26%) 21 (42%) 9 (18%) Abbreviations: AA, GA, GG - variants of polymorphism of ABCA1 gene, sߛd ns - steroidߛdependent nephrotic syndrome, sߛr ns - steroidߛresistant nephrotic syndrome, in TABLE 3.
X
ABCA1 p.Val825Ile 19341173:56:1738
status: NEW58 The V825I polymorphism of ABCA1 gene of GA variant was confirmed in 12 of 50 (24%) cases.
X
ABCA1 p.Val825Ile 19341173:58:4
status: NEW59 The V825I polymorphism of AA variant was confirmed in 1/50 (2%) case with the low HDLߛC serum level.
X
ABCA1 p.Val825Ile 19341173:59:4
status: NEW60 Overall, the V825I polyߛ morphism was demonstrated in 13 of 50 (26%) patients.
X
ABCA1 p.Val825Ile 19341173:60:13
status: NEW65 The presence of 2 gene polymorphisms (V825I and R1587K) was detected in 9 of 50 (18%) patients.
X
ABCA1 p.Val825Ile 19341173:65:38
status: NEW70 Among 13 subjects with confirmed V825I polyߛ morphisms, abnormal lipid profile was shown in the majority of cases (10; 76.9%).
X
ABCA1 p.Val825Ile 19341173:70:33
status: NEW81 The number and distribution of specific gene polymorphisms of ABCA1 are presented Table 4ߓ Distribution of significant (compared to reference data) lipid abnormalities in subgroups of patients divided with regard to ABCA1 genetic polymorphisms Polymorphism Disturbances V771M nߙ=ߙ2 (4%) V825I nߙ=ߙ13 (26%) R1587K nߙ=ߙ21 (42%) V8251ߙ+ߙR1587K nߙ=ߙ9 (18%) GA nߙ=ߙ2 AA GA nߙ=ߙ12 AA nߙ=ߙ1 GA nߙ=ߙ17 AA nߙ=ߙ4 GAߛGA nߙ=ߙ7 GAߛAA nߙ=ߙ2 TC - - 1 - 2 - 1 - TCߙ+ߙ TG 1 - 2 - 3 1 2 2 TCߙ+ߙ TGߙ+ߙ HDLߛC - - 2 - 4 1 1 - TCߙ+ߙ HDLߛC - - 1 - - 1 - - TGߙ+ߙ HDLߛC - - 1 - 1 1 - ߙ+ߙ HDLߛC - - 2 1 2 1 1 - Overall 1 50% - 10 76.9% 16 76.2% 7 77.8% No disturbances 1 50% - 3 23.1% 5 33.8% 2 22.2% Abbreviations: AA, GA, GG - variants of polymorphism of ABCA1 gene, HDLߛC - fraction HDL of cholesterol, TC - total cholesterol, ߓ TG - triglycerides, V771M, V825I, R587K - nonߛsynonymous single nucleotide polymorphisms of ABCA1 cassette gene Table 5ߓ Distribution of significant (compared to reference data) lipid abnormalities in subgroups of patients divided with regard to CETP gene polymorphisms Polymorphism Disturbances GA variant nߙ=ߙ25 (50%) AA variant nߙ=ߙ6 (12%) TCߙ+ߙTG 3 2 TCߙ+ߙTGߙ+ߙ HDLߛC 3 2 TGߙ+ߙ HDLߛC 1 - TCߙ+ߙ HDLߛC 1 - TC 4 1 - HDLߛC 4 1 Overall 22/31 71% No lipid disturbances 9/31 29% Abbreviations: AA, GA, GG - variants of polymorphism of the gene, HDLߛC - fraction HDL of cholesterol, TC - total cholesterol, TG - triglycerides was a nonߛsignificant trend (pߙ=ߙ0.067) in terms of association between the triglyceride level and R1587K genotype.
X
ABCA1 p.Val825Ile 19341173:81:307
status: NEWX
ABCA1 p.Val825Ile 19341173:81:1185
status: NEW100 There Table 6ߓ Distribution of significant (compared to reference data) lipid abnormalities in subgroups of patients divided with regard to apoE gene polymorphisms Lipid disturbances ApoE subtype b5;3b5;3 nߙ=ߙ35 (70%) b5;3b5;4 nߙ=ߙ6 b5;2b5;3 nߙ=ߙ5 b5;2b5;4 nߙ=ߙ1 b5;4b5;4 nߙ=ߙ2 b5;2b5;2 nߙ=ߙ1 TCߙ+ߙTGߙ+ߙ HDLߛC ߗ 4 2 2 1 - - TGߙ+ߙHDLߛC ߗ 1 - - - 1 - HDLߛC ߗ 5 1 1 - - 1 TC ߗ 7 1 - - - - TCߙ+ߙTG ߗ 7 1 - - - - TCߙ+ߙ HDLߛC ߗ 2 - - - - - Overall 26 (74.3%) 5 3 1 1 1 No disturbances ߗ 9 (25.7%) 1 2 - 1 - Abbreviations: apoE - apolipoprotein E, HDLߛC - fraction HDL of cholesterol, TC - total cholesterol, TG - triglycerides Table 7ߓ Distribution of lipid disturbances prevalence in children with and without specific genetic polymorphisms(summary) Polymorphism Number of patients (n) with polymorphisms and lipid abnormalities with no polymorphisms and lipid abnormalities V771M nߙ=ߙ2/50 1/2 (50%) 36/48 (76.6%) V825I nߙ=ߙ13/50 10/13 (76.9%) 27/37 (73%) R1587K nߙ=ߙ21/50 16/21 (76.2%) 21/29 (72.4%) CETP nߙ=ߙ31/50 22/31 (71%) 15/19 (78.9%) apo b5;3b5;3 nߙ=ߙ35/50 26/35 (74.35) - Other types apoE nߙ=ߙ15/50 12/15 (73.3%) - Abbreviations: apoE- polymorphism of apoE gene, CETP - polymorphism of CETP gene, 14ߓ Litwin M, a;ladowska J, Antoniewicz J, et al.: Metabolic abnormalities, insulin resistance and metabolic syndrome in children with primary hyperߛ tension.
X
ABCA1 p.Val825Ile 19341173:100:1251
status: NEW
PMID: 23152888
[PubMed]
Villarreal-Molina T et al: "The ABCA1 gene R230C variant is associated with decreased risk of premature coronary artery disease: the genetics of atherosclerotic disease (GEA) study."
No.
Sentence
Comment
132
In this regard, heterozygosity for loss of function ABCA1 mutations were associated with lower plasma HDL-cholesterol levels, but not with an increased risk of ischemic heart disease after adjusting for known cardiovascular risk factors [10]; ABCA1 variants V772M and V825I were both associated with increased HDL-C levels and increased IHD risk [12], and the ABCA1 promoter variant rs2422498 was associated with a decreased risk of 10-year vascular death in CAD patients with no apparent effect on HDL-C levels [33].
X
ABCA1 p.Val825Ile 23152888:132:268
status: NEW
PMID: 23555291
[PubMed]
Wu Y et al: "Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained."
No.
Sentence
Comment
234
Reported functional variants [ref] Reported functional variants on Metabochip Variants with strongest association at a signal Signal Ethnic group* MAF Notes PCSK9: rs28362286 (C679X) [22] Yes rs28362286 1st AA 0.009 Same variant PCSK9: rs28362263 (A443T) [29] Yes rs28362263 2nd AA 0.097 Same variant PCSK9: rs28362261 (N425S) [30] Yes rs28362261 3rd AA 0.017 Same variant PCSK9: rs67608943 (Y142X) [22] Yes rs67608943 4th AA 0.004 Same variant PCSK9: rs72646508 (L253F) [22] Yes rs72646508 5th AA 0.003 Same variant APOE: rs7412 (R176C) [23] Yes rs7412 1st AA, ASN, EUR 0.056-0.110 Same variant APOE: rs769455 (R163C) [31] Yes rs769455 2nd AA 0.020 Same variant APOA5: rs3135506 (S19W) [26] Yes rs3135506 1st AA 0.058 Same variant APOA5: rs651821(-3A.G) [32] Yes rs651821 1st ASN 0.275 Same variant APOA5: rs2075291 (G185C) [25] Yes rs2075291 2nd ASN 0.064 Same variant GCKR: rs1260326 (L446P) [28] Yes rs1260326 1st AA, EUR 0.149-0.350 Same variant SORT1: rs12740374 [18] Yes rs12740374 1st AA 0.247 Same variant CETP: rs17231520 [33] Yes rs17231520 3rd AA 0.069 Same variant LIPC: rs2070895 [34] Proxy: rs1077834 (LD r2 = 1.00) rs1077834 1st, 2nd AA, EUR 0.481 LD r2 = 1.00 APOB: rs7575840 [35] Yes rs934198 1st EUR 0.298 LD r2 = 0.98 LPL: rs328 (S447X) [36] Yes rs1803924 1st ASN 0.095 LD r2 = 0.96 LDLR: rs688 (N591N) [37] Yes rs73015011, rs112898275 1st AA, EUR ---- LD r2 ,0.01 LPL: rs1801177 (D9N) [38] Yes rs75551077, rs15285 1st AA, EUR ---- LD r2 ,0.02 HMGCR: rs3761740 (-911C.A) [39] Proxy: rs17238330 (LD r2 = 1.00) rs12916 1st EUR ---- LD r2 ,0.20 LDLR: -139C.G [40] No ---- ---- ---- ---- ---- LPL: rs268 (N291S) [41] No ---- ---- ---- ---- ---- ABCA1: rs9282541 (R230C) [42] No ---- ---- ---- ---- ---- ABCA1: rs2066715 (V825I) [43] No ---- ---- ---- ---- ---- LCAT: rs28940887(R159W) [44] No ---- ---- ---- ---- ---- PLTP: R235W [45] No ---- ---- ---- ---- ---- LIPG: rs77960347 (A396S) [46] No ---- ---- ---- ---- ---- LIPG: rs34474737 [47] No ---- ---- ---- ---- ---- *AA, African American; EUR, European; ASN, East Asian.
X
ABCA1 p.Val825Ile 23555291:234:1737
status: NEW
PMID: 24376512
[PubMed]
Nakamura A et al: "Gene-gene combination effect and interactions among ABCA1, APOA1, SR-B1, and CETP polymorphisms for serum high-density lipoprotein-cholesterol in the Japanese population."
No.
Sentence
Comment
52
doi:10.1371/journal.pone.0082046.g001 polymorphisms (SNPs) that have been reported to be associated with HDL-C levels in previous studies [11-17]: ABCA1-565C.T (rs2422493), R1587K (rs2230808), -273G.C (rs1800976), V771M (rs2066718), -17C.G (rs2740483), and V825I (rs2066715); APOA1 A61T (rs12718465); LCAT (rs4986970); CETP Taq1B (rs708272), G/T (rs3764261), I405V (rs5882), and -629C.A (rs1800775); SR-B1 A.G (rs3782287), A350A (rs5888), and V135I (rs5891).
X
ABCA1 p.Val825Ile 24376512:52:258
status: NEW146 Gene rs Number Alias Allele MAF ABCA1 rs2422493 2565C.T C.T 0.408 rs2230808 R1587K G.A 0.399 rs1800976 2273G.C G.C 0.409 rs2066718 V771M G.A 0.075 rs2740483 217C.G C.G 0.295 rs2066715 V825I G.A 0.361 APOA1 rs12718465 A61T C.T 0.068 CETP rs708272 Taq1B C.T 0.398 rs3764261 G/T G.T 0.272 rs5882 Ile405Val A.G 0.495 rs1800775 2629C.A A.C 0.445 SR-B1 rs3782287 A.G G.A 0.244 rs5888 A350A C.T 0.220 MAF, minor allele frequency.
X
ABCA1 p.Val825Ile 24376512:146:184
status: NEW
PMID: 24385509
[PubMed]
Westerterp M et al: "ATP-binding cassette transporters, atherosclerosis, and inflammation."
No.
Sentence
Comment
59
In a Mendelian randomization approach in a prospective cohort comprising ࣈ9000 individuals, heterozygosity for the ABCA1 mutation K776N led to a 2-to-3 times higher risk of ischemic heart disease.105 Furthermore, 5 single-nucleotide polymorphisms (SNPs) inABCA1 (V771M,V825I, I883M, E1172D, R1587K) were shown to predict risk of ischemic heart disease in a cohort of 9259 individuals.106 However, the same group reported more recently that heterozygosity for 4 loss-of-function mutations (P1065S, G1216V, N1800H, R2144X) was not associated with a higher risk of ischemic heart disease in 3 prospective cohorts comprising 56ߙ886 individuals.107 It must be noted, however, that only small decreases in HDL, of ࣈ28% as opposed to ࣈ50% in previously reported ABCA1 heterozygotes, were observed.94,101-103,107 Also, the residual cholesterol efflux was substantial (74%-79% for P1065S and G1216V and 48%-49% for N1800H and R2144X for homozygous mutations compared with controls),107 whereas in patients with TD there was only 20% to 30% residual cholesterol efflux.108 In addition, LDL levels were reduced by ࣈ25%, probably offsetting the effects of reduced HDL on CVD.107 Thus, the conflicting results in these studies could be related to inclusion of relatively mild ABCA1 mutations as well as offsetting effects of reduced LDL cholesterol levels.109 In a meta-analysis of genome-wide association studies, SNPs near the ABCA1 gene have been associated with HDL and total cholesterol levels,110,111 but not with cardiovascular risk.112 Although these studies have the benefit of huge statistical power, some caution is merited in the interpretation of findings.
X
ABCA1 p.Val825Ile 24385509:59:275
status: NEW
PMID: 24466114
[PubMed]
Yin YW et al: "Influence of ATP-binding cassette transporter 1 R219K and M883I polymorphisms on development of atherosclerosis: a meta-analysis of 58 studies."
No.
Sentence
Comment
28
Recently, a number of molecular epidemiological studies have been done to evaluate the associations between the ABCA1 gene polymorphisms (such as R219K, M883I, C69T, V825I, R1587K, V771M and 2565C/T) and the risk of atherosclerotic diseases [248].
X
ABCA1 p.Val825Ile 24466114:28:166
status: NEW
PMID: 25527331
[PubMed]
Yin YW et al: "ATP-binding cassette transporter 1 C69T and V825I polymorphisms in the development of atherosclerosis: a meta-analysis of 18,320 subjects."
No.
Sentence
Comment
1
This meta-analysis was performed to assess the associations of ABCA1 C69T and V825I polymorphisms with AS susceptibility.
X
ABCA1 p.Val825Ile 25527331:1:78
status: NEW7 For the ABCA1 V825I polymorphism, eight studies involving 2026 AS cases and 8696 controls were combined.
X
ABCA1 p.Val825Ile 25527331:7:14
status: NEW10 Furthermore, there was no significant association between the ABCA1 V825I polymorphism and AS risk.
X
ABCA1 p.Val825Ile 25527331:10:68
status: NEW21 In 2003, Tan et al. found that the ABCA1 V825I polymorphism was associated with the susceptibility of coronary artery disease (CAD) among Malay population [3].
X
ABCA1 p.Val825Ile 25527331:21:41
status: NEW22 In 2004, Wang et al. also found significant association between the ABCA1 V825I polymorphism and ischemic stroke (IS) risk in kazakh ethnic [4].
X
ABCA1 p.Val825Ile 25527331:22:74
status: NEW33 In 2012, Qin et al. demonstrated no significant association between the ABCA1 V825I polymorphism and IS risk among Chinese [15].
X
ABCA1 p.Val825Ile 25527331:33:78
status: NEW34 In the same year, Xue et al. showed that the I/I genotype of the ABCA1 V825I polymorphism was a protective factor for IS among Chinese [7].
X
ABCA1 p.Val825Ile 25527331:34:71
status: NEW35 It is unclear yet whether there are significant associations between the ABCA1 C69T and V825I polymorphisms and AS risk.
X
ABCA1 p.Val825Ile 25527331:35:88
status: NEW37 Here, we focused on the associations between the ABCA1 C69T and V825I polymorphisms and AS risk.
X
ABCA1 p.Val825Ile 25527331:37:64
status: NEW38 We therefore designed this meta-analysis synthesizing the data from single studies to evaluate the genetic risk of the C69T and V825I polymorphisms in ABCA1 gene for AS.
X
ABCA1 p.Val825Ile 25527331:38:128
status: NEW46 Inclusion Criteria All studies that aimed to investigate the associations between the ABCA1 C69T and V825I polymorphisms and AS risk were considered.
X
ABCA1 p.Val825Ile 25527331:46:101
status: NEW47 Any study which fulfilled the following criteria was included: (1) original (case-control or cohort studies) research evaluating the associations between the ABCA1 C69T and V825I polymorphisms and AS risk; (2) studied on human beings; (3) sufficient data to estimate an odds ratios (ORs) with their 95% confidence intervals (CIs); (4) not republished data.
X
ABCA1 p.Val825Ile 25527331:47:173
status: NEW57 ORs with 95% CIs were used to measure the associations strength between the ABCA1 C69T and V825I polymorphisms and AS risk.
X
ABCA1 p.Val825Ile 25527331:57:91
status: NEW58 In the present meta-analysis, we evaluated the overall AS risk in four comparison models: allelic model (T allele vs. C allele for C69T; I allele vs. V allele for V825I), additive model (T/T vs. C/C for C69T; I/I vs. V/V for V825I), recessive model (T/T vs. C/T + C/C for C69T; I/I vs. V/I + V/V for V825I), and dominant model (T/T + C/T vs. C/C for C69T; I/I + V/I vs. V/V for V825I).
X
ABCA1 p.Val825Ile 25527331:58:163
status: NEWX
ABCA1 p.Val825Ile 25527331:58:225
status: NEWX
ABCA1 p.Val825Ile 25527331:58:300
status: NEWX
ABCA1 p.Val825Ile 25527331:58:378
status: NEW68 After careful review, a total of 11 articles involving 14 studies (six studies for C69T polymorphism and eight studies for V825I polymorphism), comprising 3880 patients and 14440 controls, fulfilled the criteria for inclusion in this study [3-7,11-16].
X
ABCA1 p.Val825Ile 25527331:68:123
status: NEW83 For the ABCA1 V825I polymorphism, eight studies were combined.
X
ABCA1 p.Val825Ile 25527331:83:14
status: NEW85 However, significant association was found between the ABCA1 V825I polymorphism and AS risk in the IS group (for I/I + V/I vs. V/V: OR =1.19, 95% CI =1.01-1.40, p =0.040).
X
ABCA1 p.Val825Ile 25527331:85:61
status: NEW88 The included studies were limited to those conforming to HWE. Overall, the corresponding pooled ORs were not materially altered, either for the ABCA1 C69T polymorphism or for V825I polymorphism.
X
ABCA1 p.Val825Ile 25527331:88:175
status: NEW92 Furthermore, the results of Egger`s regression test also revealed no publication bias, either for the ABCA1 C69T polymorphism (p =0.469 for allelic model, p =0.464 for additive model, p =0.586 for recessive model, and p =0.297 for dominant model, respectively) or for V825I polymorphism(p =0.459 for allelic model, p =0.921 for additive model, p =0.943 for recessive model, Fig. 1.
X
ABCA1 p.Val825Ile 25527331:92:268
status: NEW97 Therefore, to clarify the earlier inconclusive results involving the associations between the ABCA1 C69T and V825I polymorphisms and AS risk, we performed the present meta-analysis.
X
ABCA1 p.Val825Ile 25527331:97:109
status: NEW98 The present meta-analysis of 14 studies, including 3880 AS cases and 14440 controls, provided the most comprehensive analysis on the associations of the ABCA1 C69T and V825I polymorphisms with AS risk.
X
ABCA1 p.Val825Ile 25527331:98:168
status: NEW102 For the ABCA1 V825I polymorphism, no significant association was found between this variant and AS risk.
X
ABCA1 p.Val825Ile 25527331:102:14
status: NEW109 As for the ABCA1 V825I polymorphism, we did not find any evidence of association between this variant and AS risk in the Asians group and IS group.
X
ABCA1 p.Val825Ile 25527331:109:17
status: NEW110 In contrast, significant association was found between the ABCA1 V825I polymorphism and AS risk in the CAD group suggesting the I allele carriers had a higher risk for developing AS (for OR = 1.19) compared to those with V allele.
X
ABCA1 p.Val825Ile 25527331:110:65
status: NEW112 Position First author Year Country Ethnicity Disease Source of controls Sample size (case/control) Genotypes distribution (case/control) HWE Y/N(P) Score C69T C/C C/T T/T C T Wang [11] 2006 China Asian CAD PB 264/278 164/183 91/87 9/8 419/453 109/103 Y(0.540) 9 Ergen [12] 2008 Turkey Caucasian CAD PB 77/50 32/23 27/20 18/7 91/66 63/34 Y(0.442) 8 Yamada [5] 2008 Japan Asian IS PB 822/2070 445/1221 305/743 72/106 1195/3185 449/955 Y(0.607) 6 Porchay-Bald&#e9;relli [6] 2009 France Caucasian CAD HB 223/2906 91/1206 106/1331 26/369 288/3743 158/2069 Y(0.953) 6 Cheng [13] 2011 China Asian CAD HB 228/200 101/83 114/107 13/10 316/273 140/127 N(0.001) 6 Yi [14] 2011 China Asian IS PB 240/240 110/115 107/104 23/21 327/334 153/146 Y(0.713) 7 V825I V/V V/I I/I V I Tan-a [3] 2003 Singapore Asian CAD PB 294/108 92/34 142/58 60/16 326/126 262/90 Y(0.276) 7 Tan-b [3] 2003 Singapore Asian CAD PB 77/123 37/62 31/52 9/9 105/176 49/70 Y(0.671) 7 Tan-c [3] 2003 Singapore Asian CAD PB 83/109 71/97 10/12 2/0 152/206 14/12 Y(0.543) 7 Wang-a [4] 2004 China Asian IS PB 58/60 3/4 13/28 42/28 19/36 97/84 Y(0.389) 7 Wang-b [4] 2004 China Asian IS PB 58/60 7/12 32/34 19/14 46/58 70/62 Y(0.297) 7 Qin [15] 2012 China Asian IS PB 252/249 74/84 120/120 58/45 268/288 236/210 Y(0.851) 8 Xue [7] 2012 China Asian IS PB 97/129 36/33 50/65 11/31 122/131 72/127 Y(0.928) 7 V/V V/I + I/I Frikke-Schmidt [16] 2008 Denmark Caucasian CAD PB 1107/7858 962/6997 145/861 - 7 PB: population-based, HB: hospital-based.
X
ABCA1 p.Val825Ile 25527331:112:741
status: NEW114 Table 2 Meta-analyses of ABCA1 C69T and V825I polymorphisms and risk of AS in each subgroup.
X
ABCA1 p.Val825Ile 25527331:114:40
status: NEW115 Position Sample size (case/control) Allelic model Additive model Recessive model Dominant model OR(95% CI) P OR(95% CI) P OR(95% CI) P OR(95%CI) P Overall analysis C69T 1854/5744 1.14[1.04,1.24] 0.005 1.39[1.12,1.73] 0.003 1.34[1.09,1.65] 0.006 1.13[1.01,1.27] 0.040 V825I 2026/8696 1.18[0.90,1.53]a 0.230 1.29[0.75,2.23]a 0.360 1.40[0.87,2.26]a 0.160 1.15[1.00,1.33] 0.060 Subgroup analysis based on ethnicity C69T (E) 300/2956 1.03[0.86,1.25] 0.740 1.05 [0.70,1.57] 0.820 1.03[0.70,1.50] 0.160 1.05[0.81,1.36] 0.710 C69T (A) 1554/2788 1.17[1.06,1.30] 0.003 1.58[1.21,2.05] b0.001 1.52[1.18,1.97] 0.001 1.15[1.01,1.31] 0.030 V825I (A) 919/838 1.18[0.90,1.53]a 0.230 1.29[0.75,2.23]a 0.360 1.40[0.87,2.26]a 0.160 1.06[0.85,1.32] 0.590 Subgroup analysis based on atherosclerotic diseases C69T (CAD) 792/3434 1.04[0.90,1.19] 0.620 1.07[0.76,1.51] 0.680 1.06[0.77,1.47] 0.720 1.04[0.87,1.25] 0.650 C69T (IS) 1062/2310 1.22[1.08,1.37] 0.001 1.68[1.26,2.24] b0.001 1.61[1.21,2.12] b0.001 1.19[1.03,1.39] 0.020 V825I (CAD) 1561/8198 1.18[0.92,1.50] 0.190 1.57[0.91,2.73] 0.110 1.61[0.97,2.67] 0.060 1.19[1.01,1.40] 0.040 V825I (IS) 465/498 1.18[0.74,1.89]a 0.490 1.13[0.46,2.81]a 0.790 1.27[0.61,2.64]a 0.520 1.04[0.78,1.40] 0.780 Sensitivity analysis C69T (BH) 1626/5544 1.16[1.05,1.27] 0.002 1.42[1.13,1.78] 0.002 1.35[1.09,1.68] 0.006 1.16[1.03,1.31] 0.020 V825I (BH) 919/838 1.18[0.90,1.53]a 0.230 1.29[0.75,2.23]a 0.360 1.40[0.87,2.26]a 0.160 1.06[0.85,1.32] 0.590 A: Asians, E: Europeans, PB: population-based, HB: hospital-based, BH: based on HWE (Studies with HWE were included), CAD: coronary artery disease, IS: ischemic stroke, a Significant heterogeneity: the random-effects model was chosen to summarize the result.
X
ABCA1 p.Val825Ile 25527331:115:267
status: NEWX
ABCA1 p.Val825Ile 25527331:115:626
status: NEWX
ABCA1 p.Val825Ile 25527331:115:1005
status: NEWX
ABCA1 p.Val825Ile 25527331:115:1115
status: NEWX
ABCA1 p.Val825Ile 25527331:115:1354
status: NEW117 In addition, considering the results produced from genetic association case-control studies may be spurious when the genotype distribution of controls deviates from HWE [28], we also performed sensitivity analyses by limiting studies to those conforming to HWE. Overall, the corresponding pooled ORs were not materially altered, either for the ABCA1 C69T polymorphism or for V825I polymorphism.
X
ABCA1 p.Val825Ile 25527331:117:375
status: NEW119 Simultaneously, the results of sensitivity analyses further strengthened the overall conclusion involving the ABCA1 C69T and V825I polymorphisms and AS risk.
X
ABCA1 p.Val825Ile 25527331:119:125
status: NEW122 So far, at least seven single-nucleotide polymorphisms at the ABCA1 gene promoter have been studied to investigate the associations between these variants and the susceptibility of atherosclerotic diseases, such as R219K, M883I, C69T, V825I, R1587K, V771M and -565C/T.
X
ABCA1 p.Val825Ile 25527331:122:235
status: NEW127 For the ABCA1 V825I polymorphism, significant between-study heterogeneity existed in the allelic model, additive model and recessive model.
X
ABCA1 p.Val825Ile 25527331:127:14
status: NEW140 Fig. 3. Forest plots for the ABCA1 V825I polymorphism and AS risk. A (I allele vs. V allele); B (I/I vs. V/V).
X
ABCA1 p.Val825Ile 25527331:140:35
status: NEW148 Funnel plots for the ABCA1 V825I polymorphism and AS risk. A (I allele vs. V allele); B (I/I vs. V/V).
X
ABCA1 p.Val825Ile 25527331:148:27
status: NEW154 In addition, no significant association was found between the ABCA1 V825I polymorphism and AS risk.
X
ABCA1 p.Val825Ile 25527331:154:68
status: NEW155 To the best of our knowledge, this is the first comprehensive meta-analysis to date investigating the associations between the ABCA1 C69T and V825I polymorphisms and AS risk.
X
ABCA1 p.Val825Ile 25527331:155:142
status: NEW